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Abstract 
Mutations in EYS are a common cause of autosomal recessive retinitis 
pigmentosa (arRP). EYS is one of the largest genes expressed in the retina and the 
role of the protein it encodes is presently unclear. It has been shown, however, that 
EYS localises to the outer segments of porcine photoreceptors and that the 
Drosophila orthologue of EYS is essential in the biogenesis of the ommatidium, 
where it interacts with prominin, a highly conserved protein implicated in 
retinopathies. The aim of this project was to examine the role of EYS in the retina 
by investigating its subcellular localisation and by identifying its interacting 
partners. 
Characterisation of the genetic structure of EYS has revealed that it has at 
least four isoforms expressed in the retina and testis. Immunocytochemistry 
studies have shown that EYS isoforms predominantly localise to the cytoplasm of 
cultured cells whereas immunohistochemistry studies in the primate retina have 
revealed that it localises to the photoreceptor ciliary axoneme. Yeast 2-hybrid 
screening has resulted in identification of one potential interacting partner of EYS, 
AIPL1, which is a molecular chaperone required for the proteostasis of the retina. 
Further analysis by co-immunoprecipitation and immunofluorescence has 
confirmed that AIPL1 interacts with the N-terminal fragment of EYS isoforms 1 and 
4 as well as EYS isoforms 2 and 3. Furthermore, co-immunoprecpietation assays 
and immunofluorescence studies have suggested that the human orthologues of 
EYS and Prominin-1 do not interact. The mutation screening of PROM1 has 
resulted in identification of seven heterozygous novel variants in six unrelated 
arRP patients; however, pathogenicity of the changes could not be established. 
Altogether, the results of the study have demonstrated that EYS may be a 
novel protein associated with the photoreceptor ciliary axoneme, where it could 
play a role in maintenance of the photoreceptor outer segments. Furthermore, the 
analysis of the interacome of EYS has demonstrated that it may require the activity 
of AIPL1 for correct folding and trafficking, and that the functional link of EYS and 
Prominin-1 described in Drosophila is unlikely to be conserved in humans. The 
knowledge gained from the study presented herein has brought us closer to 
unravelling the molecular mechanisms underlying arRP and adds to the overall 
understanding of the physiology of the retina in health and disease.  
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Chapter 1: Introduction 
1.1 The Eye 
The eye is an organ specialised in mediating vision, one of the most 
fundamental human senses. It detects and converts light energy into electrical 
impulses that are transmitted to and processed in the visual cortex of the brain.  
The eyeball is set in a protective cavity called the orbit and it is protected by 
the eyelids that secure the anterior surface of the eyeball and contain glands 
producing lubricating tear film. Muscles are attached to the outer coat of the eye 
and control movement and coordination of the eyeballs. A network of blood 
vessels supplies nutrients and a system of nerves provides innervation to the eye 
and surrounding tissues. The eyeball is made up of three distinct layers: 1) the 
external layer, formed by the sclera and cornea; 2) the intermediate layer is the 
uvea, which is divided into an anterior part comprising of iris and ciliary body, and 
a posterior part formed by the choroid; and 3) the internal, sensory layer, known 
as the retina (Figure 1.1) (Remington, 2005). The interior of the eye is divided into 
three chambers: 1) anterior chamber that lies between the cornea and the iris; 2) 
posterior chamber, located between the iris and the lens; and 3) vitreous chamber, 
which extends from lens to the retina. The first two chambers are continuous with 
each other and are filled with the aqueous humour whereas the vitreous chamber 
is replete with the viscous vitreous humour (Kolb et al., 1995). 
The sclera is the opaque white of the eye whereas the cornea is transparent 
and it allows light to enter the eye. A black-looking aperture on the anterior of the 
eyeball is the pupil, through which light enters the eye. The intermediate layer of 
the eye comprises of the iris, ciliary body and choroid. The most anterior is the iris, 
which acts as a diaphragm regulating the amount of light entering through the 
pupil and is controlled by two iris muscles. The crystalline lens is a transparent 
body located behind the iris, in the posterior chamber. It is attached to the ciliary 
body by means of ligaments called zonule fibres. The ciliary body is continuous 
with the iris and it produces the components of the aqueous and vitreous humour 
and contains the muscle that controls the shape of the lens. As a consequence of  
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Figure 1.1 A schematic view of a horizontal section through the eyeball (Image adapted 
from http://www.ganfyd.org/index.php?title=File:Eye.png; public domain). 
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ciliary muscle action, zonule fibres are subject to contraction and relaxation that 
affect the shape of the lens. This process is called accommodation and allows a 
sharp image to be focussed on the retina (Kolb et al., 1995). 
The posterior part of the uvea is the choroid that consists of a network of 
blood vessels. It surrounds the retina and transports nutrients to the outer retinal 
layers. The retinal neural tissue is located most internally; by a complex 
biochemical process, it changes light energy into a signal that is processed in the 
retina and exits the eye via the optic nerve which then forwards the signal to the 
brain (Remington, 2005). The structure that is of interest in this study is the retina.  
1.2 The Retina 
The retina is the innermost coat of the eye located between the choroid and 
the vitreous. It has been intensively studied for many years and it is believed to be 
the best understood sensory tissue. The retina, which is composed of the neural 
retina and the retinal pigment epithelium (RPE), develops from the neural 
ectoderm and it is the outermost layer of the central nervous system. It has a 
characteristic synaptic organisation and it is a useful and relatively easily 
accessible model for studying the biology of the central nervous system (Kandel 
et al., 1991). 
1.2.1 Organisation of the Human Retina 
The vertebrate retina contains one class of non-neural cells, which are 
retinal pigment epithelium cells (RPE), and five classes of neurons, which include 
photoreceptor cells, bipolar cells, amacrine cells, horizontal cells and ganglion 
cells. The retina has a laminar structure and there can be ten layers identified 
histologically (Figure 1.2): 
 The outermost layer of the retina is the retinal pigment epithelial layer 
(RPE), to which the neural retina adheres.  
 The photoreceptor layer (PR) comprises of the outer and inner segments of 
the photoreceptor cells.  
 The outer limiting membrane (OLM) is formed of intercellular junctions 
between photoreceptor cells and between photoreceptor cells and Müller 
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cells at the level of the photoreceptor inner segments; it is not a true 
membrane but a feature distinguished on the light micrograph. 
 The outer nuclear layer (ONL) comprises of photoreceptor cell bodies 
containing the nuclei. 
 The outer plexiform layer (OPL) is formed by the synapses between 
photoreceptor cells and, bipolar cells, and horizontal cells. 
 The inner nuclear layer (INL) contains the cell bodies of the retinal 
interneurons: bipolar, horizontal and amacrine cells. 
 The inner plexiform layer (IPL) is formed by the synapses between bipolar, 
amacrine and ganglion cells. 
 The ganglion cell layer (GCL) comprises of ganglion cell bodies. 
 The nerve fibre layer (NFL) if formed of axons of ganglions cells which form 
the optic nerve exiting the eye.  
 The inner limiting membrane (ILM) forms the innermost boundary of the 
retina and is composed of extensively expanded terminations of the Müller 
cells. It is a diffusion barrier between the neural retina and the vitreous 
humour (Kaufman & Alm, 2003). 
 
In the vertebrate retina, the photons of light are captured in the 
photoreceptor cells, where they are converted into an electric impulse that is 
subsequently forwarded to the brain through a series of neurons. The retinal 
neurons form complex networks that permit extensive processing of the visual 
stimuli, which makes it possible to derive different kinds of information from the 
responses generated by photoreceptors (Kaufman & Alm, 2003).  
RPE is formed of cells that are regularly arranged in single-layered cuboidal 
epithelium that contains melanin, a black pigment responsible for absorbing any 
light not captured by photoreceptors. This mechanism prevents from the light 
being reflected back into the retina, which could cause distortion of the visual 
image. What is more, RPE cells play an important role in assisting photoreceptors 
in re-synthesis of the visual pigment and phagocytosis of outer segment tips. For 
this reason photoreceptors contact the epithelial tissue directly. It makes the light 
travel through all other layers of the retina and, therefore, these cells are 
unmyelinated and transparent (Kolb et al., 1995). 
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Figure 1.2 A schematic structure of the vertebrate retina. RPE - retinal pigment 
epithelium layer, PR -  photoreceptor cell layer, OLM - outer limiting membrane, ONL - 
outer nuclear layer, OPL – outer plexiform layer, INL – inner nuclear layer, IPL – inner 
plexiform layer, GCL – ganglion cell layer, NFL – nerve fibre layer, ILM  - inner limiting 
membrane (Image adapted from http://www.ganfyd.org/index.php?title=Retina; public 
domain). 
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1.2.2 Photoreceptor Cells 
There are two types of photoreceptor cells in the human retina, rods and 
cones. Rod photoreceptors perform best at dusk or at night in the dim light 
conditions and therefore, they mediate night vision (scotopic vision). Most stimuli 
in the dim light are too weak to excite cone cells. The cone photoreceptors function 
more effciently in bright light and mediate colour vision (photopic vision). Cones 
provide higher acuity and better resolution of rapid changes in the visual image 
(Kandel et al., 1991). Due to the differences in the tasks assigned to each type of 
photoreceptor cells, rods contain more photosensitive pigment and can be excited 
by as little as a single photon of light whereas hundreds of photons are required to 
induce a similar response in cones (Kaufman & Alm, 2003).   
Although rods outnumber cones by approximately 20 to 1, the cone system 
has better spatial resolution. Firstly, cones are densely packed in the central area 
of macula, fovea, where the visual image is least distorted. Secondly, the rod 
system is convergent which means that many rods can be connected to the same 
bipolar cell whereas every cone is synapsed to one or a few bioplar cells.  Such 
arrangment enables visual information to be pooled and reinforces signals 
received from rods. This in turn increases the ability of the brain to detect dim light 
and makes the cone system much more efficient in providing spatial resolution 
(Kandel et al., 1991). Differences between rod and cone systems are summarised 
in Table 1.1. The general structure of rods and cones is relatively similar. They are 
composed of several parts, starting nearest the RPE: (1) the outer segment, 
containing the visual pigment molecules for the conversion of ligh into a neural 
signal; (2) a connecting stalk, the connecting cilium; (3) the inner segment, 
containing the metabolic apparatus; (4) the outer fibrer; (5) the cell body and (6) 
the inner fiber which ends with a synaptic terminal (Figure 1.3).   
Rod photoreceptors are slim and rod-shaped. Their outer segments are 
made up of membranous discs stacked up on each other.  The cell membrane is 
separate from the discs except for a small region at the base where invaginations 
of the cell membrane are formed and later developed into discs. Discs are 
gradually displaced outward towards the RPE by the formation of new discs. As 
they reach the tip of the outer segment they are shed off and phagocytosed by the 
RPE cells. Disc membranes in rods are shed regularly with the majority of the 
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process occuring in the morning. The rod inner and outer segments have 
approximately the same width.  
 
Rods  Cones 
• More photopigment 
• High amplification, single photon 
detection 
• Low temporal resolution: slow 
response, long integration time 
• More sensitive to scattered light 
• High sensitivity, specialized for 
night vision 
• A single cell has around 2 µm in 
diameter and is around 100 µm 
long 
• Lower sensitivity, specialized for 
day vision 
• Less photopigment 
• Low amplification 
• High temporal resolution: fast 
response, short integration time 
• Most sensitive to direct axial rays 
• A single cell has around 4 µm in 
diameter and is around 50 µm long 
Rod system Cone system 
• Low acuity: highly convergent 
retinal pathways, not present in 
the central fovea 
• Achromatic: one type of the 
visual pigment 
• High acuity: less convergent 
retinal pathways, concentrated in 
fovea 
• Chromatic: three types of cones, 
each with different pigment 
sensitive to a different part of the 
visible spectrum 
Table 1.1 An overview of differences between rod and cone visual systems. 
 
The inner segment makes contact with the cell body by the long and narrow outer 
fiber. The inner fiber extends from the cell body and terminates with a rounded, 
pear-shaped structure called a spherule. 
Cones are shorter than rods and have a conical shape. Similarly to the rod, 
the outer segment of the cone houses disc membranes; however, these in cones are 
continuous with the cell membrane. In many cones discs located at the base of the 
outer segment are wider than those at the tip giving the characteristic conical 
shape. Cone disc membranes are also subject to periodical renewal and are most 
efficiently shed off and phagocytosed by RPE at the end of the day.  The shape of 
the inner segment also contributes to the overall morphology of the cone. It is 
wider and contains more mitchondria than the rod. The outer fiber is broad and 
short and may even be abscent in the cone. The inner fiber terminates in a broad, 
flattened structure called the pedicle (Remington, 2005).  
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Figure 1.3 A schematic view of rod and cone structure (Image adapted from Shichida & 
Matsuyama, 2009; open access journal). 
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1.2.3 Physiology of the Retina 
1.2.3.1 Phototransduction Cascade 
 
The process of converting light energy into an electric impulse is called the 
phototransduction cascade. It takes place in the photoreceptor outer segment, 
which contains the machinery to conduct this biochemical process.  
The cascade begins with absorption of a photon of light by visual pigments 
embedded on disc membranes. In humans, each type of photoreceptor cells (rods 
and three types of cones) produce visual pigments with different spectral 
sensitivity (Nathans, 1999). All of these pigments are G-protein coupled receptors 
that consist of the protein moiety, opsin, and the chromophore, 11-cis-retinal, 
which is a derivative of vitamin A covalently linked to opsin by a protonated Schiff 
base.  The human cone opsins share less than 50 % of homology with rhodopsin; 
however, they exhibit similar structure with seven-transmembrane helices. The 
other phototransduction proteins including transducin, phosphodiesterase and 
cGMP channel, also have different isoforms in rods and cones. In spite of these 
differences, the biochemical events of the visual pigment in rods and cones appear 
to be very similar (Yau & Hardie, 2009). Overview of events the phototransduction 
cascade is presented in Figure 1.4. The phototransduction cascade can be divided 
into the following stages: 
 
Activation of the Cascade 
 
In rods, absorption of the photon causes isomeric alteration of 11-cis-retinal 
which is changed to all-trans-retinal. Within milliseconds the rhodopsin molecule 
is transformed to its catalytically active state metarhodopsin II (Rh*).  Rh* begins 
to activate molecules of transducin (Gt) by catalysing GDP/GTP exchange on the Gt 
α-subunit. The active Gtα dissociates from its partnering subunits βγ and binds to 
the subunit γ of the cGMP phosphodiesterase (PDEγ). This binding removes the 
inhibition of PDEγ on the catalytic PDEαβ subunits, allowing the latter to hydrolyse 
cGMP. Moreover, once GTP has been attached to Gtα, Rh* dissociates from the 
complex and activates other transducin molecules (Yau & Hardie, 2009).  
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Figure 1.4 Overview of the events of the phototransduction pathway, from the initiation 
of the photon of light all the way through to the depolarization of the photoreceptor 
membrane (Image adapted from Shichida & Matsuyama, 2009; open access journal). 
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The resulting fall in the cGMP concentration causes the cGMP gated channels (CNG 
channels) in the cell membrane to close, leading to membrane hyperpolarization 
that reduces the rate of glutamate release onto the second-order retinal neurons. 
 
Deactivation of the Cascade 
 
For complete deactivation of the cascade, each active component of the 
cascade needs to be shut down. The active state of rhodopsin (metarhodopsin II, 
Rh*) decays over a minute into an inactive state (metarhodopsin III). However, 
before that happens, Rh* is phosphorylated by a rhodopsin kinase (also known as 
G protein-coupled-receptor-kinase 1, or GRK1), which is followed by a rapid 
binding of arrestin (Arr), which recognises phosphorylated Rh*. Phosphorylated 
rhodopsin may have some catalytic function; however, in a complex with arrestin 
it loses all activity. Eventually, rhodopsin in the free-opsin state after 
metarhodopsin III decay/hydrolysis or in the regenerated rhodopsin state loses its 
bound arrestin and goes through dephosphorylation. 
Transducin deactivates itself by intrinsic GTPase activity, which converts 
the active Gtα*-GTP to inactive Gtα*-GDP. GTPase activity is facilitated by a 
GTPase-activating-protein (GAP) complex.  In rods, this complex consists of a 
protein called regulator of G protein signalling 9 (RGS9), a RGS9-anchoring protein 
(R9AP), an orphan G protein β subunit (Gβ5) and PDEγ, which is the substrate of 
Gtα*. The requirement for PDEγ ensures that Gtα*-GTP has found and activated its 
substrate before deactivation. Once GTP has been hydrolysed, the resulting 
Gtα-GDP dissociates from PDEγ and re-associates with Gtβγ, allowing PDEγ to 
resume its inhibition of PDEαβ.  
Complete recovery from the photoresponse also requires restoration of 
cytoplasmic cGMP levels. This process is mediated by guanylate cyclase (GC), 
which is an enzyme transforming GTP to cGMP. GC is activated by guanylate 
cyclase activating proteins (GCAPs), which sense the intracellular fall in Ca2+ 
concentration. It has been shown that some dark PDE activity exists in order to 
balance activity of GC (Yau & Hardie, 2009).  
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1.2.3.2 Calcium Feedback 
 
In photoreceptors the most rapidly acting form of light adaptation is 
mediated by the level of Ca2+ cations. The light induced fall in intracellular Ca2+ 
helps to maintain intracellular levels of cGMP (Burns & Pugh, 2010). In light 
conditions, closure of the cGMP-gated channels reduces or even stops the Ca2+ 
influx, but the Ca2+ efflux continues and therefore the concentration of Ca2+ rapidly 
falls.  This decrease has three effects. The first one manifests in the increase of GC 
activity. The reason is that GC requires two activating proteins, GCAP1 and GCAP2, 
which are Ca2+ binding proteins and they are in an inactive state while Ca2+ is 
bound. In light conditions, the Ca2+ decrease disinhibits the GCAPs, thus elevating 
the GC activity to chase after the light-stimulated PDE activity, producing a 
negative feedback loop. Second, rhodopsin kinase (GRK1) is negatively modulated 
by Ca2+ binding protein called recoverin or S-modulin, so that Rh* phosphorylation 
and arrestin binding are moderately slow in dim light but accelerate when Ca2+ 
progressively decreases in brighter light. It therefore reduces the active lifetime of 
Rh* and the amplification (Yau & Hardie, 2009). The third Ca2+ dependent 
mechanism is the regulation of the sensitivity of the cGMP-gated channels by 
calmodulin-like proteins. When Ca2+ falls during the light response, calmodulin 
dissociates from the channels increasing the channel’s sensitivity to cGMP (Ridge 
et al., 2003).  
 
1.2.3.3 Visual Cycle 
 
The ability of photoreceptors to function during many hours of continuous 
illumination requires the inactivated visual pigment to be continuously 
regenerated. The process of recycling the visual pigment is called the chromophore 
or visual cycle and involves metabolic processes in the photoreceptors and retinal 
pigment epithelium (Figure 1.5).  After inactivation of rhodopsin, the Schiff base is 
hydrolysed and free all-trans-retinal is released. All-trans-retinal is shuttled from 
the disc membrane to the cytoplasm by a member of an adenosine triphosphate 
(ATP) binding cassette family, ABCR.  
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Figure 1.5 A schematic representation of the pigment cycle in human photoreceptors. hν, 
photon; RDH, retinol dehydrogenase; RPE65 - Retinoid isomerohydrolase; LRAT, 
lecithin:retinol acyl transferase ("Visual cycle" by Krishnavedala - Own work, Wikimedia 
Commons - www.commons.wikimedia.org). 
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Here, all-trans-retinal is reduced to all-trans-retinol (vitamin A) by all-trans-retinal 
dehydrogenase (RDH). All-trans-retinol can subsequently diffuse to the subretinal 
space where it is bound by the interphotoreceptor retinoid-binding protein (IRBP), 
a protein that is secreted by photoreceptors and facilitates movements of ligands 
to the apical membrane of RPE cells. When entering RPE cells, all-trans-retinol is 
bound by the cytosolic retinoid-binding protein type I (CRBP-I) and by that, it is 
delivered to lecithin:retinol acyltransferase (LRAT) for its esterification into an 
all-trans-retinyl. This ester is then immediately converted by a retinoid 
isomerohydrolase (RPE65) into 11-cis-retinol, after which 11-cis-retinol is bound 
by the cellular retinalaldehyde-binding protein (CRALBP) that enables the 
11-cis-retinol dehydrogenase (11-cis-RDH) to process the final oxidation of 11-cis-
retinol into 11-cis-retinal. Transport of 11-cis-retinal back to photoreceptors is 
stimulated by IRBP, where it can recombine with opsins and continue in the 
phototransduction (Kaufman & Alm, 2003). 
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1.3 Retinitis Pigmentosa 
Retinitis pigmentosa (RP; OMIM 268000) is a heterogeneous group of 
retinal dystrophies characterised by progressive degeneration of photoreceptor 
cells. The worldwide prevalence of the disease is variably reported in about one 
case for each 3000 to 5000 individuals and there have been about 2 million 
individuals diagnosed with RP, making it the most common inherited 
photoreceptor degeneration (Chizzolini et al., 2011).  
Clinical hallmarks of RP include night blindness (nyctalopia), pigmentary 
deposits resembling bone-spicules (initially in the periphery of the retina), 
attenuation of the retinal vessels, waxy pallor of the optic disk and patchy losses of 
peripheral vision evolving to tunnel vision. Night blindness is the first symptom; 
however, it is very often ignored until the time affected individuals begin to live 
more actively after dusk (Hamel, 2006). The disease tends to manifest in the third 
decade of life, with the quality of vision progressively deteriorating and leading to 
complete blindness, usually, by the age of 60 (Hartong et al., 2006). 
On the cellular level, RP symptoms correlate with photoreceptors 
undergoing apoptosis. In most cases, rod photoreceptor system is affected 
primarily and cone cells degenerate at a later stage of the disease as a secondary 
effect. Death of photoreceptor cells is reflected in reduced thickness of the outer 
nuclear layer (ONL), lesions and deposits of pigment in the fundus (Hamel, 2006). 
To date, mutations in 84 genes have been identified to be causative of RP 
(https://sph.uth.edu/Retnet/sum-dis.htm#A-genes; accessed on 25/06/2015) 
(Table 1.2). This genetically heterogeneous disorder is inherited in all known 
modes of inheritance, including autosomal dominant (~24 %), autosomal recessive 
(~41 %) and X-linked (~22 %). The remaining cases could result from non-genetic 
factors, non-Mendelian inheritance or complex inheritance (Wright et al., 2010).  
The majority of RP cases are inherited as a monogenic trait but the disease is 
heterogeneous both clinically and genetically. Most of the genes implicated in RP 
account for a small portion of cases with the exception of rhodopsin (RHO), which 
leads to about 20 % of dominant RP cases, USH2A gene, which might cause up to 
20 % of recessive RP, and the RPGR gene, which causes approximately 70 % of 
X-linked RP (Hartong et al., 2006).  
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Table 1.2 All genes identified to be implicated in retinitis pigmentosa (RetNet database, 
https://sph.uth.edu/Retnet/sum-dis.htm#A-genes; accessed on 25/06/2015). 
 
With regards to autosomal recessive RP (arRP), recent reports have suggested a 
global involvement of the EYS gene with the prevalence ranging from 5-23.5 % in 
different populations (e.g. Spanish, Israeli, French, Japanese), making it one of the 
major genes for arRP (Abd El-Aziz et al., 2010; Arai et al., 2015; Audo et al., 2010; 
Bandah-Rozenfeld et al., 2010; Hosono et al., 2012; Iwanami et al., 2012). 
Furthermore, a digenic form of inheritance has been reported for RP and 
the disease was  caused by a heterozygous mutation in ROM1 in combination with 
a heterozygous mutations in RDS (Kajiwara et al., 1994).  
Retinitis pigmentosa is in most cases an isolated disease; however, between 
20 to 30 % of patients have associated non-ocular symptoms. There have been 
more than 30 RP syndromes reported with the most prevalent being Usher 
syndrome and Bardet-Biedl syndrome (Hartong et al., 2006). 
Usher syndrome is inherited in a recessive manner and it is the most 
frequent syndromic form of RP associated with neurosensory deafness. The 
hearing loss may be profound (type I; USH1), moderate to mild in severity and non-
progressive (type II; USH2) or normal hearing can be present in youth and the 
gradual hearing loss can occur later in life (type III; USH3) (Millán et al., 2011). To 
Inheritance Gene
Autosomal 
dominant 
(26 genes)
BEST1,  CA4, CRX, FSCN2, GUCA1B, HK1, IMPDH1, 
KLHL7, NR2E3, NRL, OR2W3, PRPF3, PRPF4, 
PRPF6, PRPF8, PRPF31, PRPH2, RDH12, RHO, 
ROM1, RP1, RP9, RPE65, SEMA4A, SNRNP200, 
TOPORS
Autosomal recessive
(55 genes)
ABCA4, ARL6, ARL2BP , BBS1, BBS2, BEST1, C2
orf71, C8orf37, CERKL , CLRN1, CNGA1, CNGB1,
 CRB1, CYP4V2, DHDDS , DHX38, EMC1, EYS , F
AM161A , GPR125, HGSNAT , IDH3B , IFT140, IFT
172, IMPG2, KIAA1549, KIZ , LRAT , MAK , MER
TK , MVK , NEK2, NEUROD1, NR2E3, NRL , PDE6
A , PDE6B , PDE6G, PRCD , PROM1, RBP3, RGR , 
RHO , RLBP1, RP1, RP1L1, RPE65, SAG, SLC7A14
, SPATA7, TTC8, TULP1, USH2A , ZNF408, ZNF5
13
X-linked
(3 genes)
OFD1, RP2, RPGR
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date, 13 genes have been implicated in Usher syndrome (RetNet, 
https://sph.uth.edu/Retnet/home.htm). 
Bardet-Biedl syndrome (BBS) is a rare ciliopathy inherited in an autosomal 
recessive manner. It is characterised by retinal dystrophy, obesity, post-axial 
polydactyly, renal dysfunction, learning difficulties and hypogonadism. Renal 
disease is usually causative of mortality of BBS patients. Weight is very often 
within standards at birth; however, children with BBS syndrome begin to 
significantly put on weight in the first year of life.  Symptoms of RP usually develop 
in the first decade of life and most of the BBS patients are legally blind by the 
second or third decade of life (Forsythe & Beales, 2013). Twenty two genes are 
currently known to be associated with BBS (RetNet, 
https://sph.uth.edu/Retnet/home.htm).  
1.4 Eys Shut Homolog (EYS) 
 The EYS gene was independently identified at the RP25 locus by two groups 
of researchers, who had previously mapped the locus in families with arRP (Abd 
El-Aziz et al., 2008; Collin et al., 2008). Abd El-Aziz et al. reported six different 
mutations in five unrelated Spanish families, including four deletions and two 
nonsense substitutions. All of these changes were predicted to result in a 
premature stop codon leading to nonsense-mediated decay (NMD) of the resulting 
mRNA (Abd El-Aziz et al., 2008). Concurrently, Collin and co-workers, using 
homozygosity mapping, reported a nonsense mutation in three arRP siblings of an 
unrelated family and a frame-shift mutation in an isolated RP patient. Both changes 
were predicted to result in a premature termination codon and protein truncation 
(Collin et al., 2008). 
Since its discovery, EYS has emerged as a major arRP gene with the 
estimated prevalence of 11 % in British and Chinese populations (Abd El-Aziz et 
al., 2007), 12 % in French (Audo et al., 2010), 5 % in Dutch and Canadian (Littink 
et al., 2010), 7 % in Israeli (Bandah-Rozenfeld et al., 2010), 15.9 % in Spanish 
(Barragan et al., 2010), and 18-23.5 % in Japanese populations (Arai et al., 2015; 
Iwanami et al., 2012). There have been at least 150 mutations identified in EYS and 
this number is continuously growing following the publication of new high-
throughput sequencing studies of arRP families. 
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The majority of individuals carrying homozygous mutations in EYS present 
with a typical and rather severe form of arRP.  Clinically, they present with night 
blindness, bone spicule pigmentation and attenuated retinal vessels. On average, it 
has been estimated that the visual field in patients with homozygous mutations in 
EYS begins to progressively deteriorate at around 30 years of age (Bonilha et al., 
2015). Histopathological analysis of retinal tissue derived from patients carrying 
mutations in EYS, revealed advanced retinal degenerative changes with near-total 
absence of rods at the periphery of the retina and fairly well preserved perifovea 
(Bonilha et al., 2015). Interestingly, there has been a report of a Japanese 
individual diagnosed with cone-rod dystrophy caused by a compound 
heterozygous mutation in EYS, suggesting that the protein product of EYS may be 
important for the homeostasis of both rods and cones (Katagiri et al., 2014). 
EYS was described as the largest gene known to be expressed in the retina, 
spanning over 2 Mb of genomic DNA. Abd El-Aziz et al. reported EYS to be 
composed of 43 exons, of which exons 4-43 encode a protein consisting of 
3144 amino acids (Abd El-Aziz et al., 2008). The study conducted by Collin and 
co-workers revealed a similar gene structure with an additional exon between 
exon 41 and 42, making the predicted protein slightly larger with a size of 3165 
amino acids. The facultative 42nd exon comprises 63 bp and lies just prior to the 
sequence encoding the fourth LamG domain (Collin et al., 2008). 
The predicted human EYS protein consists of a signal peptide followed by 
21 epidermal growth factor (EGF)-like domains, putative coiled-coil domain and 
five Laminin G-like domains that are interspersed by further EGF-like repeats 
(Figure 1.6). Furthermore, it has been suggested that the signal peptide and its 
cleavage site consensus sequence located in the N-terminal region of EYS may 
confer a secretory character to the protein or result in an intracellular or 
cytoplasmic localisation of the mature protein (Abd El-Aziz et al., 2008; Barragan 
et al., 2010; Collin et al., 2008).  
Both groups reported EYS as the human orthologue of the Drosophila 'eyes 
shut' (eys) gene, also known as spacemaker or spam, which has been shown to act 
together with prominin in the development of the Drosophila open rhabdom visual 
system (Husain et al., 2006; Zelhof et al., 2006) (see section 1.6). 
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Figure 1.6 A schematic view of the predicted domain structure of EYS protein. EYS is 
composed of a signal peptide followed by 21 epidermal growth factor (EGF)-like domains, 
putative coiled-coil domain and five Laminin G-like domains that are interspersed by 
further EGF-like repeats. 
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Intriguingly, in the course of evolution the expression of EYS orthologues has been 
lost in the lineages of mammals including armadillo, little brown bat and ruminant 
lineages. The expression of EYS orthologues is also absent in rodent genomes, 
including the mouse, rat and guinea pig.  
By performing RT-PCR analysis and immunohistochemistry experiments, it 
has been demonstrated that EYS is specifically expressed in the retina and it 
localises to the outer segments of porcine photoreceptor cells. Based on these 
observations and the data obtained from research on the Drosophila model, it has 
been suggested that EYS may play a structural role in the human photoreceptor 
cells (Abd El-Aziz et al., 2008; Collin et al., 2008; Nie et al., 2012; Zelhof et al., 
2006). 
1.5 Prominin-1 
Mutations in PROM1 gene cause clinically heterogeneous retinal 
degeneration (MIM 604365). To date, there have been 19 mutations identified in 
PROM1 and the majority of the reported cases were diagnosed with autosomal 
recessive RP. Mutations in PROM1 can also cause autosomal recessive macular 
degeneration, autosomal recessive cone-rod dystrophy and there has been one 
mutation reported to cause autosomal dominant macular degeneration 
(Appendix A). RT-PCR analysis of PROM1 expression revealed that the gene is 
expressed in many tissues of the human body, including the retina, pancreas, 
placenta, kidney, liver, lung, brain and heart (Yu et al., 2002). Nonetheless, in spite 
of the ubiquitous expression, individuals carrying mutations in PROM1 have only 
been reported to exhibit an ocular phenotype. It has been proposed that this 
phenomenon is a result of the specific tissue distribution of Prominin-1 and its 
homolog, Prominin-2. Prominin-2 has similar topology to Prominin-1 but it is not 
present in the retina. Therefore, it has been hypothesised that rescue of the 
phenotype in tissues other than the eye comes from Prominin-2, which 
compensates for the lack or impairment of Prominin-1 (Fargeas et al., 2003). 
Prominin-1, also known as CD133, was identified in two independent 
studies as a microvilli specific protein expressed in murine neuroepithelial cells 
and as a plasma membrane marker of human hematopoietic stem and progenitor 
cells (Miraglia et al., 1997; Weigmann et al., 1997). The protein was described as a 
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cholesterol binding pentaspan membrane glycoprotein with a strong preference to 
plasma membrane protrusions. It has a unique membrane topology, containing 
five transmembrane domains, two large extracellular loops containing eight 
N-linked glycosylation sites, and a cytoplasmic tail (Figure 1.7) (Miraglia et al., 
1997; Roper et al., 2000).  
There have been at least nine different transcript variants and five 
alternative promoters identified for Prominin-1; however, only seven protein 
isoforms, ranging from 826 to 866 amino acids, seem to be produced in humans 
(Fargeas et al., 2007). This discrepancy between number of transcripts and protein 
isoforms has been suggested to arise from differences at the untranslated 
regulatory regions. In the human retina, the most abundantly expressed isoforms 
are the s11 and s12 splice variants (47% and 43% respectively) (Permanyer et al., 
2010). The functional significance of this variability is not yet fully understood; 
however, the appearance of certain variants is thought to be tissue specific (Jaszai 
et al., 2011). The differences between the seven human isoforms are presented in 
Table 1.3. 
 
Isoform 
Uniprot 
Identifier 
Length 
[aa] 
Variation 
1 (s2) O43490-1 865 canonical 
2 (s1) O43490-2 856 92-100: missing 
3 (s3) O43490-3 830 
93-101: missing 
831-839: VETIPMKNM 
→ SSWVTSVQC 
840-865: missing 
4 (s10) O43490-4 833 
93-101: missing 
839-861: missing 
5 (s7) O43490-5 825 
93-101: missing 
831-861: missing 
6 (s11) O43490-6 834 831-861: missing 
7 (s12) O43490-7 842 839-861: missing 
Table 1.3 Summary of isoforms of Prominin-1 based on data derived from the UniProt 
database (www.uniprot.org). 
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Figure 1.7 A schematic view of the predicted domain structure of Prominin-1. Prominin-1 
is composed of five transmembrane domains, two large extracellular loops containing 
eight N-linked glycosylation sites, and a cytoplasmic tail. 
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The biology of Prominin-1 has been extensively studied and it has been 
argued that Prominin-1 is a key player in maintenance of the integrity of 
photoreceptors from insects to mammals, in spite of the significant differences in 
organization of their visual organs (Jaszai et al., 2007). Supporting evidence was 
provided by Maw et al., who reported that mutations in PROM1 cause retinal 
degeneration and demonstrated that Prominin-1 localises at the base of murine 
rod outer segments and more specifically, to the protrusions of plasma membrane 
that form the new basal lamellae destined to become membranous disks (Maw et 
al., 2000).   
In another study published by Zacchigna et al. in 2009 it was reported that 
knocking out expression of the orthologue of Prominin-1 in mice causes 
progressive degeneration of photoreceptors manifested by thinning of the outer 
nuclear layer and disruption of both rods and cones. The study provided further 
evidence that Prominin-1 is likely to be involved in morphogenesis of the 
photoreceptor membranous disks (Zacchigna et al., 2009). Moreover, it has been 
shown via immunoprecipitation studies that Prominin-1 interacts with 
protocadherin 21 (PCDH21) and actin filaments; both of the interactions have been 
suggested to be critical to the disk membrane morphogenesis (Yang et al., 2008). 
Further studies performed in Xenopus laevis model demonstrated that the 
frog orthologue of Prominin-1 is present in both rods and cones. It has been shown 
that it localises to the basal disks of rod outer segments and at the outer rims of 
open disk lamellae of cone outer segments, where it may play a role in maintaining 
the structure and/or morphogenesis of the photoreceptor disk membranes  (Han 
et al., 2012). 
Interestingly, an orthologue of Prominin-1 was also found in Drosophila, 
where it was demonstrated to be essential for defining the inter-rhabdomeral 
space in the compound eye through interaction with spam, the Drosophila 
orthologue of EYS (Zelhof et al., 2006). 
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1.6 EYS and Prominin-1 as Potential Interacting Partners 
The main feature of photoreceptor cells is the presence of a specialised 
compartment, whose role is to accommodate the millions of light sensing 
molecules required for efficient photon collection. In vertebrates, the light sensing 
compartments evolved as photoreceptor outer segment membranous disks 
whereas in insects there are microvilli rhabdomeres formed of the apical 
membrane (Kolb et al., 1995). 
 Insects possess compound eyes that are formed of thousands of ommatidia 
(or facets), each of which houses photoreceptor cells and acts as a light sensing 
unit (Figure 1.8). Ommatidia can have two different inner architectures of the 
rhabdom, which is understood as all of the rhabdomeres taken together. Fruit flies 
(Drosophila melanogaster) and houseflies (Musca domestica) have an open 
rhabdom system, in which each ommatidium contains seven rhabdomeres that are 
separated from one another and function as independent light guides. In contrast, 
honey bees (Apis mellifera), various mosquitoes and beetle species have a closed 
system, in which rhabdomeres are fused together and share the same visual axis 
(Figure 1.9). During ommatidium biogenesis the apical membranes of different 
photoreceptor cells separate from one another and produce the rhabdomeric 
structure needed for housing the phototransduction cascade. The process of 
production of microvilli requires coordination of membrane-membrane adhesion 
events and, in the open system, rhabdomeres partition from each other to form the 
inter-rhabdomeral space (IRS). Separation of rhabdomeres in the open rhabdom 
system improves vision resolution and allows detection of smaller moving objects 
(reviewed in Mishra & Knust, 2013; Moses, 2006). 
 The generation of the IRS is an essential event in the transition of 
compound eyes from a closed to an open system and the molecular mechanisms 
underlying this process have been extensively studied. Investigation was carried 
out using Drosophila mutants that had no IRS but had the rhabdomeres resembling 
the closed rhabdom system. The genetic screening of these mutant flies resulted in 
identification of two genes, products of which were thought to be implicated in 
formation of the IRS.  
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Figure 1.8 A schematic view of the structure of the Drosophila compund eye. The 
compound eye is formed of thousands of ommatidia (or facets), each of which houses 
photoreceptor cells and acts as a light sensing unit. Image modified from Wikmedia 
Commons (“Ommatidie" by Nono64; https://commons.wikimedia.org/wiki/File: 
Ommatidie.JPG#/media/File:Ommatidie.JPG, Kolb et al., 1995 and (Duke-Elder, 1958).  
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Figure 1.9 A schemtaic view of a cross-section through an ommatidium with a closed 
rhabdom system and an ommatidium with an open rhabdom system. Eys and prominin 
have been suggested to be key players in the morphogenesis of the IRS and the open 
rhabdom system (image modified from Karman et al., 2012; open access journal). 
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The first identified gene was spam (or spacemaker), which was later discovered to 
be an orthologue of the human EYS. The second identified gene was prom 
(prominin), whose human orthologue is PROM1 (Husain et al., 2006; Zelhof et al., 
2006). 
In Drosophila, spam encodes a polypeptide consisting of 2,165 amino acids. 
The protein comprises seven EGF-like domains followed by a linker region with 
multiple glycosylation sites and four alternating repeats of EGF-like and LamG 
domains. Prom encodes a 910 amino acid protein named prominin (prom) which 
belongs to a family of evolutionarily conserved transmembrane proteins 
associated with microvilli, whose function has not yet been fully understood 
(Husain et al., 2006; Zelhof et al., 2006).  
It has been demonstrated that spam is a secreted extracellular protein 
specifically localising to the IRS. Furthermore, spam was shown to be expressed at 
36-64 hours after puparium formation, a window of time coincident with the 
rhabdomere biogenesis. This suggests it plays a role in the development of the 
Drosophila visual system. Similarly, prominin is also expressed during rhabdomere 
biogenesis, at approximately 48 hours after puparium formation. Prominin was 
found to decorate the entire photoreceptor apical surface; however, by the time of 
eclosion it is selectively localised to the stalk membrane and tips of the microvilli.   
 The extensive analysis of Drosophila mutant prominin and spam 
phenotypes led to a conclusion that the two proteins act together in the 
architectural organisation of the Drosophila ommatidium. It has been hypothesised 
that the secretion of spam to the IRS forces the separation of the stalk membranes 
and pushes the rhabdomeres apart, and that spam is recruited to the microvillar 
surface by the binding with prominin. The interaction of spam and prominin was 
reasoned to act against the adhesive force of chaoptin, which is a membrane 
protein responsible for crosslinking of the microvilli by means of homophilic 
interactions. The published data have demonstrated that spam, prominin and 
chaoptin orchestrate the assembly of microvilli, ensure the structural integrity and 
the partitioning of rhabdomeres, and guarantee the construction of an open 
rhabdom system (Zelhof et al., 2006).  
Since both spam and prominin have orthologues expressed in humans, 
which are implicated in retinal degeneration, it has been suggested that the 
functional interaction between Drosophila spam and prominin may be 
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evolutionary conserved and be critical to the homeostasis of the human 
photoreceptor cells. This has been addressed by further studies performed using 
Drosophila models, where it was demonstrated that the human EYS and 
Prominin-1 can function in Drosophila photoreceptors and rescue the mutant 
phenotypes. The study has provided evidence strengthening the hypothesis that 
the functional link between EYS and Prominin-1 is conserved and the authors have 
suggested that it may be required for promoting structural integrity to the 
rhabdomeres and membrane disks by preventing contacts between adjacent 
membrane protrusions (Nie et al., 2012).  
Furthermore, the hypothesis that prominin binds spam was supported by 
experiments performed in cultured cell lines. In vitro experiments performed on a 
Drosophila Shneider-2 cell line showed that when cells are transfected with spam, 
the protein is secreted into the medium. However, if the same cells are instead co-
transfected with both spam and prom, spam protein localizes selectively to the 
exterior surface of the plasma membrane. These results have indicated that 
prominin may function as a binding partner for spam (Zelhof et al., 2006). 
Interesting insights into the potential role of spam was provided by Cook et 
al., who demonstrated that spam is expressed in the Drosophila mechanosensory 
neurons, where it forms an extracellular shield that guards the cells from 
environmental insult. The hypothesis was supported by experiments performed in 
vitro, where it was demonstrated that spam decorates the external surface of the 
cell membrane surface only in the presence of prominin and it makes the cell 
membrane nearly ten times stiffer than uncoated controls; this has been shown to 
protect the cell shape in exposure to the osmotic, chemical and temperature stress 
(Cook et al., 2008).  
1.7 Protein-protein Interactions 
Sequencing of the whole genome of many organisms has been an 
accomplishment with tremendous scientific impact; nonetheless, genomic 
information alone does not explain cellular functions. Most of the biological 
processes in living organisms are controlled by proteins, which rarely act alone but 
rather function in multiprotein assemblies. A critical step towards understanding 
the complex relationships between proteins in living organisms is mapping of the 
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protein-protein interactions (PPIs), a complete map of which is referred to as the 
interactome.  Interactomic data is invaluable in studies aiming to elucidate the role 
of newly identified proteins (e.g. EYS). The function of a given protein can be 
hypothesised based on the interactions it is involved in, given that the function of 
an interacting partner has already been established (reviewed in De Las Rivas & 
Fontanillo, 2010). 
By definition, PPI implies non-random physical contact between at least 
two proteins that intentionally occurs at a specific interface and time. PPIs depend 
on many factors such as cell type, developmental stage, cell cycle stage, post-
translational modifications, external conditions etc. The protein assemblies are 
usually dynamic and they undergo a continuous turnover. The PPIs can be 
classified based on the strength of binding into transient and stable interactions. It 
needs to be noted, however, that sharing a ‘functional contact‘ does not mean that 
the two proteins directly bind each other. It can be that they function in the same 
protein complex assembly but there are intermediate interactors between them, 
which together form a more elaborate network (reviewed in De Las Rivas & 
Fontanillo, 2010; Ngounou Wetie et al., 2014). 
 Methodological approaches in interactomics are versatile and involve 
various scientific disciplines including molecular and cellular biology, genomics, 
biochemistry and biophysics. A very common experimental approach in 
researching PPIs is based on the principle compared to fishing. A known protein 
(a bait) is used in an experiment to fish out one or more interacting partners 
(preys) that are subsequently identified and validated by further experiments 
(reviewed in Ivanov et al., 2011).  
Experimental methods used to investigate PPIs can be divided into genomic 
and biochemical approaches. Genomic approaches utilise the expression of a 
reporter gene upon interaction of a bait and prey. An example of such a method is 
Yeast 2-hybrid (Y2H), which is widely used to screen cDNA libraries using a known 
bait protein. The approach is based on the possibility of separating some 
transcription factors into two domains: a DNA binding domain and a transcription 
activation domain. The conventional Y2H system was developed from the GAL4 
transcription activator, DNA binding domain of which is usually fused with a bait 
protein whereas a prey is fused with the activation domain. When interaction 
between a bait and a prey occurs, the GAL4 moieties are brought in proximity, 
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reconstituting a functional transcription factor, which in turn activates 
transcription of the reporter gene (Fields & Song, 1989) (see Materials and 
Methods, section 3.2 for more detailed description of Y2H). There have been 
several modifications of Y2H system developed, e.g. LexA repressor based Y2H or 
the MYTH system, which enables investigation of membrane proteins (reviewed in 
Brückner et al., 2009). 
 From a wide range of biochemical methods, co-immunoprecipitation is one 
of the most popular methods to identify PPIs between two or more proteins. The 
principle is based on ‘fishing’ from a cell lysate using an antibody directed against 
the protein of interest and subsequent isolation of immune complex using 
immobilised protein A or G. Such approach is usually followed by mass 
spectrometry (MS) for identification of the interacting partners. An alternative 
approach can be affinity purification (AP), which is based on purification of a 
tagged protein of interest (e.g. with His, GST or FLAG tags) followed by MS (AP-MS 
approach). AP-MS does not require the use of antibodies and it is a good 
alternative to Co-IP, especially when antibodies against a protein of interest are 
unavailable (reviewed in Ivanov et al., 2011; Ngounou Wetie et al., 2014). 
Y2H method enables screening of species and tissue specific cDNA libraries 
and it identifies binary interactions. On the other hand, Co-IP and AP-MS 
approaches are used to determine components of the multiprotein complexes, 
which not necessarily all interact directly with one another (reviewed in Brückner 
et al., 2009).  
All experimental methods currently available to investigate PPIs have 
advantages as well as disadvantages and therefore, it is important to analyse novel 
PPIs using more than one approach for confirmation and validation of the results.  
This is particularly important when, for example, investigation of a human 
protein’s interactome is carried out in simpler organisms such as yeast, whose 
protein biosynthesis machinery may differ, e.g. in terms of post-translational 
modifications. Therefore, results obtained from Y2H require validation using 
biochemical methods such as immunoprecipitation or immunofluorescence, which 
allow to investigate the potential interaction in more detail using mammalian 
systems (Ngounou Wetie et al., 2014). Examples of methods that can be used for 
the purpose of Y2H validation are summarised in Table 1.4. 
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Method Type Description 
Pull-down assay in vitro 
Tagged bait is immobilized on a resin and binds prey/s 
from lysates of eukaryotic cells or of E.coli expressing 
proteins of interest. After washing steps, prey is 
detected by SDS-PAGE/immunoblotting or Mass 
Spectrometry (MS) 
Surface plasmon 
resonance 
in vitro 
Bait immobilised on the surface of a sensor chip is 
probed by injection of prey onto the surface. Protein 
interaction is detected by the use of the change in 
refractive index at the sensor surface. After elution, 
proteins are analysed by MS. 
Co-immunoprecipitation ex  vivo 
A specific antibody is used to precipitate the bait from 
cell lysates on a pull-down assay. After washing steps, 
co-immunoprecipitated prey is detected by SDS-
PAGE/immunoblotting and MS 
In situ hybridization in situ 
Hybridization of a labelled complementary DNA or 
RNA strand (i.e. probe) to a specific DNA or RNA 
sequence in a tissue section. Visualises expression of 
specific genes to evaluate potential co-expression of 
proteins of interest in the same cell of a given tissue. 
 
Immunohistochemistry, 
immunocytochemistry 
in situ 
Proteins in fixed cells or tissue sections are detected 
by immuno-labelling with fluorescently tagged 
antibodies, e.g. using confocal microscopy. Visualises 
co-expression of proteins of interest in the same cell 
and potential subcellular co-localization. 
Fluorescent detection in 
live cells 
in vivo 
Proteins in living cells are detected with fluorescently 
tagged antibodies or they are expressed with 
fluorescent tags. Visualises co-localization of proteins 
of interest. 
Fluorescence resonance 
energy transfer (FRET) 
in vivo 
Bait and prey are fused to two different fluorescent 
tags with overlapping emission/excitation spectra. If 
both proteins are in close proximity, excitation of the 
first fluorophore (donor) leads to energy transfer to 
the second fluorophore (acceptor). Acceptor 
fluorescence can be observed in vitro (fluorimeter) or 
in living cells (confocal microscopy). 
Bioluminescencer 
resonance 
energy transfer (BRET) 
in vivo 
Similar to FRET, but with bait fused to bioluminescent 
luciferase, thus avoiding the external excitation step 
susceptible to generate background. Detection as with 
FRET. 
Table 1.4 Overview of methods that can be used to validate the results obtained from Y2H 
(adapted from Brückner et al., 2009). 
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1.8 Aims and Objectives 
 
The aim of this project is to investigate the molecular mechanisms 
underlying the phenotype of arRP associated with mutations in EYS. EYS is a major 
gene implicated in arRP; however, the function of the protein it encodes has not yet 
been fully understood.  
The EYS protein has been found to localise to the photoreceptor outer 
segments of the porcine retina and it has been suggested that it may play a 
structural role (Abd El-Aziz et al., 2008). Studies conducted in Drosophila have 
demonstrated that the Drosophila orthologue of EYS is a key player in the 
organisation of the open rhabdom system in the Drosophila ommatidium, where it 
interacts with prominin during the biogenesis of the inter-rhabdomeral space 
formation (Zelhof et al., 2006). Furthermore, in the Drosophila mechanosensory 
neurons, EYS has been shown to provide protection from environmental stress by 
stiffening the cell membrane (Cook et al., 2008).  
 Taken together data from the previous studies, it can be hypothesised that 
EYS is likely to be a structural protein which is necessary for stability of human 
photoreceptors and that it may be involved in morphogenesis of the photoreceptor 
outer segments via the interaction with Prominin-1.  
The approach undertaken in this study will be to identify and characterise 
novel retinal interacting partners of EYS, which will be achieved by performing 
Yeast 2-hybrid screening against a human retinal cDNA library. This will be 
followed by in-depth analysis and validation of the identified interactions. 
Moreover, the putative interaction of EYS and Prominin-1 will be investigated in 
detail to verify whether it may be conserved in humans. Since mutations in human 
PROM1 have been shown to be causative of retinal dystrophies, a cohort of 96 
unrelated arRP patients will also be screened for novel mutations. Identified 
mutations may be used in the part of the project devoted to investigation of 
potential interaction of EYS and Prominin-1. 
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Chapter 2: Materials and Methods 
2.1 General Methods 
2.1.1 DNA Techniques 
2.1.1.1 Polymerase Chain Reaction (PCR) 
 
PCRs were carried out at several stages of the project, using two different 
polymerases depending on the purpose: MangoTaq DNA Polymerase (Bioline, UK) 
and KOD polymerase (Toyobo Novagen, Japan). Optimal annealing temperatures 
were established for each primer pair using control DNA.  A negative control 
including no DNA template was included in every run to check for contamination 
of reagents. Conditions of reaction were polymerase specific and are summarised 
in Table 2.1. 
Unless otherwise stated, PCR primers were designed using the relevant 
reference sequences, avoiding areas of high GC content and repeats. Primers were 
designed to be 18-28 nucleotides in length, with GC content between 50-60 %. 
Temperatures of annealing (Tm) were desired to be within a range of 50-65 ˚C.  
Specific primers used in the study will be described in the following, 
corresponding subsections. 
2.1.1.2 Agarose Gel Electrophoresis 
 
DNA molecules were separated on 1 % agarose gels for the purpose of 
visualisation, quantification or for subsequent gel extraction. Agarose gel was 
prepared by dissolving agarose powder in TAE buffer, to which GelRed Nucleic 
Acid Gel Stain (10 000X) was added. The solution was poured onto a sealed casting 
plate with a comb and allowed to set. Samples (0.5 – 5.0 μl) were loaded on the gel 
and run at 80-150 V until desired separation was achieved. For PCR products 
amplified with KOD polymerase, 1X DNA loading dye (Bioline, UK) was added for 
visualisation. For fragments amplified with MangoTaq it was not necessary since 
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the reaction buffer is pre-stained. Separated DNA was visualised on a UV 
transilluminator (UVP). 
 
Reagent MangoTaq KOD 
MangoTaq Reaction buffer 3 µl  - 
KOD polymerase buffer  - 2.5 µl 
50 mM MgCl2 0.45  µl  
25 mM MgSO4  - 1.5 µl (2.5 µl for baits 7 and full length) 
100 mM dNTP Mix 0.15  µl 2.5 µl (5 µl for baits 7 and full length) 
Template DNA 1  µl 1 µl 
10 mM forward primer 0.4  µl 0.75 µl 
10 mM reverse primer 0.4  µl 0.75 µl 
MangoTaq Polymerase 0.1  µl  - 
KOD polymerase  - 0.5µl 
DMSO  - 2.5 µl (used where required) 
Water (ddH2O) 9.5  µl 15.5 µl (9.5 µl for baits 7 and full length) 
TOTAL VOLUME 15  µl 25 µl 
Step MangoTaq KOD 
Initial denaturation 96 ˚C, 5' 95 ˚C, 2' 
Number of cycles 35 35 
Denaturation 96 ˚C, 30'' 95 ˚C, 20'' 
Annealing as optimized, 30'' as optimized, 10'' 
Elongation 72 ˚C, 30'' 70 ˚C, 25'' per 1 kb 
Final elongation 72 ˚C, 5' 70 ˚C, 60'' per 1 kb 
Final hold 4 ˚C,∞ 4 ˚C,∞ 
Table 2.1 The summary of PCR conditions used throughout the project. 
 
2.1.1.3 DNA Purification 
 
Three different methods were used to purify DNA, depending on the purpose of 
further experiments: 
 
1. For the purpose of sequencing: The ExoSAP-IT reagent (Affymetrix, USA) 
was used to remove excess dNTPs and primers that were not consumed in 
PCRs. The Exo-SAP-IT reagent includes two hydrolytic enzymes, 
Exonuclease I and Shrimp Alkaline Phosphatase. The Exonuclase I degrades 
residual primers and any other single-stranded DNA produced by PCR. The 
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Shrimp Alkaline Phosphatase hydrolyses dNTPs unused in the reaction that 
could interfere with the sequencing reaction. The clean-up reaction was 
optimized according to manufacturer’s recommendations and comprised of 
1-2 μl of PCR product, 0.5 μl of ExoSAP-IT and double-distilled water 
(ddH20) added to a final volume of 15 μl. Reactions were carried out for 
15 minutes at 37 °C and were followed by a 15 minute incubation period at 
80 °C to inactivate both enzymes.  
 
2. For the purpose of cloning and from agarose gel: PCR fragments were 
cleaned using the Wizard®SV Gel and PCR Clean-Up System (Promega, UK). 
A slice of excised gel containing DNA was placed in a 1.5 ml microcentrifuge 
tube and the Membrane Binding Solution was added (10 μl per 10 mg of 
gel). Tube was vortexed and incubated at 50-65 ˚C until the gel slice was 
completely dissolved. For PCR product processing, an equal volume of the 
Membrane Binding Solution was added to the reaction volume and mixed 
gently. Dissolved gel mixture or prepared PCR product were placed onto the 
Minicolumn assembly, incubated for 1 minute and centrifuged at 
14 000 rpm for 1 minute. The collection tube was emptied and 700 μl of 
Membrane Wash Solution, previously diluted with absolute ethanol, was 
added onto the membrane. This step was followed by centrifugation at 
14 000 rpm for 1 minute. The flow-through was discarded and the 
membrane was washed using 500 μl of Membrane Wash Solution. The 
column assembly was centrifuged at 14 000 rpm for 5 minutes and 
afterwards, the flow-through was discarded and the column was re-
centrifuged for 1 minute with the microcentrifuge lid open to allow 
evaporation of residual ethanol. The column was later transferred to a clean 
1.5 ml microcentrifuge tube. For elution of DNA, 50 μl of ultra-pure water 
was dropped on the membrane and allowed to stand at room temperature 
for 1 minute. This step was followed by final centrifugation at 14 000 rpm 
for 1 minute. The column was discarded and eluted DNA stored at 4 ˚C or at 
-20 ˚C (long term storage). 
 
3. From Escherichia coli:  A single colony of transformed E.coli was grown 
overnight at 37 ˚C in 5 ml of LB medium supplemented with the relevant 
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antibiotic for selection. Plasmid DNA was extracted from bacterial cells 
using the PureYield™ Plasmid Miniprep System (Promega, UK). Overnight 
bacterial culture (600 μl) was transferred to a 1.5 ml microcentrifuge and 
lysed by inverting with 100 μl of Cell Lysis Buffer. Cold Neutralisation 
Solution (350 μl) was then added to the tube and mixed thoroughly by 
invertion. This step was followed by centrifugation at 14 000 rpm for 
3 minutes. Supernatant was transferred onto a PureYield™ Minicolumn, 
caring not to disturb the cell debris pellet. The Minicolumn was then placed 
on a collection tube and centrifuged at 14 000 rpm for 15 seconds. The 
flow-through was discarded and 200 μl of Endotoxin Removal Wash (ERB) 
was added to the assembly and then centrifuged at 14 000 rpm for 
15 seconds. After removing the flow-through, 400 μl of Wash Buffer was 
added and the column was again centrifuged at 14 000 rpm for 30 seconds. 
The washed column was subsequently placed in the fresh 1.5 ml 
microcentrifuge tube and eluted using 30 μl of ultra-pure water. The 
column was allowed to stand at room temperature for 1 minute. This step 
was followed by final centrifugation at 14 000 rpm for 15 seconds to elute 
plasmid DNA. Concentration of obtained samples was checked on the 
spectrophotometer (NanoDrop) and they were stored at 4 ˚C or at -20 ˚C 
(long term storage). Plasmid DNA isolated with this method was used 
directly for sequencing and cloning. 
 
4. From Saccharomyces cerevisiae  
Plasmid DNA was isolated from yeast cells using Easy Yeast Plasmid 
Isolation Kit (Clontech, USA). To isolate plasmid DNA from yeast cells, it is 
first necessary to disrupt the cell wall, which is achieved by enzymatic 
treatment using Zymolyase (component of the kit).  Fresh patches of 
transformed yeast (approximately 1 cm x 1 cm) were prepared each time 
prior to plasmid isolation and colonies no older than 3 days were used. Half 
of the patch was collected using a sterile inoculation loop and re-suspended 
in a 1.5 ml microcentrifuge tube containing 500 µl of the supplied 10 mM 
EDTA. The cells were then pelleted by centrifugation at 14 000 rpm for 
1 minute and the supernatant was removed. The cell pellets were carefully 
re-suspended in 200 µl of ZYM buffer and 20 µl of the Zymolyase were 
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added. Samples were mixed by inverting the tubes 2-3 times to ensure a 
uniform suspension of Zymolyase and incubated with gentle shaking at 
30 ˚C for 1 hour. Afterwards, the spheroplasts were pelleted by 
centrifugation at 4000 rpm for 1 minute and the supernatant was 
discarded. To lyse the spheroplasts, the pellets were re-suspended in 250 µl 
of Y1 Buffer/RNase A solution. Then, 250 µl of Y2 Lysis buffer were added 
and the tubes were gently mixed by inverting 6-8 times and incubated at 
room temperature for the maximum of 5 minutes. Following this, 300 µl of 
Y3 Neutralisation buffer were added and the solution was again mixed 
gently by inverting the tubes 6-8 times. This step was followed by 
centrifugation at 14 000 rpm for 5 minutes at room temperature. The 
supernatant was transferred to a fresh tube and the centrifugation was 
repeated. A Yeast Plasmid Spin Column was placed inside a 2 ml collection 
tube and the supernatant obtained in the previous step was loaded. The 
columns were centrifuged at 14 000 rpm for 1 minute and the flow-through 
was discarded. Then 450 µl of Y4 Wash Buffer were added and the columns 
were centrifuged at 14 000 rpm for 3 minutes. The flow-through was 
removed and the centrifugation step was repeated to completely remove 
any residual Wash Buffer. To elute plasmid DNA, the columns were placed 
inside sterile 1.5 ml microcentrifuge tubes and 50 µl of YE Elution Buffer 
was applied to the columns. This step was followed by 1 minute incubation 
at room temperature. The final centrifugation was carried out at 
14 000 rpm for 1 minute and the concentration of eluted plasmid DNA was 
assessed using the NanoDrop. Samples were stored at 4 ˚C. 
2.1.1.4 DNA Sequencing 
 
DNA sequencing was performed using a BigDyeTM Terminator v3.1 Cycle 
Sequencing Kit (Applied Biosystems, UK) and ABI PRISM® 3100 Genetic Analyzer. 
DNA samples (5-20 ng) were mixed with 1X BigDyeTM v3.1 Cycle ready mix 
(containing ddNTPs, dNTPs, Amplitaq® DNA polymerase, pyrophosphatase and 
MgCl2), 1X BigDyeTM Sequencing Buffer, primer and dH2O. The reaction mix and 
temperature cycling profile are summarised in Table 2.2. 
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In case of exon 25 of PROM1, which is flanked by poly-T tracks, it was 
necessary to supplement the reaction mix with a Hairpin DNA & GC Rich 
Sequencing Premix For BigDye™ 3.1. The reaction mix used is summarised in Table 
2.3. 
 
Reagent Volume 
BigDye ready mix 0.5 μl 
Sequencing buffer 2.5 μl 
Primer  0.5 μl 
Template DNA 1-5 μl 
dH20 11.5-15.5 μl 
Total volume 20μl 
Step Conditions 
Initial 
denaturation 
96 ˚C, 3' 
Number of cycles 25 
Denaturation 96 ˚C, 30'' 
Annealing 50 ˚C, 30'' 
Elongation 60 ˚C, 4' 
Final hold 4 ˚C,∞ 
Table 2.2  Sequencing reaction mix and temperature cycling profile. 
 
 
Reagent Volume 
BigDye ready mix 0.5 μl 
Hairpin DNA Sequencing Premix  4 μl 
Primer  0.5 μl 
Template DNA 1-5 μl 
dH20 up to 10 μl  
Total volume 10 μl 
Table 2.3 Sequencing reaction for GC rich regions of DNA. 
 
Sequencing reactions were purified using Sephadex® G-50 powder (Sigma-
Aldrich, UK). Samples were transferred to the pre-washed Sephadex® G-50 Plate 
and cleaned by centrifugation of the plate at 910 rpm for 5 minutes; the cleaned 
PCR product was eluted into a clean 96-well plate, leaving any impurities in the 
Sephadex® gel.  
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2.1.1.5 Cloning 
Cloning was performed at several stages of the project and two cloning 
system were utilised. First was based in ligation of the DNA fragments and the 
second was based on a recombination reaction between the compatible DNA 
sequences (Gateway system). 
 
Cloning via Ligation 
 
PCR products were prepared using primers containing a desired restriction 
site. The PCR products were purified using Wizard®SV Gel and PCR Clean-Up 
System (Promega, UK). Next, restriction enzyme digests were performed on the 
amplified insert and the desired vector, using approximately 1-5 μg of DNA per 
digest. The reactions were set using 1-2 units of a restriction enzyme, 1X of a 
corresponding restriction buffer and sterile water added to the total volume of 
40 µl. The reactions were then incubated at a temperature indicated by the 
manufacturer of an enzyme for at least one hour per enzyme.  
PCR insert fragments were cloned into the linearized vectors using the 
LigaFast Rapid DNA Ligation System (Promega, UK), according to the 
manufacturer’s instructions. The recommended ratio of vector:insert was 1:2 and 
each reaction contained 3 units of T4 DNA Ligase, 2X Rapid Ligation Buffer and 
sterile water in the final volume of 10 μl. The reaction mix was incubated at room 
temperature for 2 hours and transformed into competent bacterial cells.   
 
Gateway Cloning 
 
The Gateway® Cloning Technology (Invitrogen, UK) is based on the 
bacteriophage-lambda site specific recombination system, which facilitates 
integration of the phage into Escherichia coli chromosome and switch between the 
lytic and lysogenic pathways. Lambda recombination occurs between site-specific 
attachment sites (att) (attB on E.coli chromosome and attP on the lambda 
chromosome) which serve as binding sites for recombination proteins.  Upon 
integration, recombination occurs between attB and attP sites to give rise to attL 
and attR sites. The lysogenic pathway is catalysed by the bacteriophage λ Integrase 
(Int) and E. coli Integration Host Factor (IHF) proteins (in Gateway: BP Clonase™ 
Materials and Methods 
62 
 
enzyme mix catalysing BP reaction). The lytic pathway is catalysed by the 
bacteriophage λ Int and Excisionase (Xis) proteins, and the E. coli Integration Host 
Factor (IHF) protein (in Gateway: LR Clonase™ enzyme mix catalysing LR 
reaction).  
In Gateway Technology, wild-type λ att recombination sites were modified 
to improve the efficiency and specificity of recombination reactions. Importantly, 
BP and LR reactions are conservative which means there is no gain or loss of 
nucleotides. It is also of prominent advantage that recombination can occur 
between DNAs of any topology (i.e. supercoiled, linear or relaxed), however the 
efficiency may vary. Schematic view of BP and LR reactions is depicted in Figure 
2.1 and the recombination reactions are described as follows: 
 
• BP Reaction: Facilitates recombination of an attB substrate (attB-PCR product 
or a linearized attB expression clone) with an attP substrate (donor vector) to 
create an attL-containing entry clone. This reaction is catalysed by BP Clonase™ 
enzyme mix. 
 
• LR Reaction: Facilitates recombination of an attL substrate (entry clone) with an 
attR substrate (destination vector) to create an attB-containing expression clone. 
This reaction is catalysed by LR Clonase™ enzyme mix. 
 
Presence of the ccdB gene in Gateway® vectors allows negative selection 
after transformation into E.coli. The CcdB protein interferes with E.coli gyrase and 
by that it inhibits growth of transformed bacteria. However, when recombination 
occurs, the ccdB gene is replaced by the gene of interest. Cells which take in non-
recombined vectors carrying the ccdB gene or by-product molecules retaining the 
ccdB gene, will fail to grow. 
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Figure 2.1 Schematic view of BP and LR recombination reactions (Image adapted from 
The Gateway® Technology Manual, 2010). 
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For the purpose of cloning, PCR fragments flanked by attB sites were 
generated by the use of attB primers and amplification with KOD polymerase. 
AttB-PCR products were purified using the Wizard®SV Gel and PCR Clean-Up 
System (Promega, UK). The purified PCRs were subsequently used for the BP 
reaction with pDONR-Zeo vector to generate the entry clones. The reaction mix is 
shown in Table 2.4. BP reaction mix was incubated at 25 ˚C for 1 hour and 
afterwards, terminated by addition of 1 μl proteinase K and incubation at 37 ˚C for 
10 minutes. The reaction mix was then used for transformation of competent 
E.coli, strain DH5α (section 3.3.3). Transformed bacteria were plated on LB agar 
media supplemented with zeocin (40 μg/ml).    
 
Reagent Amount 
attB-PCR 75 ng 
pDONR-Zeo vecor 75 ng 
BP Clonase™ mix II 1 μl 
TE buffer (pH 8) up to 5 μl 
Table 2.4 BP recombination reaction mix. 
 
Isolated and sequenced entry clones were subsequently used for the LR 
reaction with the relevant destination vectors to generate expression clones.  The 
reaction mix is summarized in Table 2.5 and the reaction conditions were exactly 
the same as the BP reaction. 
 
Ragent Amount 
pDONR-zeo/'bait' 75 ng 
Destination vector 75 ng 
LR Clonase™ mix II 1 μl 
TE buffer (pH 8) up to 5 μl 
Table 2.5 LR recombination reaction mix. 
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2.1.1.6 Bacterial Transformation 
 
In the project, two strains of competent E.coli cells were used: DH5α 
(Invitrogen, UK) and JM109 (Promega, UK) and the transformation was performed 
using an identical protocol.  
The competent cells were thawed on ice and aliquoted (50-150 μl per 
transformation) into pre-chilled 1.5 ml microcentrifuge tubes. A range of 1-10 ng 
of plasmid DNA was used per transformation. DNA was added to the competent 
cells, gently mixed and incubated on ice for 30 minutes.  Afterwards, samples were 
incubated at 42 ˚C for 45 seconds (heat-shock) and then immediately cooled on ice 
for 2 minutes. Cells were subsequently mixed with 900 μl of SOC medium 
(Invitrogen, UK) and incubated at 37 ˚C for an hour with shaking at 225 rpm.  This 
step was followed by centrifugation at 10 000 rpm for 3 minutes. Supernatant was 
removed and the cell pellet was re-suspended in 100-200 μl of the LB medium. 
Transformed bacteria were spread on LB agar plates supplemented with the 
relevant antibiotic and incubated at 37 ˚C for 18-20 hours. On the next day, single 
colonies were picked and grown in LB-broth supplemented with the relevant 
antibiotic for 18-20 hours at 37 °C with shaking at 225 rpm. For long term storage, 
30 % glycerol stocks were prepared and if needed, the plasmid DNA was isolated 
and subjected to further analysis. The antibiotics used in the project are 
summarised in Table 2.6.  
 
 
 
Table 2.6 Summary of antibiotics used in the study. 
  
Antibiotic Final Concentration
Ampicilin (Amp) 100 µg/ml
Chloramphenicol (Cam) 170 µg/ml
Kanamycin (Kan) 100 µg/ml
Zeocin (Zeo) 40 µg/ml
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2.1.2 RNA Techniques 
2.1.2.1 Isolation of RNA from Cell Lines 
 
In the project, RNA was isolated from mammalian cell lines using PureLink 
RNA Mini Kit (Life Technologies, UK) and the manufacturer’s protocol was 
followed. The RNA extrication was carried out at the room temperature in an area 
cleaned with RNase removing detergents and RNase free tubes and pipette tips 
were used. Fresh amount of Lysis Buffer was prepared by adding 1 % 
2-mercaptoethanol before each purification procedure.  
For each of the isolations, 1x107 cells were used and the cells were prepared 
depending on whether they grow in suspension or as a monolayer. In case of 
suspension cells, the relevant volume of the culture was transferred to an RNase 
free tube and centrifuged at 350 rpm for 10 minutes at 4 ˚C. The supernatant was 
discarded and the cells were rinsed with sterile PBS and centrifuged again at 
350 rpm for 10 minutes at 4 ˚C. The PBS wash was repeated once. Following the 
last wash, the cell pellet was re-suspended in 1.2 ml of Lysis Buffer containing 
2-mercaptoethanol. 
For the monolayer of cells, the culture dishes were washed twice with PBS 
and the Lysis Buffer containing 2-mercaptoethanol was added. The cells were 
scraped off the culture dish and transferred to a 1.5 ml tube. 
The tubes were then vortexed at high speed until the cell pellet was 
completely dispersed. The lysate was passed 5-10 times through an 18-gauge 
needle attached to a 2 ml syringe.  Next, one volume of 70 % ethanol was added to 
each volume of cell homogenates. The tubes were vortexed thoroughly until any 
visible precipitate was dispersed. Then, the spin cartridge was assembled by 
placing the spin column in a collection tube and 700 µl of the sample were 
transferred to the spin column. The cartridges were then centrifuged at 
14 000 rpm for 15 seconds at room temperature and the flow-through was 
removed. The two last steps were repeated until the entire sample was processed. 
Afterwards, 700 µl of Wash Buffer I was added to each of the columns which were 
then centrifuged at 14 000 rpm for 15 seconds at room temperature. The flow-
through was discarded and the spin columns were placed into new collection 
tubes. The next wash was performed with 500 µl of Wash Buffer II and the 
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cartridges were centrifuged at 14 000 rpm for 15 seconds at room temperature. 
The wash with Wash Buffer II was repeated once. The flow-through was discarded 
after each wash and then, the cartridge was centrifuged at 14 000 rpm for 2 
minutes at room temperature to dry the membrane with attached RNA. Following 
this, the collection tube was discarded and the column was placed into a fresh 
RNase free 1.5 ml tube. To elute RNA, 50 µl of RNase free water were added to the 
centre of the membrane and the column was incubated for 1 minute at room 
temperature and then centrifuged at 14 000 rpm for 15 seconds at room 
temperature. The eluted RNA was stored at -80 ˚C. 
2.1.2.2 cDNA Synthesis via Reverse Transcription PCR (RT-PCR) 
 
cDNA was synthesised using RNA isolated from cell lines available in the 
laboratory as well as a commercially available panel of RNA samples isolated from 
human tissues (Clontech, USA). In the project, QuantiTect Reverse Transcription 
Kit (Qiagen, The Netherlands) was used and the manufacturer’s protocol was 
followed. 
The first step was to purify the RNA samples by setting up a genomic DNA 
elimination reaction with gDNA Wipe-out Buffer. The reaction mix is summarised 
in Table 2.7.  The samples were incubated for 2 minutes at 42 ˚C and then 
immediately placed on ice.  
In the next step, the reverse transcription reaction was set up following the 
recipe shown in Table 2.8. The RNA template was added as the last component and 
the samples were incubated for 15 minutes at 42 ˚C. To inactivate the Quantiscript 
Reverse Transcriptase, the samples were incubated for 3 minutes at 90 ˚C. The 
samples were immediately used for further experiments or stored at -20 ˚C.  
 
 
Component Volume 
gDNA Wipeout Buffer, 7X 2 µl 
Template RNA, 1 µg variable 
RNase free water variable 
TOTAL 14 µl 
Table 2.7 Summary of a genomic DNA elimination reaction mix. 
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Component Volume 
Quantiscript Reverse Transcriptase 1 µl 
Quantiscript RT Buffer, 5X 4 µl 
RT Primer Mix 1 µl 
Template RNA (entire gDNA elimination reaction) 14 µl 
TOTAL 20 µl 
Table 2.8 Summary of components of reverse-transcription reaction. 
 
2.1.3 Protein Techniques 
2.1.3.1 Preparation of Protein Extracts from Mammalian Cells 
 
Protein extracts were prepared from both suspension and monolayer cell 
lines. In the project, proteins were extracted on many occasions from both 
transfected and wild type cell lines. The optimised extraction protocol was uniform 
for all of the applications except the initial stages.  
In case of suspension cell lines, the relevant volume of the culture was 
transferred to the test tube and centrifuged at 350 rpm for 10 minutes at room 
temperature. The supernatant was aspirated and the cell pellet was re-suspended 
in sterile PBS and centrifuged again at 350 rpm for 10 minutes at room 
temperature. The supernatant was discarded and the pelleted cells were 
re-suspended in the cell lysis buffer.  
For cells growing as a monolayer, the culture media was aspirated and the 
cells were rinsed twice with sterile PBS. The cells were then scraped off the dish in 
PBS and transferred to a test tube. The tubes were centrifuged at 1000 rpm for 10 
minutes at 4 ˚C, the supernatant was discarded and the pellet was re-suspended in 
the cell lysis buffer. 
Prior to each extraction, the cell lysis buffer was supplemented with the 
mixture of protease inhibitors (ProeaseArrest 100X, Gbiosciences, USA) and 1 ml 
of the lysis buffer was used for approximately 5x107 of cells. The tubes were placed 
on a tube rotator and mixed at 4 ˚C for 30 minutes. The homogenates were then 
passed through a 21-gauge needle attached to a 2 ml syringe and centrifuged at 
14000 rpm for 15 minutes at 4 ˚C. The supernatants containing the total protein 
extracts were collected and subjected to further analysis or stored at -80 ˚C. 
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2.1.3.2 Preparation of Protein Extracts from Yeast Cells 
 
Preparation of yeast culture for protein extraction 
 
Protein extracts were prepared from liquid yeast cultures. Transformed 
yeast strains were cultured in appropriate liquid SDO selective media to keep 
selective pressure on the plasmid, whereas untransformed yeast strains were 
cultured in liquid YPDA medium. The growth rates differ between yeast strains 
and they may be affected by the presence of fusion proteins in certain 
transformants. Generally, the doubling time of most strains growing in SDO media 
is twice as long as in YPDA. In order to prepare a culture of a desired yeast strain, 
1 colony (not older than 4 days) was inoculated in 5 ml of relevant media and 
incubated overnight at 30 ˚C with shaking (220-250 rpm). The next day, the 
cultures were centrifuged at 1200 rpm for 5 minutes and the media was removed. 
The pellets were re-suspended in 10 ml of YPDA and incubated for 3-5 hours at 
30 ˚C with shaking (220-250 rpm) to obtain the mid-log phase cultures 
(OD600=0.4-0.6). Next, the cultures were pelleted at 1200 rpm for 5 minutes at 
4 ˚C and the supernatants were discarded. The pellets were washed twice with ice-
cold water, centrifuged as before and frozen at -70 ˚C or kept on ice if extractions 
were to be performed immediately after. 
 
SDS/Urea Method 
 
Complete cracking buffer was prepared just prior to protein extraction and 
pre-warmed to 60 ˚C; 100 μl of cracking buffer was used per 7.5 OD600 
(6x108 cells/ml) of yeast cells. Previously prepared cell pellets were thawed by 
re-suspending in warm cracking buffer. The initial excess of PMSF in the cracking 
buffer degrades quickly and therefore, an additional aliquot (4.5 μl per 7.5 OD600 of 
cells) was added after 15 minutes and approximately every 7 minutes thereafter 
until the process was complete and extracts were ready to be frozen. Cell 
suspensions were transferred to 1.5 ml microcentrifuge tubes, containing 80 μl 
glass beads (425-600 μm) per 7.5 OD600 of yeast cells and incubated at 70 ˚C for 
10 minutes. After incubation, samples were vigorously vortexed for 1 minute and 
centrifuged at 14 000 rpm for 5 minutes at 4 ˚C. The supernatant was transferred 
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to a fresh 1.5 ml microcentrifuge tube and placed on ice (first supernatant).  Pellets 
were then boiled in a water bath for 5 minutes, vortexed vigorously for 1 minute 
and centrifuged at 14 000 rpm for 5 minutes at 4 ˚C. The second supernatant was 
combined with the first one. Prepared samples were subsequently briefly boiled 
and immediately used for SDS-PAGE or, frozen on dry ice and stored at -80 ˚C.  
 
TCA Method 
 
 TCA buffer and TCA-Laemmli loading buffer were prepared just prior to 
use. Cell pellets were thawed on ice for 10-20 minutes, re-suspended in ice-cold 
TCA buffer (100 μl per 7.5 OD600 of yeast cells) and placed on ice. Cell suspensions 
were transferred to fresh 1.5 ml microcentrifuge tubes containing glass beads 
(425-600 μm) and ice-cold 20 % TCA buffer. A mixture of 100 μl of glass beads and 
100 μl of ice-cold 20 % TCA buffer were used per 7.5 OD600 of yeast cells. To 
disrupt the cell wall, samples were vigorously vortexed for 10 minutes at 4 ˚C. 
Supernatant was then transferred to fresh 1.5 ml microcentrifuge tubes (first 
supernatant) and placed on ice. Afterwards, glass beads were washed with 500 μl 
of an ice-cold 1:1 mixture of 20 % TCA and TCA buffer and vortexed at 4 ˚C for 
5 minutes. Any liquid from above the glass beads (second supernatant) was 
combined with the first supernatant. Tubes were kept on ice to allow any carry-
over glass beads to settle and then supernatants were transferred to fresh 1.5 ml 
microcentrifuge tubes. Proteins were pelleted by centrifugation at 14 000 rpm for 
10 minutes at 4 ˚C. Supernatants were discarded and pellets re-suspended in TCA-
Laemmli buffer (10 μl of buffer per 1 OD600 of cells). Tubes were subsequently 
placed in a water bath at 100 ˚C for 10 minutes. After boiling, samples were 
centrifuged at 14 000 rpm for 10 minutes at room temperature. Supernatants were 
collected in 1.5 ml microcentrifuge tubes and immediately used for SDS-PAGE or 
frozen on dry-ice and stored at -80 ˚C.  
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Y-PER Plus Based Method 
 
Y-Per Plus reagent (Thermo Scientific, USA) uses a mild detergent 
formulation for protein extraction and the procedure is carried out at room 
temperature. Prior to extraction, a desired volume of Y-Per was supplemented 
with DTT to final concentration of 0.1 M and 100X ProteaseArrest mix 
(G-Biosciences, USA). Pellets of yeast cells were weighed and 2.5 ml of the lysis 
buffer were used per 1 g of cell paste. The pellets were re-suspended in the buffer 
until the mixture was homogenous. The samples were then placed on a rotary 
shaker for 20 minutes at room temperature. Afterwards cell debris were collected 
by centrifugation at 14 000 rpm for 5 minutes and the supernatant were subjected 
to further analysis. 
 
2.1.3.3 Bicinchoninic acid assay (BCA assay) 
 
The concentration of protein in total cell lysates was assessed by 
performing BCA assay after each extraction. The BCA assay is based on a biuret 
reaction, in which bivalent copper ions are reduced to monovalent ions in the 
presence of protein in an alkaline solution. The monovalent copper ions chelate 
with bicinchoninic acid, a chromogenic reagent, producing a purple complex with 
strong absorbance at 562 nm (Smith et al., 1985).  
In the project, the BCA Protein Assay Kit (Novagen, UK) was used and the 
manufacturer’s protocol was followed. The standards were prepared using BSA 
stock solution at 2 mg/ml and the cell lysis buffer. The concentration was 
measured using a Nanodrop spectrophotometer and a pre-set BCA programme.  
 
2.1.3.4 Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-
PAGE) 
Proteins were separated using sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) with a discontinuous, 1X TRIS–glycine–SDS buffered 
system. In this study, gels of various percentages were used depending on the size 
of the protein of interest (Table 2.9) and recipe for resolving gels of various 
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percentages are summarised in Table 2.10. The stacking gel had a common 
composition for every SDS-PAGE run and the recipe is summarised in Table 2.11. 
Alternatively, ready-made Mini-PROTEAN TGX Precast Gels (BioRad, USA) were 
used. Before loading, 6X Laemmli buffer (Alfa Aesar, UK) was added to each 
sample, which were then incubated at 70-100 ˚C for 5-10 minutes, depending on 
the experiment. Typically, 20-30 µg of a total protein extract was loaded to each 
well. Precision Plus Protein Dual Standards (BioRad, UK) and Hi-Mark Pre-Stained 
High Molecular Weight Protein Standard (Life Technologies, UK) were used as 
markers for protein band size estimation. Gels were subject to electrophoresis 
until suitable separation of the marker was achieved, typically at 100 V, 3 A, 30 W.  
 
 
Protein Size Percentage 
Over 100 kDa ~7 % 
50-100 kDa ~10 % 
20-50 kDa ~12 % 
<20 kDa ~15 % 
Table 2.9 Percentage of the resolving polyacrylamide resolving gels.  
 
Ingredient 5 % 7.50 % 10 % 12 % 15 % 17.50 % 
dH20 8.5 ml 7.25 ml 6 ml 5 ml 3.5 ml 2.25 ml 
30 % acrylamide 2.5 ml 3.75 ml 5 ml 6 ml 7.5 ml 8.75 ml 
1.5 M Tris, pH 8.8 3.75 ml 3.75 ml 3.75 ml 3.75 ml 3.75 ml 3.75 ml 
10 % (w/v) SDS 150 μl 150 μl 150 μl 150 μl 150 μl 150 μl 
10 % (w/v) APS 100 μl 100 μl 100 μl 100 μl 100 μl 100 μl 
TEMED 25 μl 25 μl 25 μl 25 μl 25 μl 25 μl 
Table 2.10 Composition of the resolving polyacrylamide gels.   
 
 
Ingredient Volume 
H20 3 ml 
30 % acrylamide 625 μl 
0.5M Tris, pH 6.8 1.25 ml 
10 % (w/v) SDS 50 μl 
10 % (w/v) APS 30 μl 
TEMED 10 μl 
Table 2.11 Composition of a polyacrylamide stacking gel.  
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2.1.3.5 Immunoblotting (Western blotting) 
Separated proteins were transferred on to nitrocellulose membrane 
(45 μm, BioRad) using two methods, depending on size of the protein. Typically, a 
semi-dry transfer was used; however, for the purpose of transferring EYS 
isoform 1 (350 kDa) wet transferred was preferred. Semi-dry transfer was 
performed using a BioRad Trans-Blot Turbo system. The process was carried out 
at 25 V, 1 A for 30 minutes. Wet transfer was carried out in a Mini Trans-Blot 
Electrophoretic Transfer Cell (BioRad, USA) at 100 V, 0.35 A for 2 hours. When 
Mini-PROTEAN TGX Precast Gels were used, transfer was performed using Trans-
Blot Turbo Mini PVDF Transfer Packs and the Trans-Blot Turbo system; pre-set 
programmes were used depending on the protein size.  
To check whether proteins were transferred onto the membrane, Ponceau 
Red staining was performed using the ready-made Ponceau Red solution (Sigma, 
USA). The membrane was submerged in the solution for 5 minutes to visualise 
protein bands and then, the membrane was rinsed with TBS-T solution until the 
stain was completely removed. Blocking of the membrane was carried out using 
5 % milk or 5 % BSA in dissolved in 1X TBS-T for 1 hour at room temperature with 
gentle agitation.  
Immunolabelling was performed with the relevant primary antibodies at 
optimised dilutions, which were prepared in the blocking solution. Incubation with 
primary antibodies was performed overnight at 4 ˚C. Afterwards, membranes were 
washed 3 times 10 minutes in 1X TBS-T. HRP conjugated secondary antibodies 
were used, typically at 1:10000 dilutions prepared in 1X TBST-T, and the 
incubation was carried out for 1 hour at room temperature with gentle agitation. 
After the incubation, the membrane was washed 2 times 15 minutes in 1X TBS-T 
and then 2 times 10 minutes in 1X TBS. For the development, ECL solution 
(BioRad, USA) was prepared, spread on the membrane and incubated for 1 min. 
The visualisation was performed using the GelDoc XR+ System (BioRad, USA) and 
the images were processed using the Image Lab software (BioRad, USA). 
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2.1.4 Cell Culture Techniques  
2.1.4.1 Mammalian Cell Lines 
The cell lines used in the study were already available in the Bhattacharya 
laboratory. The cells were grown in plastic culture vessels and the incubation 
conditions were set to maintain the temperature at 37 ˚C, the level of CO2 at 5 % 
and humidity at a minimum of 80 %.  
The day-to-day maintenance of the cell cultures involved media changes 
and passaging the cells to maintain the desired confluence level. To detach 
adherent cells from the surface of the culture dishes, the media was aspirated, the 
cells were rinsed with sterile PBS and incubated with 1X 0.05% Trypsin-EDTA 
(Life Technologies, USA) for 5-10 minutes. The cultures were then split, usually at 
a ratio of 1:3. In case of suspension cells, the culture was transferred to a suitable 
size tube and centrifuged at 350 rpm for 10 minutes at room temperature. The 
supernatant was discarded, the cell pellet re-suspended in sterile PBS and the 
centrifugation step repeated. The cell pellet was suspended in the fresh volume of 
media and incubated as usually.  
The cell stocks were prepared by collecting approximately 1x106 cells and 
suspending them in 1 ml of the Recovery Cell Culture Freezing Medium (Life 
Technologies, USA). The mammalian cell stocks were kept at -80 ˚C. 
 
Y79 cell line 
 
Y79 cell line is a suspension cell line derived from human retinoblastoma. The cell 
line was maintained in RPMI 1640 medium (Life Technologies, USA) supplemented 
with 20 % FCS and 1 % penicillin/streptomycin antibiotic mixture.  
 
HeLa cell line 
 
HeLa cell line grows as an adherent monolayer and was derived from a human 
epitheloid cervix carcinoma. The cells were cultured in DMEM medium (Life 
Technologies, USA) supplemented with 10 % FCS and 1 % penicillin/streptomycin 
antibiotic mixture. 
 
Materials and Methods 
75 
 
SK-N-SH cell line 
 
SK-N-SH cell line was derived from human neuroblastoma and the cells grow as a 
monolayer. The cells were cultured in DMEM-F12 medium (Life Technologies, 
USA) supplemented with 10 % FCS and 1 % penicillin/streptomycin antibiotic 
mixture. 
 
ARPE-19 cell line 
 
ARPE-19 is a human retinal pigment epithelial cell line derived from a healthy 
tissue. The cells grow as a monolayer and were cultured in DMEM-F12 medium 
(Life Technologies, USA) supplemented with 10 % FCS and 1 % 
penicillin/streptomycin antibiotic mixture. 
2.1.4.2 Cell Counting 
When required, cells were counted using a hemacytometer (Cascade 
Biologicals, USA), following the protocol recommended by the manufacturer. The 
suspension of cells was prepared and carefully pipetted to disperse any clumps to 
obtain a uniform suspension of single cells. Next, 1:1 dilution of the cell suspension 
in trypan blue was prepared and 20 µl of the mixture were used to charge the 
chambers. Trypan blue allows for determination of viability of cells and it is 
excluded from viable cells. The cells were viewed under a microscope and the cell 
number overlying four 1 mm2 areas was determined. The number of cells was 
calculated by the following the formula according to the manufacturer’s protocol: 
 
Number of cells counted in 4 mm2/4/dilution factor=number of cells x 104/ml 
 
2.1.4.3 Transfections  
Two reagents for transfecting adherent cell lines were used in the study, 
Lipofectamine 2000 (Life Technologies, USA) and Effectene (Qiagen, The 
Netherlands). 
 For transfection with Lipofectamine 2000, cells were plated to be 90-95 % 
confluent on the day of transfection and the manufacturer’s protocol was followed. 
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Briefly, on the day of transfection the cells were rinsed twice with sterile PBS and 
the culture media was changed to DMEM supplemented with 10 % FCS but lacking 
the antibiotic mixture. The dilutions of DNA and Lipofectamine 2000 were 
prepared in Opti-MEM media (Life Technologies, USA) according to the 
manufacturer’s recommendations. The dilution of Lipofectamine 2000 was 
incubated for 5 minutes at room temperature before being mixed with the dilution 
of DNA. In all experiments, the ratio of DNA (µg):Lipofectamine 2000 (µl) was 
1:2,5. The mixture was incubated at room temperature for 20 minutes to allow 
complex formation and then, it was added directly into the culture vessels. Media 
was changed 4 hours later to DMEM supplemented with 10 % FCS 1 % 
penicillin/streptomycin antibiotic mixture.  
 Effectene (Qiagen, The Netherlands) was used to transfect adherent cell 
lines with constructs carrying full sized EYS isoform 1 (9435 bp). The cells were 
plated to be 40-80 % confluent on the day of transfection.  Prior to transfection, the 
media from above cells was aspirated and the cells were rinsed with sterile PBS. 
The volume of media added to the cells was split into two portions; one constituted 
75 % and the second 25 % of the total volume. The first, 75 % portion of DMEM 
supplemented with 10 % FCS but lacking the antibiotic mixture was added to the 
cells. The desired amount of DNA was diluted in the provided TE buffer and 
incubated with an Enhancer for 5 minutes. Then, Effectene Transfection Reagent 
was added and the mixture was incubated at room temperature for 10 minutes to 
allow transfection complex formation. For all transfections performed with tagged 
EYS isoforms 1 constructs the ratio of DNA (µg):Enhancer (µl):Effectene 
Transfection Reagent (µl) was 1:8:25. The complex was mixed with the remainder 
of culture media and added directly to the culture vessel. Media was changed 4 
hours later to DMEM supplemented with 10 % FCS 1 % penicillin/streptomycin 
antibiotic mixture.   
 Cell lines grown in suspension were first seeded onto to pre-treated 
coverslips (see section 2.1.4.4) and then transfected following the same protocol as 
described for adherent cell lines. 
2.1.4.4 Y79 Cell Attachment and Differentiation 
Since Y79 cells grow in suspension, it was necessary to optimise 
immobilisation protocols in order to be able to perform transfections followed by 
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immunocytochemistry experiments. A modified protocol for cell attachment and 
growth enhancement was used (Kyritsis et al., 1984). 
In this study, glass coverslips were coated with poly-L-lysine (Sigma, USA) 
at concentration 2 µg/cm2. The glass coverslips were placed in a 24-well plate and 
500 µl of poly-L-lysine were added. The plate was then incubated at 37 ˚C for 
2 hours. Next, the glass coverslips were rinsed twice with sterile water and 500 µl 
of the cell suspension were added. Y79 cells typically grow in RPMI 1640 media; 
however, for the purpose of cell attachment they were suspended and seeded in 
complete DMEM media. More than 90 % of cells were attached to the coated glass 
coverslips after 2 hours post seeding.  
In order to enhance the growth of Y79 cells, they were treated with 
dibutyryl cyclin AMP (dbcAMP) (Sigma, USA). Once the cells were attached to the 
coated coverslips, the media was aspirated, the cells were rinsed twice with sterile 
PBS and DMEM (serum and antibiotics free media) was added. dbcAMP was added 
to the media at the final concentration of 2 mM and was re-administered every 2 
days with media changes. After 5 days of treatment the cells were fixed and 
immunolabelled.  
2.2 Yeast 2-hybrid (Y2H) 
In 1989, Fields and Song revolutionised analysis of PPIs by elaborating a 
genetic system to detect direct interactions between proteins in Saccharomyces 
cerevisiae (Fields & Song, 1989). They were inspired by results obtained by Keegan 
et al. who discovered the structure of GAL4, a transcriptional activator in yeast 
(Keegan et al., 1986). The group demonstrated that GAL4 binds to a specific DNA 
sequence (UAS, upstream activation sequence) and activates transcription in the 
presence of galactose. Moreover, they showed that when separated into two 
fragments, the N-terminal fragment of GAL4 can bind to the DNA sequence but 
cannot activate transcription whereas the C-terminal fragment of the protein does 
not bind DNA but is capable of initiating transcription by recruitment of RNA 
polymerase II. Both fragments are, however, able to bind non-covalently to each 
other and reconstitute the structure of GAL4. As a result of this study, two 
functional domains of GAL4 were identified: an N-terminal DNA binding domain 
(GAL4 DBD) and C-terminal activation domain (GAL4 AD) (Keegan et al., 1986) 
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(Figure 2.2 A). Fields and Song exploited these findings to create a system 
monitoring PPIs. The basic idea of the system was to fuse the bait protein to the 
GAL4 DNA BD and the prey protein to the GAL4 AD. Expression of both fusion 
proteins in yeast and interaction between them brings the GAL4 DBD and GAL4 AD 
domains in proximity and activates transcription of a reporter gene, e.g. 
GAL1-LacZ. This gene encodes the enzyme β-galactosidase which labels yeast cells 
when using a colorimetric substrate (Fields & Song, 1989) (Figure 2.2 B, C).  
Y2H has become a popular tool for investigating PPIs due its 
cost-effectiveness, simplicity and suitability for high-throughput screening of cDNA 
libraries. It not only allows for identification of new binary interactions but also 
enables their further exploration by using protein fragments and mutated 
constructs of proteins of interest. 
In spite of many advantages of Y2H, the method has some limitations. The 
main drawback of GAL4 based Y2H is that the interacting complex needs to be 
transported to the nucleus in order to activate transcription of the reporter genes. 
This makes it impossible to investigate integral membrane proteins or proteins 
with strong cytoplasm tropism. These issues have been addressed by creating 
modified Y2H system, e.g. development of split-ubiquitin Y2H systems (or 
membrane Y2H; MYTH) enabled detection of interacting partners of proteins 
bound to the cell membrane. Furthermore, Y2H is characterised by low 
reproducibility of the results, which was estimated to be approximately 20 %, and 
by a high number of false positive results. It can also happen that some bait protein 
fragments can be toxic to yeast cells or produce spontaneous transcription 
activation activity of the reporter gene.  To address these issues, many control 
experiments preceding Y2H screening are required to ensure that a bait is suitable 
for the use in Y2H. Also, Y2H results always need to be subjected to validation 
experiments in order to provide additional evidence in their support (reviewed in 
Ivanov et al., 2011; Ngounou Wetie et al., 2014).  
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Figure 2.2 Overview of Y2H technology. Image ‘A’ demonstrates the activity of GAL4 
transcription activator in wild type conditions: GAL4 DBD binds to the UAS sequence and 
GAL4 AD initiates transcription by recruitment of RNA polymerase II. Image ‘B’ illustrates 
events in Y2H when a bait fused to GAL4 DBD interacts with a prey fused to GAL4 AD and 
brings the two GAL4 moieties in proximity, thereby activating transcription of the reporter 
gene. Conversely, image ‘C’ depicts the scenario when a bait fused to GAL4 DBD does not 
interact with a prey fused to GAL4 AD and the transcription is not activated. DBD – GAL4 
DNA binding domain, AD – GAL4 activation domain, UAS – upstream activation sequence. 
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In this study, the Matchmaker Gold Yeast Two-Hybrid System (Clontech, 
USA) was used. This is a classic Y2H system exploiting the modular nature of the 
GAL4 transcription factor. Cloning of baits was performed using the Gateway 
cloning system (Life Technologies, USA) and the pBD-DEST vector (Stratagene, 
USA) was used as a destination vector, enabling expression of bait fusion proteins. 
The retinal cDNA library was previously constructed in the Bhattacharya 
laboratory, using the pGADT7-Rec vector (Clontech, USA). It was additionally 
confirmed that the vectors manufactured by Clontech and Stratagene are 
compatible and can be used together.  
Yeast cells can grow as haploid organisms or they can mate and form 
diploid cells. Traditionally, bait and prey plasmids are co-transformed into a single 
yeast strain; however, it is also possible to transform them into two separate yeast 
strains of opposite sex type and mate them to enable the bait and prey to come 
together. The Matchmaker Gold Yeast Two-Hybrid System is based on the yeast 
mating procedure. Two strains of Saccharomyces cerevisiae are provided in the 
system: Y2HGold and Y187. Y2HGold cells are of mating type a (MATa) and are 
used for production of baits whereas preys are hosted in Y187 yeast strain of 
mating type α (MATα). Mating can occur only between yeast cells of opposite 
mating type and yeast strains provided by Clontech were modified so that cells are 
incapable of switching their sex type, as may happen in wild type strains.  
When interaction between bait and prey occurs, expression of reporter 
genes is activated. The Y2HGold strain has four reporter genes and the Y187 strain 
incorporates two. The reporter genes have two main functions: firstly to 
distinguish transformed haploid cells, and secondly, to help identify mated diploid 
cells containing potential interactions. The number and/or combination of 
reporter genes can be used to moderate the stringency of the Y2H. Reporter genes 
used in the Matchmaker Gold Yeast Two-Hybrid System are summarised in Table 
2.12. Promoters controlling four reporter genes in Y2HGold cells are unrelated 
except for the short protein binding sites in the upstream activating sequences 
(UAS) region that are specifically bound by GAL4 DNA BD. This means that prey 
proteins which can interact with sequences flanking or within UAS and cause false 
positive results, are screened out. 
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Yeast 
strain 
Gene Promoter Description 
Y2HGold AUR1-C M1 
A dominant mutant version of the AUR1 gene that 
encodes the enzyme inositol phosphoryl ceramide 
synthase. In Saccharomyces cerevisiae, its expression 
confers strong resistance (AbAr) to the otherwise highly 
toxic drug Aureobasidin A (AbA). This drug reporter is 
preferable to nutritional reporters alone due to lower 
background activity.  
Y2HGold MEL1 M1 
MEL1 encodes α-galactosidase, an enzyme occurring 
naturally in many yeast strains. As a result of two-hybrid 
interactions, α-galactosidase is expressed and secreted 
by the yeast cells. Yeast colonies that express MEL1 turn 
blue in the presence of the chromogenic substrate X-α-
Gal. 
Y2HGold HIS3 G1 
Y2HGold is unable to synthesize histidine and is therefore 
unable to grow on media that lack this essential amino 
acid. When bait and prey proteins interact, GAL4-
responsive HIS3 expression permits the cell to 
biosynthesize histidine and to grow on –His minimal 
medium. 
Y2HGold ADE2 G2 
Y2HGold is also unable to grow on minimal media that 
does not contain adenine. However, when two proteins 
interact, Ade2 expression is activated, allowing these cells 
to grow on –Ade minimal medium. 
Y187 lacZ G1 
LacZ gene encodes for β-galactosidase.  The presence of 
an active β-galactosidase is detected by X-gal, which 
produces a characteristic blue dye when cleaved by 
β-galactosidase. This reporter gene is not used in this 
project and may be used as an alternative to MEL1. The 
difference is that β-galactosidase is not secreted and 
therefore, a β-galactosidase assay needs to be performed 
to prove occurrence of an interaction. 
Y187 MEL1 M1 as above 
Table 2.12 Summary of reporter genes used in Matchmaker Gold Yeast Two-Hybrid 
System manufactured by Clontech. 
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2.2.1 Yeast Media 
A wide range of media were used to culture yeast in this study depending 
on the purpose of an experiment. Wild type yeast strains were cultured in YPDA 
medium which contains all ingredients required for an optimal growth of 
Saccharomyces cerevisiae.  
Single drop-out (SDO) media lack an amino acid which is used as a 
nutritional marker to select colonies that have been transformed with a vector 
encoding an enzyme required for the biosynthesis of the missing amino acid. 
Depending on the type of a vector used for transformation, SDO media lacking 
tryptophan or leucine were used (SDO/-Trp or SDO/-Leu respectively). Following 
the same principle, double drop-out (DDO) media lack two amino acids and select 
for yeast cells that carry two of the vectors encoding the missing nutrients (mated 
diploid cells or co-transformed haploid cells). Triple drop-out (TDO) and 
quadruple drop-out (QDO) lack three or four amino acids respectively and they 
additionally select for interaction between bait and prey which, if present, will 
activate biosynthesis of amino acids adenine and histidine. Yeast media can 
additionally be supplemented with X-α-Gal which is a chromogenic substrate 
which can be used to demonstrate -galactosidase activity. Another supplement 
used in yeast media was Aureobasidin A (AbA) which is a highly toxic anti-fungal 
agent. Only yeast cells expressing AbAr resistance gene are able to grow in 
presence AbA in the media. X-α-Gal and AbA were used as markers for detecting 
interaction between bait and prey.  
All of the yeast media could have liquid or solid form and the latter was 
achieved by supplementing the media with agar. The recipes of media used in the 
study are summarised in section 2.9. 
2.2.2 Yeast Cell Stock Maintenance  
Untransformed Y2HGold and Y187 yeast strains were maintained in YPDA 
medium with 25 % glycerol at -80 ˚C. Additionally, both strains were maintained 
on solid media by re-streaking on fresh YPDA agar plates every 30 days. 
Transformed yeast cells were also stored as glycerol stocks at -80 ˚C in relevant 
selective media and on SDO agar media, being re-streaked onto fresh plates every 
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30 days. SDO media allow nutritional selection and were used to culture 
transformed yeast cells. Depending on the type of a vector used for transformation, 
SDO media lacking tryptophan or leucine were used (SDO/-Trp or SDO/-Leu 
respectively). 
2.2.3 Determination of Yeast Cells Number in Liquid Culture 
In order to evaluate the number of cells in liquid culture, the optical density 
of 1 ml of liquid culture was measured at 600 nm wavelength (OD600). The result 
multiplied by the total volume of the culture to determine the total OD600, as shown 
below: 
 
Total OD600 = obtained OD600 x final culture volume 
 
The number of yeast cells is calculated following the below equation: 
 
OD600 of 1 = 8x107 cells/ml 
 
2.2.4 Designing Y2H Baits 
Baits for Y2H screening were designed using the reference sequence of EYS 
gene, derived from Ensembl database (transcript ID: ENST00000503581). In this 
study, the cDNA of EYS isoform 1 was available, which comprises of 9435 bp. 
Altogether, nine fragments were designed, including the full length gene. Every 
bait spans a different part of the protein encompassing particular domains. Baits 
were constructed by PCR amplification of the desired fragments using KOD 
polymerase and primers compatible with the Gateway cloning system that are 
listed in Table 2.13. First the fragments were cloned into pDONR/Zeo to obtain 
entry clones and the expression clones were obtained by subsequent cloning into 
pBD-DEST vectors.  Detailed information regarding baits is presented in 
Table 2.14. 
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Table 2.13  Summary of primers used for Gateway cloning of Y2H EYS bait fragments. 
AttB1 sequence is shown in green, attB2 sequence in blue and stop codon are in red. 
Expected amplicon sizes are indicated. Tm – melting temperature of the primer pair. 
 
Fragment 
name
Forward primer (5'->3') Reverse primer (5'->3')
Product 
size 
[bp]
Tm 
[˚C]
Bait 1
ggggacaagtttgtacaaaaaagcaggcttc
ATGACTGACAAATCAATCGTCATTC
ggggaccactttgtacaagaaagctgggtg
TTACAAACCAGTGGTTGGGAGAAT
3994 75
Bait 2
ggggacaagtttgtacaaaaaagcaggcttc
ACAGTTATGGCAAGTGGTCCATCAC
ggggaccactttgtacaagaaagctgggtg
TTACAAACCAGTGGTTGGGAGAAT
3547 75
Bait 3
ggggacaagtttgtacaaaaaagcaggcttc
ACAGTTATGGCAAGTGGTCCATCAC
ggggaccactttgtacaagaaagctgggtg
TTAACTCTTTTTAGAAGGAAATAAA
4522 60
Bait 4
ggggacaagtttgtacaaaaaagcaggcttc
AACATCTGTGAGATAGATACTGAAG
ggggaccactttgtacaagaaagctgggtg
TTAACTCTTTTTAGAAGGAAATAAA
3058 60
Bait 5
ggggacaagtttgtacaaaaaagcaggcttc
CAACGGCTGATGATTTCTGATTTCA
ggggaccactttgtacaagaaagctgggtg
TTATGTAACCTCATTTTGTTCATCT
3874 70
Bait 6
ggggacaagtttgtacaaaaaagcaggcttc
AAAGCCTTCAATCCCAGTGAATATC
ggggaccactttgtacaagaaagctgggtg
TTATGTAACCTCATTTTGTTCATCT
4945 70
Bait 7
ggggacaagtttgtacaaaaaagcaggcttc
ACAGTTATGGCAAGTGGTCCATCAC
ggggaccactttgtacaagaaagctgggtg
TTATGTAACCTCATTTTGTTCATCT
9052 55
Bait 8
ggggacaagtttgtacaaaaaagcaggcttc
AGACCTGGGTTTTCTGGATCTCTG
ggggaccactttgtacaagaaagctgggtg
TTAACACTGGCCAACACTGCGTCC
5140 50
Bait - Full 
length
ggggacaagtttgtacaaaaaagcaggcttc
ATGACTGACAAATCAATCGTCATTC
ggggaccactttgtacaagaaagctgggtg
TTATGTAACCTCATTTTGTTCATCT
9699 55
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Table 2.14 Summary of EYS bait fragments designed for the purpose of Y2H screening. 
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2.2.5 Preparation of Competent Yeast Cells  
Competent cells were prepared under sterile conditions using the 
Yeastmaker™ Yeast Transformation System 2 User Manual (Clontech, USA). 
A single colony of the relevant yeast strain was inoculated in 3 ml of YPDA medium 
in a sterile 50 ml tube and incubated for 8-12 hours at 30 ˚C with shaking at 
225 rpm. An aliquot (500 μl) of the culture was subsequently transferred to 50 ml 
of YPDA medium in a sterile 250 ml flask and incubated at 30 ˚C with shaking at 
225 rpm for 16-20 hours, until the OD600 reached 0.8-1.0. The culture was then 
equally divided into two sterile conical 50 ml tubes and centrifuged at 1700 rpm 
for 5 minutes at room temperature. The supernatant was discarded and pellets 
were re-suspended in 30 ml of sterile water. The centrifugation step was repeated, 
supernatant discarded and pellets re-suspended in 1.5 ml of 1.1 TE/LiAc solution. 
Each cell suspension was transferred to a 1.5 ml microcentrifuge tube and 
centrifuged at 14 000 rpm for 20 seconds. Supernatant was removed, pellets 
re-suspended in 600 μl of 1.1 X TE/LiAc solutions and placed on ice. Competent 
cells were used for transformation within 2 hours of preparation. 
2.2.6 Transformation of Yeast Competent Cells 
Prior to transformation of freshly prepared yeast competent cells, 
Yeastmaker Carrier DNA (provided in Yeastmaker™ Yeast Transformation System 
2; 10 μg/μl) was denatured at 95 ˚C for 5 minutes. Denatured Yeastmaker Carrier 
DNA (5 µl) was combined with 100 ng of plasmid DNA, added to the 1.5 ml 
microcentrifuge tube containing 50 µl of yeast competent cells and gently mixed. 
PEG/LiAc (500 µl) was then added; suspensions were gently mixed and incubated 
at 30 ˚C for 30 minutes, mixed gently by tapping every 10 minutes.  After 
incubation, 20 µl of DMSO was added to suspensions and tubes were incubated at 
42 ˚C for 15 minutes, being gently mixed by tapping every 5 minutes. Cells were 
subsequently centrifuged at 14 000 rpm for 15 seconds, supernatant was 
discarded and pellets re-suspended in 1 ml of YPD Plus Medium provided in the 
kit. Cells were then incubated at 30 ˚C for 1 hour with shaking at 225 rpm. After 
incubation, cells were pelleted by centrifugation at 14 000 rpm for 15 seconds and 
re-suspended in 500 µl 0.9 % NaCl solution. Cell suspensions were diluted 1:10 
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and 1:100, and 100 µl of each dilution was spread using sterile glass beads (3 mm) 
onto single drop out (SDO) agar media supplemented with relevant drop-out 
solution (-Trp or -Leu depending on the vector used). Plates were incubated 
upside down at 30 °C for 3 to 5 days, until colonies appeared. 
 
2.2.7 Determination of Transformation Efficiency 
 Transformation efficiency was determined after every transformation. The 
number of colonies grown (colony forming units; cfu) was evaluated and efficiency 
of transformation was calculated according to the equation below: 
 
Transformation efficiency [
cfu
µg
]
=
cfu x suspension volume [ml]
volume plated [ml]x amount of DNA [µg]
x dilution factor 
 
2.2.8 Small Scale Mating 
 Small scale mating was performed between Y2HGold and Y187 yeast strains 
carrying bait and prey vectors respectively. A single colony of each previously 
transformed yeast strain was picked up from SDO agar plates and both colonies 
were inoculated together in 500 µl of 2X YPDA in a 15 ml tube. The tube was then 
incubated for approximately 24 hours at 30 ˚C with shaking at 225 rpm. 
Afterwards, dilutions of mated culture were prepared (1:10, 1:100 and 1:1000) 
and 100 µl of each were plated on relevant selective 15 cm agar plates. 
Alternatively, wherever the number of colonies was not important for calculations, 
10-20 µl of diluted cultures were dropped on the desired type of media plate. 
2.2.9 Control Mating 
 Control mating was performed in order to confirm that the Y2H system 
used in our laboratory was working and that vectors used for cloning of bait and 
prey fragments are compatible. This was necessary as the vectors were 
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manufactured by two different companies (pBD-DEST vector from Stratagene and 
vectors supplied in the Clontech Y2H kit). Three control vectors were used in this 
study: 
 
1. pBD-DEST-p53 encoding the GAL4 BD fused with p53 protein (bait). 
2. pBD-DEST-pLc encoding GAL4 BD fused with human lamin C (bait). 
3. pGADT7-T encoding the GAL4 AD fused with SV40 large T antigen (prey). 
 
It is known that p53 protein interacts with SV40 large T antigen and 
therefore this interaction was used as a positive control. Conversely, pLc protein 
does not interact with SV40 large T antigen and this relationship was used as a 
negative control. The vectors were first transformed into the relevant yeast 
strains: pBD-DEST-p53 and pBD-DEST-pLc were transformed into Y2HGold strain 
whereas pGADT7-T was transformed into Y187 strain. Mated yeast cultures were 
afterwards plated on the following solid media: 
 
 SDO/-Trp (Single drop-out medium lacking tryptophan) 
 SDO/-Leu (Single drop-out medium lacking leucine) 
 DDO (Double drop-out medium lacking tryptophan and leucine) 
 DDO/X/A (Double drop-out medium lacking tryptophan and leucine, 
supplemented with X-α-gal and AbA) 
 
Plated cultures were incubated for 3-5 days, until yeast colonies appeared. 
The experiment procedure and expected phenotypes are summarised in Table 
2.15. 
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Strains mated 
Type of 
minimal agar 
medium 
Selection for 
Expected 
MEL1 
phenotype 
P
o
si
ti
ve
 c
o
n
tr
o
l 
Y2hGold[pBD-
DEST/p53] x 
Y187[pGADT7-
T] 
SDO/-Leu pGADT7-T white 
SDO/-Trp pBD-DEST/p53 white 
DDO (-Leu /-
Trp) 
Diploids containing pGBKT7-T 
and pBD-DEST-p53 
white 
DDO/X/A (-
Leu/-Trp/X-α-
Gal, AbA) 
Diploids that have also 
activated Aureobasidin A 
resistance and α-galactosidase 
through protein-protein 
interactions 
blue 
N
eg
at
iv
e 
co
n
tr
o
l 
Y2hGold[pBD-
DEST/p53] x 
Y187[pGADT7-
Lam] 
SDO/-Leu pGADT7-Lam white 
SDO/-Trp pBD-DEST/p53 white 
DDO (-Leu /-
Trp) 
Diploids containing pGBKT7-
Lam and pBD-DEST-p53 
white 
DDO/X/A (-
Leu/-Trp/X-α-
Gal, AbA) 
Diploids that have also 
activated Aureobasidin A 
resistance and α-galactosidase 
through protein-protein 
interactions 
no growth 
observed 
Table 2.15 Overview of the control mating experiment conducted before Y2H screening. 
Vectors used, yeast strain and expected phenotype of yeast colonies are summarised. The 
experiment also tested whether the p-BD-DEST (Stratagene, USA) and pGADT7 (Clontech, 
USA) vectors, manufactured by two different companies, can be used together.  
 
2.2.10 Testing Baits for Auto-Activation 
Baits used in Y2H screening should not activate transcription of reporter 
genes on their own as it would cause obtaining false positive results. Therefore, 
every bait needs to be tested for auto-activation of reporter genes before it can be 
used in Y2H screening. In this experiment, bait constructs were transformed into 
Y2HGold yeast strain and serial dilutions of the cultures were prepared. Next, 
10-20 μl of each dilution were dropped on relevant single drop-out selective 
media. The following types of solid media were used: 
 SDO/-Trp (Single drop-out medium lacking tryptophan) 
 SDO/-Trp/X (Single drop-out medium lacking tryptophan supplemented 
with X-α-gal) 
 SDO/-Trp/X (Single drop-out medium lacking tryptophan supplemented 
with X-α-gal and AbA) 
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As a positive control, a mated culture of Y2HGold [pBD-DEST/p53] x 
Y187[pGADT7-T], obtained in the control mating experiments was used. Media 
plates were incubated at 30 ˚C for 3-5 days.  
If a bait is able to activate transcription of reporter genes, it should form 
blue colonies on SDO/X and SDO/X/A agar media. Otherwise, colonies grown on 
SDO/X will be white and no growth will be observed on SDO/X/A agar plates. 
2.2.11 Testing Baits for Toxicity 
To ensure that baits do not have a toxic effect on the host strain of yeast, 
pBD-DEST-‘baits’ and pGBKT7-WT (encoding GAL4 DNA BD only) vectors were 
transformed into Y2HGold strain. After transformation, yeast cells were plated on 
SDO/-Trp solid media in 1:10 and 1:100 dilutions and incubated at 30 ˚C for 
3-5 days. After colonies appeared, the agar plates were placed on a light box and 
the colonies were manually counted to determine the transformation efficiency. 
The colonies were also measured in diameter and the sizes of colonies carrying 
baits and wild type GAL4 DNA BD were compared. The average size of a healthy 
transformed colony was between 1-2 mm; if a bait is toxic to yeast cells, their 
growth will be slowed down (forming smaller colonies) or inhibited completely.  
2.2.12 cDNA Library Screening Using Mating 
The cDNA library screening was performed by mating an Y2HGold strain 
transformed with a particular bait and an aliquot of a cDNA library prepared in 
Y187 cells. To prepare a culture of the bait strain, one fresh colony was inoculated 
in 50 ml of SDO/-Trp liquid medium and incubated with shaking at 250-270 rpm at 
30 ˚C for 16-20 hours, until the OD600 reached 0.8. Then, the culture was 
centrifuged to pellet cells (1200 rpm for 5 minutes) and the supernatant was 
discarded. The culture was re-suspended in SDO/-Trp medium to obtain a cell 
density of >1x108 cells per ml (4-5 ml). Next, an aliquot of a cDNA library was 
thawed and 10 μl were removed for library titering (section 2.2.15). The library 
was combined with the dilution of the bait strain and transferred to a 2 L sterile 
flask containing 45 ml of 2X YPDA medium supplemented with kanamycin 
(50 μg/ml). The library vial was rinsed twice with 1 ml of 2X YPDA which was 
added to the 2 L flask. The culture was incubated at 30 ˚C for 20-24 hours, slowly 
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shaking at 30-50 rpm. After the incubation, a drop of a culture was examined 
under a light microscope to see whether diploid cells are present. If so, the culture 
was collected and centrifuged at 1200 rpm for 10 minutes. The 2 L flask was rinsed 
twice with 50 ml of 0.5X YPDA (supplemented with 50 μg/ml kanamycin; 0.5X 
YPDA/Kan), the rinses were combined and used to re-suspend the pelleted cells. 
The cells were centrifuged again at 1000 g for 10 minutes and the supernatant was 
discarded. The cell pellet was re-suspended in 12 ml of 0.5X YPDA/Kan liquid 
medium and the total volume of the culture was measured. From the mated 
culture, 100 μl of 1/10, 1/100, 1/1000 and 1/10000 dilutions were spread on 
SDO/-Trp, SDO/-Leu and DDO media plates (selecting respectively for the 
presence of bait plasmids, prey plasmids or both). This was necessary for the 
purpose of evaluation of the mating efficiency and the number of screened clones. 
The remainder of the culture was plated pure/undiluted onto selective media 
plates; 100 μl were spread on one plate using sterile glass beads (3 mm) and the 
plates were incubated at 30 ˚C for 3-5 days. In initial screens, DDO/X/A media 
plates were used, however, the conditions were then modified and the mated 
cultures from further screens were spread on TDO/X media plates.  
Following incubation, the plates were reviewed and any blue colonies 
grown were transferred onto increased stringency media plates (sequentially on 
TDO/X/A, QDO/X and QDO/X/A media plates). Blue colonies growing on the most 
stringent plates were subjected to further analysis. 
The colonies grown on the control plates were counted and the numbers 
were used for calculating the mating efficiency and the number of screened clones.  
2.2.13 Determination of Mating Efficiency 
 Each mating was followed by determination of mating efficiency which had 
to be no less than 2 %. It was calculated following the equation below: 
 
Mating efficiency [% of diploids] =
number of 
cfu
ml  of diploids
number of 
cfu
ml  of limiting partner
 x 100 % 
 
The strain (bait or prey) with the lower viability, which is equal to the number of 
clones on SDO medium, is considered to be the “limiting partner”. 
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2.2.14 Determination of the Number of Screened Clones 
The number of screened clones (diploid cells) was determined after each 
screen and it was imperative to screen at least 1 million of diploids. Screening less 
than 1 million of diploids would result in smaller chances of detecting interactions.  
To calculate the number of screened clones, DDO plates (selecting for the presence 
of both bait and prey plasmids) were placed on a light box and the grown colonies 
were manually counted. The equation given below was used to determine the 
number of screened clones: 
 
Number of Screened Clones
= number of 
cfu
ml
 of diploids x resuspension volume [ml] 
 
2.2.15 cDNA Library Tittering 
 In each screen an aliquot of the library used was titered in order to verify its 
viability and it was a requirement that there are at least 2 x 107 cells per 1 ml of 
library. To check the titer, 10 μl were removed from the library aliquot, serial 
dilutions were prepared (1/100, 1/1000 and 1/10000) and 100 μl of each were 
plated on SDO/-Leu medium, selecting for prey plasmids. The colonies were then 
counted and the library titer was calculated using the equation below: 
 
Library titer [
cfu
ml
] =
number of colonies
plating volume x dilution factor
  
 
2.2.16 Yeast Colony PCR 
Yeast colony PCR was performed to amplify prey fragments from yeast 
colonies able to grow on the highest stringency media. For this purpose, fresh 
patches of colonies were prepared to make sure that the yeast cells are not older 
than 4 days. A dab of yeast cell paste from each patch was collected with a 10 μl 
pipette tip and transferred to 20 μl of 20 mM NaOH solution. The samples were 
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incubated at 98 ˚C for 45 minutes in order to lyse the yeast cells; 1 μl was then 
taken from each sample and used as a template for PCR reaction. MangoTaq 
Polymerase (Bioline, USA) was used for the reaction, and 5 μl of each PCR reaction 
were separated using agarose gel electrophoresis to verify the size of the insert. 
The remainder was purified and used for sequencing of prey fragments with prey 
vector specific primers.  
2.2.17 Human Retinal cDNA Library 
The human retinal cDNA was constructed and characterised in the 
Bhattacharya laboratory by Dr Barbara Czub and Dr Amna Shah. The library was 
prepared directly in Y187 yeast strain using the Make Your Own “Mate & Plate™” 
Library System (Clontech, USA) which utilises the SMARTTM cDNA synthesis 
technology.  
Briefly, the first cDNA strand was transcribed from the total human retinal 
RNA purchased from Clontech using a 1:1 ratio of two types of primers: a modified 
oligo-dT primer (CDS III Primer) and a random primer (CDSIII/6 Primer). The 
former hybridises to the 3’ end of poly A+ RNA, which results in sequences located 
towards the 5’ end being under-represented. The CDS III/6 Primer is able to 
hybridise to a variety of sequences on the RNA template, making a library 
generated using this primer containing a wider range of sequences. In this study, a 
library prepared using both primers was used. The cDNA was then amplified using 
long distance PCR (LD-PCR) and double-stranded cDNA was purified using the 
CHROMA SPIN TE-400 Columns (Clontech). The columns allowed fractionation of 
the cDNA according to size and it selected for molecules larger than 200 bp. Next, 
large scale co-transformation of Y187 yeast strain was performed using the 
purified cDNA and pGADT7-Rec vector. The highly potent homologous 
recombination machinery of Saccharomyces cerevisiae allowed obtaining a cDNA 
library of prey vectors. Recombination process occurs between sequences 
introduced by primers used in LD-PCR and complementary fragments present in 
pGADT7-Rec vector. A total volume of approximately 500 ml of library was 
obtained and cell density was adjusted to yield at least 2x107 per 1 ml. The library 
was aliquoted and stored at -80 ˚C. 
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2.3 Immunofluorescence (IF) 
2.3.1 Immunocytochemistry (ICC) 
2.3.1.1 Paraformaldehyde (PFA) Cell Fixation 
In all experiments performed in the study, fixation of cells was performed 
with PFA, which forms cross-links between protein and thereby preserves the 
morphology of the cell. For the purpose of immunocytochemistry, cells were 
grown on glass coverslips placed in a 24-well plate. Before fixation, media was 
aspirated from the cells and two washes with sterile PBS were performed. Fixation 
was carried out using 300 µl of 4 % PFA for 20 minutes at room temperature. Next, 
to permeabilise the cell membrane, the cells were incubated for 5 minutes in the 
solution made up of 0.3 % Triton-X in 1X PBS. The cells were then washed twice 
with the solution of 20 mM glycine in 1X PBS and incubated for 15 minutes in the 
same solution. The cells were then used for subsequent experiments or stored in 
0.5 % BSA solution at 4 ˚C. 
2.3.1.2 Immunolabelling of Fixed Cells 
 
The coverslips with fixed cells were transferred to a fresh 24-well plate and 
incubated in 300 µl of the blocking solution (6% BSA, 0.3% Tween 20 in 1X PBS) 
for 1 hour at room temperature. In the meantime, a humid chamber was prepared 
by placing a piece of wet 2 mm filter paper in a plastic dish. Next, a piece of 
parafilm was placed on the wet blotting paper and 10 µl of primary antibody 
dilutions were dropped on the surface of the parafilm. The blocked coverslips were 
transferred to the humid chamber and placed on the drops of antibody dilutions 
upside down, i.e. the side with fixed cells was facing down. The incubation with 
primary antibodies was carried out for 2 hours at room temperature or overnight 
at 4 ˚C. Next, the coverslips were transferred back to the 24-well plate, making sure 
that the side of the coverslip with attached cells is facing up. The coverslips were 
washed 3 times 10 minutes with 500 µl of PBS-T (0.1 % Tween 20 in 1X PBS) and 
gentle agitation. Afterwards, the dilutions of fluorophore conjugated secondary 
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antibodies were prepared in the blocking solution and 150 µl of the desired 
dilution were added per well. The incubation was carried out for 1 hour at room 
temperate with gentle agitation and was followed by three 10-minute washes with 
500 µl of PBS-T and gentle agitation. To stain DNA, incubation with a solution of 
4',6-Diamidino-2-Phenylindole (DAPI; Sigma) was carried out for 10 minutes at a 
working dilution of 1:5000. The cells were then washed 3 times 10 minutes in PBS 
with gentle agitation and mounted on glass slides using the Dako Mounting 
Fluorescence medium (Dako, Denmark). Visualisation of immuno-labelled cells 
was performed using the Zeiss LSM 700 confocal microscope. 
 
2.3.2 Immunohistochemistry (IHC) 
2.3.2.1 Retinal Cryosections 
Retinal cryosections used in the project were kindly provided by Professor 
Glenn Jeffery, UCL. The sections were derived from two 2 year old Macaca 
fascicularis monkeys. The eyes were fixed in 4 % PFA for 2 days and stored in 30 % 
sucrose at 4 ˚C. Next, the retina and RPE were removed, embedded in OCT and 
sectioned at 10 microns. The slides were stored at -80 ˚C. 
2.3.2.2 Immunolabelling of Retinal Cryosections 
Before IHC was performed, retinal cryosections were taken out of the -80 ˚C 
freezer and kept at room temperature for 2 hours. Then, the slides were washed in 
PBS (3 times for 10 minutes) with gentle agitation. Antigen unmasking was 
performed by incubating the slides in 0.1 M citrate buffer (Antigen Unmasking 
Buffer, Vector Laboratories) and warming them up in a microwave in three steps: 
P100 for 3 minutes, P80 for 2 minutes and P10 for 10 minutes, where P stands for 
the microwave power. The slides were then washed in PBS (3 times for 10 
minutes) with gentle agitation and incubated for 4 hours in a blocking reagent 
made up of 0.3 % Tween 20, 1 X PBS, 6 % BSA and 5 % normal donkey/goat serum.  
The incubation with primary antibodies was carried out overnight at 4 ˚C 
and the antibody dilutions were prepared in the blocking solution. The incubation 
was followed by washes in PBS-T (3 times 10 for minutes) with gentle agitation 
and then, the slides were incubated for 1 hour with secondary antibodies diluted in 
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the blocking reagent. The slides were washed 3 times for 10 minutes in PBS-T, 2 
times for 10 minutes in PBS and incubated for 10 minutes in DAPI (1:5000 
dilution). Next, three 10 minute washes in PBS were carried out and the slides 
were mounted using the Dako Mounting Fluorescence medium (Dako, Denmark). 
Visualisation of immuno-labelled cells was performed using the Zeiss LSM 700 
confocal microscope. Every assay was accompanied by control experiments aiming 
to confirm the specific binding of primary antibodies and to verify the strength of 
autofluorescence.  
2.4 Immunoprecipitation (IP) 
Immunoprecipitation (IP) was used in the project to test whether the two 
proteins of interest complex together and in such case the method was referred to 
as co-immunoprecipitation (Co-IP). The assays were performed using SureBeads 
Protein G Magnetic Beads (BioRad, USA) according to the manufacturer’s 
recommendations. The interactions were tested in protein extracts obtained from 
transfected or non-transfected cells. To test the interaction, 100 µl of protein 
extract (at the concentration of total protein extract of 1-1.5 mg/ml) were 
transferred to a 2 ml microcentrifuge tube, which was then placed on a magnetic 
tube rack. Once the beads magnetised, the supernatant was discarded and the 
beads were washed three times with 1 ml of PBS-T (0.1 % Tween 20 in 1X PBS). 
Next, 10 µg of antibody were added in a final volume of 200 µl; the volumes were 
adjusted with PBS-T. The tubes were placed on a rotary shaker and mixed for 
10 minutes at room temperature. The beads were then magnetised, the 
supernatant removed and three washes with PBS-T were performed. Antigen 
containing lysate was then added to the beads and typically, 100-150 µg of the 
total protein extract per sample were used. The tubes were mixed on a rotary 
shaker at room temperature for 1 hour. Afterwards, the beads were magnetised, 
the supernatant removed and three washes with PBS-T were performed. To elute 
the pulled down protein complexes, 40 µl of 1X Laemmli buffer were added and 
the tubes were incubated at 70 ˚C for 10 minutes. The eluted samples were 
immediately resolved by SDS-PAGE and analysed by immunoblotting.     
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2.5 Mutation Screening 
2.5.1 Patients 
Mutation screening was carried out on a panel of 96 unrelated autosomal 
recessive retinitis pigmentosa (arRP) patients. Informed consent was obtained 
from each patient, in accordance with guidelines established by the Declaration of 
Helsinki and was approved by the Moorfield’s Eye Hospital Ethics Committee. 
Genomic DNA was provided by Dr Naushin Waseem and Ms Beverley Scott. 
2.5.2 Primer Design and Mutation Screening 
Primers for mutation screening were designed using the reference 
sequence derived from Enembl database (PROM1, Transcript ID: 
ENST00000510224). Primers were anchored in introns so that the full sequences 
of exons as well as splicing sites are covered. The primers used for mutation 
screening of PROM1 are summarised in Table 2.16. It is necessary to mention that 
the primers shown in the table cover all of the coding exons in 7 isoforms of human 
PROM1 but additional primer pairs had to be designed for exons 24 and 25 of 
isoform 3 (s3). This was necessary because isoform 3 differs from the canonical 
isoform of Prominin-1 in that it has an amino-acid change from 
VETIPMKNM to SSWVTSVQC at the position 831-839. This change localizes at the 
C-terminus of the protein and is not included in any of the conserved domains. 
The DNA fragments were amplified using MangoTaq polymerase 
(Bioline, UK) and the sequencing was performed using BigDyeTM Terminator v3.1 
Cycle Sequencing Kit (Applied Biosystems, UK), as described in section 2.1.1. 
The sequencing electropherograms obtained were analysed using 
Lasergene DNASTAR® software (DNASTAR, Inc). Any variations found were 
annotated in accordance with recommendations by Human Genome Variation 
Society (www.hgvs.org/mutnomen). Nucleotide numbering reflects cDNA 
numbering with +1 corresponding to the A of the ATG translation initiation codon 
in the reference sequence. The initiation codon is codon 1 and there is no 
nucleotide or codon 0. 
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Potential pathogenicity of novel substitutions was assessed using 
Polyphen2 (http://genetics.bwh.harvard.edu/pph2/; Adzhubei et al., 2010) and 
SIFT (http://sift.jcvi.org/; Ng & Henikoff, 2002) software.  
 
 
Table 2.16 Summary of primers used to perform mutation screening of PROM1. Tm – 
optimised melting temperatures of primers.  
  
Exon Froward Primer (5'->3') Reverse Primer (5'->3')
Product 
Size 
[bp]
Tm 
[˚C]
1 CGCGGTGAGTATGTTTAAGGA CCTACTCCCGCTGTGG 890 51
2 CTGGAGCAGGTTGTGTG CCTCGCAACCTATGTAACC 764 54
3 GGCTTCTGGCTAGAGGTC GGTGGTTCAATATTCCATG 384 54
4 CACCCAATTTCCTCCTTG GTACATTTGATAACACAGCCTTTC 495 54
5 AAAAGAACTTTGTACACCATGGAATG CATTACAACGCTAATGTCTG 499 55
6 GAAGGATGTGGGAGGAG CAGATAACACCAGTCTACGC 397 54
7 CTAGGAACTTGCTGGTTACC GGCTAGATTCTAATCGCTG 359 54
8 CAGTTGGTGCGGAGAC CCAAGCCAGCTCTCAG 369 54
9 CTAGCGATGCTCCTGTATTC CTAACTGTTCTCCAAGTCAGG 495 54
10 CAGCAAGAGACCTCCAGAC CATGCCACTTCACACATC 500 54
11 GACTCTTGATGACCATATAATG GTCCGAATGACACAATTG 379 54
12 CGATGGTCTTGGCTATATTC GCGAGCACTTCAAATTC 498 55
13 CACTCAACATTATTGTCCTCTG GCAGGATCTCTCCTCCTC 450 57
14 CTCCTAGGTGGATGATCTG GCAATCCACATTGAGC 548 55
15 GTTGGAAATCAACCAGAAAAATAATG CCAGAGATTATTGGAGAGCGAGA 476 55
16 CAAGGCAAGAAGTCAGAAG GAGGTGAAGGTTACACAGC 431 55
17 GAGATGCCAGTCAAGTGC CCACCGAATTGCTCAC 580 55
18 GTTTCTGACCTCACATGATTAC GACACACACAAGAGAGGTG 333 55
19 CATCATTGCATGCTTATGTC GGCCAGCTCAACTTCTG 354 55
20 CACATTGTTAATTGTGTTGG GATGAGGTCTGCACTTAGAG 400 52
21 CCTCTTAACTAGCAGGTCCAG GTCTTGGTCCTGCACATC 552 55
22 CCTCTTAACTAGCAGGTCCAG GTCTTGGTCCTGCACATC 552 55
23 CCTGTCTTAGAGGACATGG GTCTATTAGCATCTCAATACACTG 369 55
24 GGTCCACATGACATTCTC CGAGAGAGAGGAACTGC 541 54
25 CATTCTGTGTCTGGTGAATG GCCTGTACAGATCTGCTG 331 55
26 GTCCTTTGGTCTTTGAAG GAGCATGATTGGAGACTAG 392 55
27 GTCAAGGCCATTATCACAGAG GAATCAATCGGTGGATGTG 763 55
28 GCTTTGCAACAAACATATTG GGAGTTACGCAGGTTTCTC 825 55
24 (s3) GGTCCACATGACATTCTC CGAGAGAGAGGAACTGC 541 54
25 (s3) GCATAAGACTTGATAACTCTTGG CTGTGGACCGTTAAGGAAG 351 54
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2.6 Summary of Vectors 
Plasmid vectors used in the study were available in the Bhattacharya 
laboratory and were purchased directly from the manufactures, unless stated 
otherwise. The summary of vectors used in the study is presented in Table 2.17.  
Vector Purpose Features 
pDONR/Zeo (Life 
Technologies, USA) 
Gateway donor vector 
used to generate entry 
clones 
Resistance to zeocin, ccdB 
gene used as negative 
selection marker 
pBD-DEST (Stratagene, USA) 
Gateway entry vector 
used to generate 
expression clones, 
N-terminally tagged with 
GAL4 DBD 
Resistance to 
chloramphenicol, TRP1 
nutritional reporter gene , 
ccdB gene used as 
negative selection 
marker; gift from Dr 
Ronald Roepman 
pAD-DEST (Stratagene, USA) 
Gateway entry vector 
used to generate 
expression clones, N-
terminally tagged with 
GAL4 AD 
Resistance to ampicillin, 
LEU2 nutritional reporter 
gene, ccdB gene used as 
negative selection 
marker; gift from Dr 
Ronald Roepman 
GBKT7 (Clontech, USA) 
Vector encoding GAL4 
DBD used to express wild 
type GAL4 DBD in yeast , it 
can be used to generate 
'baits' as an alternative to 
pBD-DEST 
Resistance to kanamycin, 
TRP1 nutritional reporter 
gene 
pBD-p53 (Stratagene, USA) 
Destination vector 
encoding GAL4 DBD fused 
to p53 protein, used in 
Y2H control experiments 
Resistance to 
chloramphenicol, TRP1 
nutritional reporter gene , 
ccdB gene used as 
negative selection marker 
pGADT7 -T (Clontech, USA) 
Vector encoding GAL4-AD 
fused to SV40 large T 
antigen protein, Used in 
Y2H control experiments 
Resistance to ampicillin, 
LEU2 nutritional reporter 
gene 
pGBKT7 -Lam (Clontech, USA) 
Vector encoding GAL4-BD 
fused to human lamin C 
protein, used in Y2H 
control experiments. 
Resistance to kanamycin,  
TRP1 nutritional reporter 
gene 
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pcDNA 3.2/V5-DEST (Life 
Technologies, USA) 
Gateway destination 
vector to generate C-
terminally V-5 tagged 
proteins 
Resistance to ampicillin, 
ccdB gene used as 
negative selection marker 
p3xFLAG-Myc-CMV (Sigma, 
USA) 
Vector used to generate 
proteins tagged with 
3xFLAG tag from N-
terminus and/or c-myc tag 
from C-terminus 
Resistance to ampicillin 
pEGFP-C3 (Clontech, USA) 
Vector used to generate 
proteins N-terminally 
tagged with eGFP  
Resistance to kanamycin 
pDsRed-Monomer-Hyg-N1 
(Clontech, USA) 
Vector used to generate 
proteins C-terminally 
tagged with DsRed 
Resistance to ampicillin 
pcDNA 3.1/EYS isoform 1 
Vector carrying cDNA 
sequence of EYS 
isoform 1; used as 
template for amplification 
Resistance to ampicillin 
pcDNA 3.1/PROM1 
Vector carrying cDNA 
sequence of PROM1; used 
as template for 
amplification 
Resistance to ampicillin; 
gift from Prof Andrew 
Zelhof, Indiana University 
pCMV-Tag3C/AIPL1 
Vector encoding 
N-terminally c-myc tagged 
AIPL1 
Resistance to kanamycin; 
gift from Dr Jacqueline 
van Der Spuy, UCL IoO 
pCMV-Tag3B/NUB1 
Vector encoding 
C-terminally c-myc tagged 
NUB1 
Resistance to kanamycin; 
gift from Dr Jacqueline 
van Der Spuy, UCL IoO 
Table 2.17 Summary of vectors used in the project.  
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2.7 Summary of Antibodies and Dyes 
Primary antibodies used in the study are summarised in Table 2.18 
whereas secondary antibodies used are listed in Table 2.19. Dyes that were applied 
in immunofluorescence are listed in Table 2.20. Concentrations of the antibodies 
and dyes used were experimentally optimised for every assay. 
 
Antibody Animal raised in   Manufacturer 
Working 
Dilution 
anti-GAL4 DBD Rabbit 
SantaCruz, 
USA 
IB: 1:500 
anti-acetylated alfa-tubulin Mouse Sigma, USA 
ICC: 1:5000 
IHC: 1:1000 
anti-AIPL1* Rabbit Custom made 
IB: 1:30000, 
 ICC: 1:15 000 
anti-alfa-tubulin Mouse Sigma, USA ICC: 1:3500 
anti-arrestin Mouse 
SantaCruz, 
USA 
IHC: 1:500 
anti-c-myc Mouse Genron, UK ICC: 1:1000 
anti-EYS1 Rabbit Custom made 
IB: 1:500 
ICC: 1:300 
anti-EYS2 Rabbit Custom made IHC: 1:50 
anti-EYS3 Goat 
SantaCruz, 
USA 
ICC: 1:300 
anti-GFP Mouse 
SantaCruz, 
USA 
IB: 1:500 
anti-giantin Mouse Abcam, UK IB: 1:250 
anti-Prominin-1 Mouse 
Miltenyi 
Biotec, 
Germany 
IB: 1:100 
ICC: 1:10 
ICH: 1:10 
anti-s-opsin Goat 
SantaCruz, 
USA 
ICH: 1:20 
anti-V5 Goat 
SantaCruz, 
USA 
IB: 1:500 
ICC: 1:300 
Table 2.18 Summary of primary antibodies used in the study. *- anti-AIPL1 rabbit 
antibody was kindly provided by Dr Jacqueline van der Spuy, UCL Institute of 
Ophthalmology. IB – immunoblotting, ICC– immunocytochemistry, ICH - 
immunohistochemistry. 
  
Materials and Methods 
102 
 
Antibody Animal raised in   Manufacturer 
Working 
Dilution 
HRP anti-mouse Goat 
Jackson 
ImmunoResearch, USA 
IB: 1:15000 
HRP anti-rabbit Goat 
Jackson 
ImmunoResearch, USA 
IB: 1:15000 
HRP anti-goat Rabbit 
Jackson 
ImmunoResearch, USA 
IB: 1:15000 
Cyanine 3 anti-rabbit Donkey 
Jackson 
ImmunoResearch, USA 
IF: 1:500 
Cyanine 3 anti-goat Donkey 
Jackson 
ImmunoResearch, USA 
IF: 1:500 
Cyanine 3 anti-mouse Donkey 
Jackson 
ImmunoResearch, USA 
IF: 1:500 
Cyanine 3 anti-mouse Goat 
Jackson 
ImmunoResearch, USA 
IF: 1:500 
AlexaFluor 488 anti-rabbit Donkey LifeTechnologies, USA IF: 1:500 
AlexaFluor 488 anti-rabbit Goat LifeTechnologies, USA IF: 1:500 
AlexaFluor 488 anti-goat Donkey LifeTechnologies, USA IF: 1:500 
AlexaFluor 633 anti-mouse Goat LifeTechnologies, USA IF: 1:500 
AlexaFluor 633 anti-rabbit Goat LifeTechnologies, USA IF: 1:500 
AlexaFluor 594 anti-goat Donkey LifeTechnologies, USA IF: 1:500 
Table 2.19 Summary of secondary antibodies used in the study. IB – immunoblotting, IF – 
immunofluorescence. 
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Dye Manufacturer Working Dilution 
DAPI Sigma, USA IF: 1:5000 
AlexaFluor 594 Phalloidin LifeTechnologies, USA IF: 1:800 
AlexaFluor 488 WGA LifeTechnologies, USA IF: 1:800 
TexasRed-X WGA LifeTechnologies, USA IF: 1:800 
TexasRed-X PNA LifeTechnologies, USA IF: 1:800 
Table 2.20 Summary of dyes used in the study. IF – immunofluorescence. 
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2.8 Summary of Materials 
Materials used in the projects are summarised in Table 2.21 
Item Company 
1 M lithium acetate (10X) (LiAc (10X)) Clontech, USA 
10X Loading Buffer, Bromophenol Blue Sigma, USA 
10X Tris-glycine-EDTA 
Flowgene Bioscience, 
UK 
2-Mercaptoethanol Sigma, USA 
50X TAE VWR, USA 
5-Bromo-4-chloro-3-indolyl alpha-D-galactopyranoside (X-
alpha-gal) 
Glycosynth, UK 
6X Laemmli Bufer Alfa Aesar, UK 
Adenine hemisulphate Sigma, USA 
Agar VWR, USA 
Agarose Sigma, USA 
Antigen Unmasking Buffer 
Vector Laboratories, 
UK 
Aprotinin Sigma, USA 
Benzamidine Sigma, USA 
BigDye® Terminator v3.1 Cycle Sequencing Kit 
Applied Biosystems, 
USA 
Coomassie Brilliant Blue Sigma, USA 
Dako Mounting Fluorescence medium  Dako, Denmark 
DAPI  Sigma, USA 
Dibutyryl cyclin AMP (dbcAMP) Sigma, USA 
Dimethyl Sulfoxide, DMSO Sigma, USA 
DMEM  Life Technologies, USA 
dNTPs Bioline, USA 
Ethanol BDH Chemicals, UK 
Ethylenediaminetetraacetic acid (EDTA) Sigma, USA 
ExoSAP-IT Affymetrix, USA 
GAL4 BD monoclonal antibody (mAb; raised in mouse) Clontech, USA 
GelRed Biotium, USA 
Glass beads (3 mm) Merck, USA 
Glass beads (425-600 μm) Sigma, USA 
Glycerol BDH Chemicals, UK 
Glycine Sigma, USA 
Hi-Mark Pre-Stained High Molecular Weight Protein 
Standard 
Life Technologies, USA 
Hi-Mark Pre-Stained High Molecular Weight Protein 
Standard  
Life Technologies, USA 
Horseradish peroxidise (HRP) anti-mouse antibody (raised in 
goat) 
Jackson 
ImmunoResearch 
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Hydrochloric acid VWR, USA 
Hyper Ladder I Bioline, USA 
Instant Dried Skimmed Milk 
The Co-operative Food, 
UK 
KOD Hot Start DNA Polymerase Kit 
Toyobo Novagen, 
Japan 
Leupeptin hemisulfate salt Sigma, USA 
Lipofectamine 2000 Life Technologies, USA 
MangoTAQ polymerase Kit Bioline, USA 
Opti-MEM media  Life Technologies, USA 
Paraformaldehyde EMS, UK 
PBS tablets Oxoid, UK 
Pepstatin A Sigma, USA 
Phenylmethyl-sulfonyl fluoride (PMSF) Sigma, USA 
Poly-L-lysine Sigma, USA 
Ponceau-Red stock solution Sigma, USA 
Precision Plus Protein Dual Standards BioRad, USA 
Precision Plus Protein Standards, Dual Color BioRad, USA 
Primers Sigma, USA 
ProteaseArrest 100 X G-Biosciences, USA 
RPMI Media Life Technologies, USA 
S.O.C. Medium Liquid Life Technologies, USA 
Sodium Chloride (NaCl) Sigma, USA 
Sodium Chloride, NaCl Fischer Scientific, USA 
Sodium dodecylsulfate, SDS Sigma, USA 
SureBeads BioRad, USA 
TRIS base Sigma, USA 
Triton-X Sigma, USA 
Trypan Blue  Sigma, USA 
Trypsin-EDTA  Life Technologies, USA 
Tryptone Merck, USA 
Tween 20 Sigma, USA 
Yeast Extract Sigma, USA 
Yeastmaker Carrier DNA Clontech, USA 
YPD Broth Sigma, USA 
YPD Plus Liquid Medium Clontech, USA 
Y-Per ThermoScoentific, USA 
Table 2.21 Summary of materials used in the project. 
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2.9 Summary of Solutions 
Solutions used in the study are summarised in the following tables.  
 
 
Table 2.22 Recipe for LB media. 
 
 
 
Table 2.23 Recipes for YPDA media. 
 
 
 
Table 2.24 Recipe for SDS-PAGE running buffer. 
 
 
 
Table 2.25 Recipe for transfer buffer used for electroblotting.  
 
 
LB Agar Medium  LB Liquid Medium
4 g Tryptone 4 g Tryptone
2g Yeast Extract 2 g Yeast Extract
3.2 g NaCl 3.2 g NaCl
6 g Agar  - 
400 ml dH2O 400 ml dH2O
YPDA Agar Medium C 1X YPDA Liquid Medium C 2X YPDA Liquid Medium
25 g YPD 25 g YPD 50 g YPD
0.02g adenine hemisupfate 0.02g adenine hemisupfate 0.04g adenine hemisupfate
12.5g agar powder  -  - 
500 ml dH2O 500 ml dH2O 500 ml dH2O
SDS-PAGE running buffer
100 ml of 10X Tris+glycine+SDS
900 ml of dH2O
Transfer buffer for electroblotting
100 ml of 100 ml of 10X Tris+glycine+SDS
200 ml of methanol
800 ml of dH2O
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Table 2.26 Recipe for blocking solution used in immunoblotting. 
 
 
 
Table 2.27 Recipe for 10X TBS. 
 
 
 
Table 2.28 Recipe for 1X TBS-T. 
 
 
 
Table 2.29 Recipe for 1X PBS-T. 
 
 
 
Table 2.30 Recipe for 10 % Ponceau Red solution. 
 
Blocking solution for immunoblotting
5 % of non-fat milk
0.1 % of Tween-20
1X TBS to the maximum volume
TBS 10X:
24.23 g of Tris-HCl
80.06 g of NaCl
800 ml of ultra-pure H2O, pH to 7.6
Top up to 1 L
1X TBS-T
100 ml of TBS 10X
1 ml of Tween-20
900 ml of ultra-pure H2O
1X PBS-T
100 ml of PBS 10X
1 ml of Tween-20
900 ml of ultra-pure H2O
Ponceau Red 10 %
1 ml of Ponceau Red stock solution
9 ml of dH2O
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Table 2.31 Recipe for solutions used in Coomassie staining. 
 
 
 
Table 2.32 Recipe for TAE buffer. 
 
 
 
Table 2.33 Recipe for synthetic minimal media. 
 
 
 
Table 2.34 Recipe for TE/LiAc solution. 
'Coomassie 1 mixture’
 40 % of dH2O
10 % of acetic acid
50 % methanol
‘Coomassie staining mixture’
40 % of dH2O
 10 % of acetic acid
50 % methanol
  0.25 % Coomassie brilliant blue R250
 Coomassie destaining  mixture’
67.5 % dH2O
 7.5 % acetic acid
25 % methanol
TAE
2 M TRIS-Acetate
0.05 M EDTA
Synthetic Minimal Media
3.35 g Yeast nitrogen base
91.1 g D-sorbitol
500 ml dH2O
pH 5.8
20 g agar
Autoclave-sterilised
0.37 g of relevent dropout solution
20 ml 50 % glucose
1.1X TE/LiAc Solution
1.1 ml 10X TE (supplied with the kit)
1.1 ml 1 M LiAc (10X) (supplied with the kit)
7.8 ml sterile dH2O
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Table 2.35 Recipe for PEG/LiAc Solution. 
 
 
 
Table 2.36 Recipe for 0.9 % NaCl solution. 
 
 
 
Table 2.37 Recipe for cracking buffer stock solution. 
 
 
 
Table 2.38 Recipe for complete cracking buffer. 
 
PEG/LiAc Solution
8 ml 50 % PEG 3350 (supplied with the kit)
1 ml 10X TE Buffer (supplied with the kit)
1 ml 1 M LiAc (10X) (supplied with the kit)
0.9 % (w/v) NaCl Solution
0.9 g NaCl
100 ml dH2O
Cracking Buffer Stock Solution
8 M Urea
5 % (w/v) SDS
40 mM Tris-HCl, pH 6.8
0.1 mM EDTA
0.4 mg/ ml bromophenol blue
dH2O
Complete Cracking Buffer
1000 μl Cracking Buffer Stock Solution
10 μl β-mercaptoethanol
70 μl pre-chilled protease inhibitor solution
50 μl 100X PMSF stock solution
0.4 mg/ ml bromophenol blue
dH2O
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Table 2.39Recipe for TCA buffer. 
 
 
 
Table 2.40 Recipe for SDS/glycerol stock solution 
 
 
 
Table 2.41 Recipe for Tris-EDTA solution. 
 
 
 
Table 2.42Recipe for TCA Laemmli loading buffer. 
 
TCA Buffer (10 ml)
200 μl of 1M Tris-HCl (ph 8)
66.6 μl of 7.5M Amonium acetate
40 μl of 0.5M EDTA
9.7 H2O
SDS/glycerol stock solution
3.5 ml of 25% SDS
3.5 of 100% glycerol
1 ml of 1M Tris-base
spatula tip-full of bromophenol blue
dH2O up to 12 ml
Tris-EDTA solution
2 ml of 1M Tris-base
0.4 ml of 0.5M EDTA
7.6 ml of dH2O 
TCA-Laem mli loading buffer
480 μl of SDS/glycerol stock solution
400 μl of Tris/EDTA solution
50 μl of β-mercaptoethanol
20 μl of PMSF stock solution
20 μl of protease inhibitor solution
30 μl of dH2O
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Table 2.43 Recipe for blocking solution used in ICC. 
 
 
Table 2.44 Recipe for blocking solution used in ICH. 
Bloking solution for ICC
6 % BSA
0.3 % Tween 20
1X PBS
Blocking solution of ICH
6 % BSA
0.3 % Tween 20
1X PBS
5% normal donkey/goat serum
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Chapter 3: Identification of Novel Interacting Partners of EYS 
 A powerful approach to investigate the function of a newly discovered 
protein is to study its interactome. Identifying interacting partners of EYS could 
provide useful insights into the biological processes it is involved in and it could 
help hypothesise its role in the human retina. This in turn could help answer the 
question of why mutations in EYS cause arRP. Understanding the role of EYS would 
be invaluable to the clinical management of arRP patients and it would provide 
critical knowledge for the design of future therapies. 
The method of identification of novel interacting partners used in this study 
was Yeast 2-hybrid (Y2H). 
3.1 Construction of EYS Baits 
The first step of preparation for Y2H screening was construction of baits. In 
the study, cDNA of EYS isoform 1 was available and the constructed baits included 
the full length sequence as well as shorter fragments. The shorter bait fragments 
were constructed not only to perform Y2H screening but also to characterise 
potential interactions, i.e. to map the region of EYS responsible for mediating the 
protein-protein interactions. A schematic view of baits constructed in the study is 
shown in Figure 3.1. DNA fragments of EYS were amplified using attB-primers and 
KOD Hot Start DNA Polymerase Kit (Toyobo Novagen, Japan). Amplification of all 
EYS amplicons was successful as confirmed by agarose gel electrophoresis 
separation (Figure 3.2). AttB-PCR products were purified and cloned into 
pBD-DEST vectors using Gateway technology and direct sequencing was used to 
verify the sequence integrity. Purified expression clones were transformed into 
Y2HGold yeast cells and the transformants were examined in control experiments. 
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Figure 3.1 A schematic overview of bait fragments used in the study.  
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Figure 3.2 Bait fragments of EYS amplicons separated by electrophoresis on 1 % agarose 
gel. M- Hyperladder I molecular weight marker, 1 - bait 1 (3930 bp), 2 - bait 2 (3483 bp), 3 
– bait 3 (4458 bp), 4 – bait 4 (2994 bp), 5 – bait 5 (3810 bp), 6 – bait 6 (4881 bp), 7 – bait 7 
(8988 bp), 8- bait 9 FL (9435 bp), 9 – bait 8 (5079 bp). 
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3.2 Y2H Control Mating and Characterisation of the Baits 
Before Y2H screening of a cDNA library can be performed, it is necessary to 
carry out a series of control experiments aiming to characterise baits and test the 
functionality of the system used. Characterisation of bait fragments includes 
verification of whether they possess features of an ideal Y2H bait, which should: 
 not be toxic to yeast cells 
 not activate transcription of the reporter genes 
 be expressed in transformed yeast cells 
 
It is important to note that not all of the bait fragments were used in Y2H 
screening and some of them were constructed with the aim to use them for 
characterisation and mapping of the putative interactions.  
3.2.1 Y2H Control Mating 
The control mating was performed in order to ensure that all components 
of the system used in our laboratory are functional and to obtain positive and 
negative controls for use later in the screen. In the first step, pBD-DEST-p53 
(encoding p53 fused to GAL4 BD) and pBD-DEST-pLc (encoding Lamin C fused to 
GAL4 DBD) vectors were transformed into the Y2HGold yeast strain whereas 
pGADT7-T vector (encoding SV40 large T antigen fused to GAL4 AD) was 
transformed into Y187. Single colonies of each type of transformed yeast were 
mated as follows: 
 Positive control: Y2HGold [pBD-DEST-p53] x Y187[pGADT7-T] 
 Negative control: Y2HGold [pBD-DEST-pLc] x Y187[pGADT7-T] 
 
Mated cultures were plated on relevant solid selective media as described in 
section 2.2.9. In the positive control, colonies of transformants grew on all types of 
selective solid media used (Figure 3.3). Growth on SDO/-Leu plate confirmed that 
pGADT7-T vector was successfully transformed into Y187 cells whereas colonies 
that grew on SDO/-Trp could only do so if they contained pBD-DEST-p53 plasmids. 
DDO medium selected for the presence of both plasmids, i.e. proper diploid cells, 
and DDO/X/A medium was used to additionally select for the interaction between  
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Figure 3.3 Control Y2H mating, positive control. Growth on selective media is only 
possible for yeast cells successfully transformed with a particular vector enabling 
synthesis of an amino acid absent in the medium. On media plates additionally 
supplemented with AbA, yeast cells need to activate the AUR1-C reporter gene in order to 
sustain growth. Activation of MEL1 reporter genes results in yeast colonies turning blue on 
media supplemented with X-α-Gal. Colonies grown on selective media used in this 
experiment represent:  SDO/-Leu: Y187 cells transformed with [pGADT7-T]; SDO/-Trp: 
Y2HGold [pBD-DEST-p53]; DDO: diploid cells carrying both pGADT7-T and pBD-DEST-
p53 vectors. DDO/X/A: diploid cells carrying both pGADT7-T and pBD-DEST/p53 vectors 
this medium additionally selects for interaction between the bait and prey proteins, hence 
the blue colour of the colonies and the surrounding area.  
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the fusion proteins. Since p53 protein and SV40 large T antigen are known to 
interact, expression of the AUR1-C and MEL1 reporter genes was activated. This 
resulted in diploid yeast cells being able to grow on media supplemented with 
Aureobasidin A (A; AbA), an antifungal agent which restricts yeast cells from 
growth unless the resistance is provided by the expression of AUR1-C reporter 
gene. The secretion of α-galactosidase was responsible for the hydrolysis of 
X-α-Gal (X) and the resulting blue colour of the colonies and the surrounding 
medium.  
Results of the negative control mating of Y2HGold [pBD-DEST-pLc] with 
Y187 [pGADT7-T] cells are presented in Figure 3.4.  Growth on SDO/-Leu and 
SDO/-Trp confirmed that transformation with the control vectors was successful 
and the growth of colonies on DDO medium was only possible for diploid cells 
containing both of the control plasmids. As there is no interaction between human 
Lamin C and SV40 large T antigen, reporter genes were not activated and 
therefore, no colonies were observed on DDO/X/A medium. 
Results obtained from the control Y2H mating confirmed the functionality 
of the system and produced positive and negative controls. These were vital during 
subsequent stages of the project where it was necessary to assess putative 
interaction by the growth and colour of yeast colonies.  
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Figure 3.4 Control Y2H mating, negative control. Growth on selective media is only 
possible for yeast cells successfully transformed with a particular vector enabling 
synthesis of an amino acid absent in the medium. On media plates additionally 
supplemented with AbA, yeast cells need to activate the AUR1-C reporter gene in order to 
sustain growth. Activation of MEL1 reporter genes results in yeast colonies turning blue on 
media supplemented with X-α-Gal. Colonies grown on selective media used in this 
experiment represent:  SDO/-Leu: Y187 cells transformed with [pGADT7-T]; SDO/-Trp: 
Y2HGold cells transformed with pBD-DEST-pLc; DDO: diploid cells carrying both pGADT7-
T and pBD-DEST/p53 vectors. DDO/X/A: diploid cells carrying both pGADT7-T and 
pBD-DEST-p53 vectors; this medium additionally selects for interaction between the bait 
and prey proteins, hence growth of yeast colonies is not observed. 
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3.2.2 Bait Toxicity Assay 
To verify potential toxicity of EYS bait fragments, Y2HGold yeast cells were 
transformed with each of the bait constructs as well as the wild type GAL4 DBD 
control vector. Transformants were plated on solid SDO/-Trp medium and the 
growth and morphology of colonies were assessed after 5 days of incubation at 
30 ˚C. The number of colonies grown on each plate is summarised in Table 3.1.  
 pBD-DEST/bait 7 and pBD-DEST/bait 9 (full length EYS) transformants 
formed fewer colonies compared with the positive control and other bait 
fragments. This could be due to the large size of these baits, which could reduce the 
efficiency of yeast transformation and/or protein translation. Nonetheless, as 
shown in Figure 3.5, all of the transformants formed healthy looking colonies that 
did not differ in size compared with the positive control. Based on these 
observations, it was concluded that none of the EYS bait constructs is toxic to the 
host Y2HGold yeast strain and therefore, they were considered suitable to be used 
in Y2H. 
 
Construct 
Number of 
colonies 
pBD-DEST/bait 1 25 
pBD-DEST/bait 2 56 
pBD-DEST/bait 3 28 
pBD-DEST/bait 4 45 
pBD-DEST/bait 5 46 
pBD-DEST/bait 6 41 
pBD-DEST/bait 7 17 
pBD-DEST/bait 8 33 
pBD-DEST/bait 9 
(full length EYS) 
10 
pGBKT7 34 
Table 3.1 The number of transformed Y2HGold colonies grown on SDO/-Trp medium in a 
toxicity assay. pBD-DEST bait constructs encode respective EYS bait fragments fused to 
the GAL4 DNA binding domain; pGBKT7 control vector encodes the wild type GAL4 DBD 
only. 
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Figure 3.5 Bait toxicity assay. Snapshots of SDO/-Trp plates depict the number and size of 
colonies formed by transformed Y2HGold yeast cells. Each plate represents a different 
transformant: A - pBD-DEST/bait 1; B - pBD-DEST/bait 2; C - pBD-DEST/bait 3; 
D - pBD-DEST/bait 4; E - pBD-DEST/bait 5; F - pBD-DEST/bait 6; G - pBD-DEST/bait 7; 
H - pBD-DEST/bait 8; I - pBD-DEST/bait 9 (full length); J - control transformation with 
pGBKT7 encoding wild type GAL4 DNA binding domain. 
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3.2.3 Bait Auto-activation Assay 
The Y2H system relies on a number of reporter genes that are activated 
when an interaction between the bait and prey occurs. Expression of the reporter 
genes is triggered by the GAL4 transcription regulator. As it was described in 
section 2.2, the GAL4 transcription regulator consists of a DNA binding domain 
(GAL4 DBD) and an activation domain (GAL4 AD). In Y2H, the GAL4 DBD is fused 
with a bait protein whereas the GAL4 AD is fused with a prey protein. When bait 
and prey interact, GAL4 moieties are brought in proximity (effectively 
reconstituting the transcriptional regulator) and the expression of reporter genes 
is activated. It could, however, happen that the expression of the reporter genes is 
not activated by the GAL4 transcription regulator but the bait itself. This would 
lead to obtaining false positive results and such a scenario must be excluded before 
a bait is used in Y2H. 
 To assess whether the EYS bait fragments have the ability to activate 
expression of the reporter genes, the bait auto-activation assay was performed. 
pBD-DEST/bait constructs as well as the wild type GAL4 DBD control vector 
(pGBKT7 wild type vector) were transformed into Y2HGold yeast cells and plated 
on a range of selective media at three different dilutions. Diploid cells carrying 
Y2HGold [pBD-DEST-p53] and Y187 [pGADT7-T] vectors were used as a positive 
control of interaction. As shown in Figure 3.6, all of the transformants formed 
white/pink colonies on SDO/-Trp medium, which confirms that the vectors were 
successfully transformed into Y2HGold. SDO/-Trp/X medium was supplemented 
with X-α-Gal, which is hydrolysed when the MEL1 reporter gene is 
activated/expressed, resulting in blue yeast colonies. This was not the case for any 
of the baits, except for bait 4 transformants that formed pale blue colonies, 
suggesting that bait 4 could trigger low level expression of MEL1. SDO/-Trp/X/A 
medium was additionally supplemented with AbA and no transformant colonies 
were observed on SDO/-Trp/X/A medium, implying that the baits did not activate 
the expression of AUR1-C reporter gene and therefore, were unable to grow. Here, 
it was also shown that bait 4 could be used for Y2H screening as it was not able to 
activate the expression of two reporter genes simultaneously; nevertheless, it was 
considered as a bait of second choice. 
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Figure 3.6 Bait auto-activation assay. Each of the transformants was plated in three 
dilutions (columns) on three different media plates. Each transformant was plated in a 
separate row: 1 - pBD-DEST/bait 1; 2 - pBD-DEST/bait 2; 3 - pBD-DEST/bait 3; 
4 - pBD-DEST/bait 4; 5 - pBD-DEST/bait 5; 6 - pBD-DEST/bait 6; 7 - pBD-DEST/bait 7; 
8 - pBD-DEST/bait 8; 9 - pBD-DEST/bait 9 (full length). 10 - pGBKT7 (wild type GAL 4 
DNA binding domain); 11 – positive control formed of diploid cells :  Y2HGold [pBD-
DEST/p53] x Y187[pGADT7-T]. 
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In summary, the auto-activation assay demonstrated that the baits were 
suitable to be used in Y2H since they were incapable of activating transcription of 
the reporter genes. 
3.2.4 Bait Expression Assay 
The last control experiment aimed to confirm whether EYS bait fragments 
were expressed in yeast cells. To do that, protein extracts were prepared from 
transformed Y2HGold strains and Western blot analysis was performed. In order 
to prepare the extracts, single colonies of transformed Y2HGold strains were 
inoculated in liquid selective medium (SDO/-W). Cultures transformed with wild 
type pGBKT7 and pBD-DEST-WT vectors were used as positive controls whereas 
wild type Y2HGold yeast strain was used as a negative control.  Inoculated colonies 
were not older than four days, otherwise the extraction of proteins would have 
been hindered due to thickening of the yeast cell wall.  The cultures were kept in 
the log phase of growth, which was necessary to enable expression of the bait 
fragments. In the late log phase, the expression of bait fragments could have been 
impeded by the increasing concentration of ethanol that accumulates in the culture 
medium as a by-product of yeast metabolism. The manual provided by Clontech 
recommends two extraction methods, Urea/SDS method and TCA method. Both of 
the methods were tested, however, bands corresponding to the bait fragments 
were not observed in Western blotting. 
 The methods recommend by Clontech involve many steps and disruption of 
yeast cells is achieved by vortexing the cultures with glass beads. These generally 
time consuming and rather harsh procedures could have had an impact on 
degradation of the proteins of interest during extraction. Therefore, another 
reagent enabling extraction of proteins from yeast, named Y-Per Plus (Thermo 
Scientific, USA) was used. Y-Per Plus is a detergent based lysis buffer allowing fast 
extraction of yeast proteins that is carried out at room temperature and the use of 
glass beads is not required. In order to obtain as high concentration of proteins as 
possible, only 40 µl of extract were prepared from each of the 5 ml overnight 
cultures. The concentrations obtained were checked using a BCA assay and the 
extracts were resolved by SDS-PAGE, transferred to PVDF membranes and probed 
with anti GAL4 DBD antibody. The developed membranes are shown in Figure 3.7.  
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Figure 3.7 Western blot analysis of the expression of EYS bait fragments in Y2HGold yeast 
cells. Extracts were prepared using Y-Per plus reagent and resolved on pre-cast 4-20 % 
gradient gels. Loading was optimised using BCA assay and approximately 40 µg of total 
protein extract were loaded in each well. Immunoblotting (IB) was performed with using 
anti-GAL4 DBD rabbit antibody and the secondary antibody was HRP-conjugated goat 
anti-rabbit. Bio-Rad Precision Plus Protein Standard was used to assess the size of protein 
bands. Samples 1-13 represent different samples run in the experiment and the expected 
size of each protein band is given in brackets. The red arrow indicates the band of wild 
type GAL4 DBD fused with 132-236 amino acids of wild type fragment C of lambda cI 
repressor (positive control 2). 
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There were two positive control samples, each of which contained 
GAL4 DBD wild type. In the first positive control GAL4 DBD wild type was 
expressed from the pGBKT7 wild type vector (lane 1) and in the second, 
a pBD-DEST-WT vector was used (lane 13). The band obtained from the latter 
appeared higher as this control vector encodes GAL4 DBD fused with 132-236 
amino acids of wild type fragment C of lambda cI repressor. As it can be observed, 
there is a clear intense band in lane 1, but a weaker band was detected in lane 13 
(marked with red asterisk). The presence of bands in the positive controls proves 
that the protein extraction was effective and that the conditions of SDS-PAGE and 
Western blotting were properly optimised. Clear bands were not, however, seen 
for any of the bait fragment proteins. Upon in-depth analysis of blots, it can be 
noticed that, in the lanes representing EYS bait fragments, there is a smeared 
signal in the range of approximately 75-350 kDa. The smeared signal suggests that 
the proteins in this range could have degraded during extraction, sample 
processing or gel separation. One could argue that degradation should not have 
been an issue since the wild type GAL4 DBD did not give a smeared signal. It 
should be pointed out, however, that there are two bands visible in lane 1, one at 
the size of wild type GAL4 DBD (~22 kDa) and the second one at about ~12 kDa. 
Even though the signal was not smeared, the presence of the second band implies 
that some level of degradation had happened and resulted in the appearance of 
two protein bands. Furthermore, it is necessary to highlight that the sizes of EYS 
bait fragments are relatively large and, therefore, the expected bands would have 
been detected at a lot higher molecular weights than wild type GAL4 DBD. It is also 
natural that the extraction of higher molecular weight proteins is more challenging 
and a lot more liable to potential sample degradation. The size of bait fragments 
may have had an impact on the efficiency of expression in yeast cells and another 
scenario could be that the expression level of bait fragments was not sufficient 
enough for the Western blotting to detect the protein.  
Distinctly visible protein bands of the bait fragments were not detected and 
therefore, the important question of whether the baits were expressed in Y2HGold 
yeast cells could not be clearly answered. However, the baits passed the previous 
control experiments proving that the expression of proteins from the bait vectors 
was taking place – otherwise cultures would not have been able to grow on 
selective media lacking crucial amino acids that were encoded on the bait vectors 
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for the purpose of selection. Based on that, it was concluded that the EYS bait 
fragments were suitable for Y2H screening. 
3.3 Y2H cDNA Library Screening 
Y2H screens were performed using a human retinal cDNA Y2H library, 
which had previously been prepared in the Y187 yeast strain by members of the 
Bhattacharya laboratory at UCL. The library was screened by mating the Y2HGold 
yeast strains carrying the bait of interest with an aliquot of a human retinal cDNA 
library. 
The use of bait fragments for screening was prioritised according to their 
size and domain structure. The aim was to use as long bait fragment as possible to 
replicate the natural three-dimensional structure of EYS protein. Following such a 
strategy was important for ensuring that the identified interactions were genuine.  
Before each mating, an aliquot (10 µl) of the library culture was removed 
for the purpose of library titering. Also, an aliquot of the mated culture was taken 
each time and plated in relevant serial dilutions on control solid media plates for 
the purpose of assessing the efficiency of mating and the number of screened 
clones. The presence of zygotes in the mated culture was established in each 
screen prior to plating on selective solid media; an image shown in Figure 3.8 
depicts an example of a mated culture seen under a light microscope (zygotes are 
indicated by red arrows). Plating of the mated culture on relevant selective media 
allowed identification of clones in which an interaction of bait and prey had 
occurred. 
The first Y2H screen was performed using Y2HGold [pBD-DEST/bait 9] 
strain, which carried the full length EYS protein. As recommended by the 
manufacturer of the Y2H system, the mated culture was plated on DDO/X/A media 
plates and incubated for five days at 30 °C; however, no yeast colonies were 
observed upon examination of the media plates. Since the control experiments 
showed that the conditions of mating were in line with recommendations of the 
manufacturer (Table 3.2), it was concluded that the failure of the screen was due to 
some features of the bait. Full length EYS contains a signal peptide the role of 
which has not yet been fully investigated but it has been speculated that it might 
direct EYS protein to a secretory pathway. 
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Figure 3.8 A micrograph showing a sample of a mated yeast culture. Red arrows indicate 
zygotes, which typically have a 3-lobed structure. The lobes represent the two haploid 
parental cells and the budding diploid cell. 
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Y2H screen 1 2 3 
Primary selective media DDO/X/A DDO/X/A DDO/X/A 
Bait Bait 9 Bait 7 Bait 8 
Cell density of bait culture 
(recommended minimum = 1x108 
cells/ml) 
1.24x108 
cell/ml 
2.61x108 
cell/ml 
1.43x108 
cell/ml 
Library titre (recommended 
minimum = 2x107 cells/ml) 
3x106 cell/ml 
1.04x107 
cell/ml 
1.12x107 
cell/ml 
Mating efficiency (required minimum  
2% required) 
2.40 % 6.75 % 6.50 % 
Number of screened clones 
(minimum 1x106 required) 
9x106 1.012x106 1.087x106 
Table 3.2 Summary of the conditions of Y2H screens performed with bait 9, 7 and 8. 
DDO/X/A media plates were used to seed the mated cultures for the purpose of screening.  
 
It could, therefore, happen that yeast cells secreted the bait, which in turn impeded 
possibility of identifying potential interacting partners, and subsequently, did not 
allow for the activation of the reporter genes. 
In order to verify whether this might be the case, it was decided to use the 
Y2HGold [pBD-DEST/bait 7] strain, containing full size EYS protein lacking the 
sequence encoding the signal peptide. The mated culture was plated on DDO/X/A 
media plates as previously, but once more no growth of colonies was observed. 
Even though bait 7 does not contain the signal peptide, it constitutes 
approximately 95 % of the full-length protein, which is around 345 kDa including 
the GAL4 DBD. Therefore, it may have happened that it was the size of the bait 
protein that prevented the Y2H system from working. Another issue may have 
been the size or folding of the bait that prevented the complex of bait and prey to 
enter the nucleus and activate the expression of the reporter genes. In order to 
reduce this risk in the next screen, the Y2HGold [pBD-DEST/bait 8] strain was 
used. Bait 8 comprises of nine N-terminal EGF domains, a putative coiled-coil and 
three LamG domains; it reflects the domain structure of the full length EYS protein 
in its diminished form and constitutes around 53 % of the full size molecule. The 
mating procedure was performed as previously described and the culture of 
diploids was plated on DDO/X/A. The growth of positive diploid colonies was not 
observed.   
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 Parameters of the screens performed to this point did not deviate from the 
protocol described by the manufacturer of the system used (Table 3.2). Also, 
colonies grown on the control media plates looked healthy and did not differ in any 
way from the colonies observed during pre-screening control experiments. This 
suggested that the failure of the screens may have been caused by some specific 
features of the bait fragments such as size, conformation, localisation or expression 
level. Another possible scenario was that the interaction of bait and preys were 
transient or not strong enough to overcome restrictive conditions imposed by 
DDO/X/A media. The Y2H system used in this study incorporates AUR1-C gene as 
one of the interaction reporters. AUR1-C confers strong resistance to the otherwise 
highly toxic Aureobasidin A (AbA), which provides high stringency of the screening 
conditions but it may at the same time cause weaker interactions to be missed. The 
workflow recommended by the manufacturer states that in the first instance a 
mated culture should be plated on DDO/X/A media and blue colonies should be re-
patched to higher stringency QDO/X/A, which additionally lack adenine and 
histidine. These two amino acids are used as nutritional markers and diploids can 
grow on them only when a bait protein interacts with a prey protein, and activates 
their respective promoters. Such a procedure ensures high stringency of screening 
and reduces possible background and false positive results. In order to assess 
whether such stringent screening conditions are appropriate for EYS protein and 
its fragments, the strategy of Y2H screening was amended and less stringent 
conditions were allowed in the first place, and any colonies obtained were then re-
patched onto media plates of increasing stringency. In more detail, mated cultures 
were initially plated on triple drop-out media (TDO) lacking tryptophan, leucine 
and histidine. Such media plates were able to select for diploid cells and a potential 
interaction using one nutritional marker (hisitidine). Any colonies grown on TDO 
plates were re-patched onto more stringent TDO/X media plates and any blue 
colonies grown here were subsequently re-patched on QDO/X. Yeast colonies that 
grew blue on QDO/X media where transferred onto QDO/X/A media plates which 
were the ultimate and most stringent media used in the screening. Furthermore, it 
was decided to use shorter bait fragments in order to lower the risk of the system 
not working due to the bait size. To allow comprehensive screening of the library, 
bait fragments needed to cover the full sequence of EYS proteins. The fourth screen 
was performed using bait 3, which encompasses the N-terminal part of EYS 
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including all of the N-terminal EGF domains and the putative coiled-coil domain 
(Figure 3.1). The fifth screen was carried out using bait 6, which begins with a 
coiled-coil domain at the N-terminus and covers the entire C-terminal fragment 
comprising of EGF and LamG domains. Next, bait 8 was used as it mimics the 
domain structure of the full sized EYS and bait 7 was utilised to verify whether any 
interaction can be identified using the full sequence of EYS and less stringent 
screening conditions. The parameters of Y2H screens performed in the modified 
conditions are summarised in Table 3.3. In the fourth screen performed using 
Y2HGold [pBD-DEST/bait 3], a total number of 37 white colonies grew on TDO 
media plates. These colonies were transferred onto TDO/X media plates and 28 
colonies re-grew, 24 of which grew blue and four grew white. All of the colonies 
were re-patched onto QDO/X media plates and only the blue colonies were able to 
grow, meaning that the interaction between the bait and prey in the white colonies 
was not strong or abundant enough to activate the expression of more than one 
reporter gene. Blue colonies were eventually re-patched from QDO/X onto 
QDO/X/A and all of them were able to grow. The phenotypes of the colonies grown 
in this screen are summarised in Table 3.4  and the QDO/X/A is shown in 
Figure 3.9. 
  
Y2H screen 4 5 6 7 
Primary selective media TDO TDO TDO TDO 
Bait Bait 3 Bait 6 Bait 8 Bait 7 
Cell density of bait culture 
(recommended minimum = 1x108 
cells/ml) 
1.25x108 
cells/ml 
1.20x108 
cells/ml 
1.50x108 
cells/ml 
1.43x108 
cells/ml 
Library titer (recommended minimum 
= 2x107 cells/ml) 
1.19x107 
cells/ml 
8.50x106 
cells/ml 
1.23x107 
cells/ml 
7.6x106 
cells/ml 
Mating efficiency (required minimum  
2% required) 
11.13% 19.91% 13.04% 11.32% 
Number of screened clones (minimum 
1x106 required) 
1.18x106  2.47x106 1.84x106 1.72x106 
Table 3.3 Summary of the Y2H screens performed with bait 3, 6, 8 and 7. The mated 
cultures were spread on TDO media plates for the purpose of screening. 
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Medium type 
Colony 
number 
TDO/X QDO/X QDO/X/A 
1 blue blue blue 
2 blue blue blue 
3 blue blue blue 
4 blue blue blue 
5 blue blue blue 
6 blue blue blue 
7 blue blue blue 
8 blue blue blue 
9 blue blue blue 
10 blue blue blue 
11 blue blue blue 
12 blue blue blue 
13 white x x 
14 blue blue blue 
15 blue blue blue 
16 blue blue blue 
17 blue blue blue 
18 white x x 
19 blue blue blue 
20 blue blue blue 
21 blue blue blue 
22 blue blue blue 
23 blue blue blue 
24 blue blue blue 
25 blue blue blue 
26 blue blue blue 
27 white x x 
28 white x x 
Table 3.4 Summary of phenotypes of colonies grown in Y2H screen 4, which was 
performed using the Y2HGold [pBD-DEST/bait 3] strain. Out of 28 colonies grown 
altogether, 24 grew blue and 4 grew white on TDO media plates. Only the blue colonies 
were able to grow on QDO/X and QDO/X/A media plates. ‘x’ denotes no growth of yeast 
colonies. 
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Figure 3.9 QDO/X/A media plate with patches of colonies grown in Y2H screen 4, which 
was performed using the Y2HGold [pBD-DEST/bait 3] strain. Yeast colonies numbered 13, 
18, 27 and 28 grew white on the TDO plate and did not grow in the most stringent 
conditions on the QDO/X/A plate, which indicates the interaction in those colonies was 
not strong or abundant enough to activate all of the reporter genes. The blue colour of the 
colonies grown on the QDO/X/A indicates activation of four reporter genes and only these 
results should be considered true positive. 
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 In the fifth Y2H screen performed in the project, it was attempted to 
identify proteins interacting with the C-terminal part of EYS protein and the 
Y2HGold [pBD-DEST/bait 6] strain was used. Upon examination of TDO media 
plates, 14 white colonies were observed and re-patched onto TDO/X media plates. 
Of these, only three white colonies regrew and were subsequently re-patched onto 
QDO/X and QDO/X/A media plates (Table 3.5). One of the colonies remained 
consistently white regardless of the media plate, but the two other initially white 
colonies re-grew pale blue (Figure 3.10).  
In order to survive the restrictive environment of selective media, yeast 
diploids had to express reporter genes encoding missing amino acids and the 
enzyme protecting them from the toxicity of AbA. In this screen only three colonies 
of yeast were able to grow on the selective media but they were unable to 
efficiently activate the expression of MEL1 gene encoding α-galactosidase. This 
may raise concerns over reliability of the results obtained in this screen; however, 
since there were only three colonies grown altogether, they were all subjected to 
further analysis to verify credibility of the results. 
 
 
 
Medium type 
Colony 
number 
TDO/X QDO/X QDO/X/A 
1 white white white 
2 white 
pale 
blue 
pale blue 
3 white 
pale 
blue 
pale blue 
Table 3.5 Summary of phenotypes of colonies grown in Y2H screen 5, which was 
performed using the Y2HGold [pBD-DEST/bait 6] strain. Out of 14 colonies grown on TDO 
media plates, only 3 were able to grow on TDO/X, QDO/X and QDO/X/A media plates. One 
of the colonies grew white on all of the media plates used and two re-grew pale blue on 
QDO/X and QDO/X/A media plates.  
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1 2 3 
Figure 3.10 QDO/X/A media plate with patches of colonies grown in Y2H screen 5, which 
was performed using the Y2HGold [pBD-DEST/bait 6] strain. Three yeast colonies were able 
to grow on the most stringent QDO/X/A media plate. Colony 1 grew white whereas colonies 
2 and 3 grew very pale blue, which means that none of the interactions was strong or 
abundant enough to activate all of the reporter genes.  
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The next Y2H screen (screen 6) was performed using Y2HGold 
[pBD-DEST/bait 8] strain. As previously, the mated culture was plated on TDO 
media plates in the first instance, resulting in growth of nine white colonies, which 
were subsequently re-patched onto TDO/X media plates. Out of nine white 
colonies grown on TDO/X, five were blue and four grew white. In the next stage of 
the screen, two of the white colonies were unable to regrow on QDO/X media 
plates and the other two regrew blue or pale blue. All five blue colonies were 
consistently growing blue on all selective media supplemented with X-α-gal. Table 
3.6 summarises the phenotypes of colonies obtained in Y2H screen and the 
QDO/X/A plate showing the yeast patches is presented in Figure 3.11.  
 
 
 
Medium type 
Colony 
number 
TDO/X QDO/X QDO/X/A 
1 blue blue blue 
2 blue blue blue 
3 white pale blue pale blue 
4 blue blue blue 
5 white x x 
6 blue blue blue 
7 white x x 
8 blue blue blue 
9 white blue blue 
Table 3.6 Summary of phenotypes of colonies grown in Y2H screen 6, which was 
performed using the Y2HGold [pBD-DEST/bait 8] strain. Nine white colonies were patched 
on TDO/X media plates, five of which grew blue and four were white. The blue colonies 
were also able to grow on more stringent media as well as two of the white colonies, which 
re-grew blue on QDO/X and QDO/X/A media plates. Two of the white colonies were 
unable to grow in more stringent conditions.  
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Figure 3.11 QDO/X/A media plate with patches of colonies grown in Y2H screen 6. 
Seven out of nine initially obtained colonies were able to grow blue or pale blue; two of 
the colonies were unable to survive the restrictive conditions of QDO/X/A media, which 
means that the interaction in these colonies were not strong or abundant enough to 
activate all of the reporter genes.   
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The final Y2H screen was carried out using the Y2HGold [pBD-DEST/bait 7] 
strain and the screen resulted in the growth of only one colony on TDO media. The 
colony was re-patched onto TDO/X, QDO/X and QDO/X/A media plates and grew 
blue on all of them (Table 3.1, Figure 3.12) 
Altogether, seven Y2H screens were performed in the study resulting in 41 
yeast colonies obtained on the low stringency media plates (TDO/X). Out of these, 
35 colonies were able to survive more stringent conditions and re-grew on media 
additionally supplemented with AbA and X-α-gal, and lacking one more amino acid 
(QDO/X and QDO/X/A). Interestingly, some of the colonies initially grew white and 
became blue or pale blue when re-patched to more stringent conditions. This may 
be due to the interaction of bait and prey becoming more abundant over time or 
the yeast colonies overcoming restrictive conditions by adjusting their metabolism 
(revertant colonies). The latter scenario could shed negative light on the results 
obtained from colonies that changed colour from white to blue and these 
interactors would have to be disregarded based on such an assumption, following 
a general belief that the most genuine positive clones activate all of the reporter 
genes simultaneously. 
 
 
 
Medium type 
Colony 
number 
TDO/X QDO/X QDO/X/A 
1 blue blue blue 
Table 3.7 Summary of the phenotype of the only colony grown in Y2H screen 7, which was 
performed using Y2HGold [pBD-DEST/bait 7]. The colony was able to grow blue on all of 
the selective media used.  
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Figure 3.12 QDO/X/A media plate with a patch of the only yeast colony obtained in 
Y2H screen 7. The colony grew on all selective media used in the screen. 
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3.4 Identification of Putative Interacting Partners of EYS 
The next step of the Y2H protocol was to identify the preys pulled out in 
screening. Since there were relatively few positive colonies obtained altogether, all 
colonies grown on TDO/X media were subjected to the analysis. The prey library 
inserts were amplified by yeast colony PCR and the products were run on an 
agarose gel. Following the Matchmaker™ Gold Yeast Two-Hybrid System User 
Manual, amplicons smaller than 200 bp were disregarded from further analysis as 
the peptides synthesised from them would be too short to provide reliable results. 
The PCR products larger than 200 bp were purified and sequenced using vector 
specific primers.  The output sequences where afterwards analysed using online 
alignment tools (NCBI BLAST and UCSC Blat) in order to identify putative 
interacting partners of EYS. The information obtained from the online databases 
was used to identify genes encoding the preys that interacted with the bait and to 
check whether these gene fragments overlapped with the coding sequence. This 
was an important aspect of the analysis since the cDNA library used in the study 
was constructed using total retinal RNA, meaning that the prey inserts could also 
contain intronic sequences as well as fragments of ribosomal RNA and transfer 
RNA. Such preys had to be disregarded since the prey proteins translated from 
these sequences were artefacts. Another important aspect was to verify whether 
the prey inserts had been cloned in frame with the GAL4 AD; however, it is 
necessary to mention that it is a known fact that yeast can tolerate frameshifts, 
skip stop codons and continue with translation. It means that prey fragments 
which had not been cloned in frame, should not be completely disregarded but, as 
recommended by the system manufacturer, they should be re-cloned in frame and 
analysed further.  
In the Y2H screen 4, growth of 28 yeast colonies was observed on TDO/X 
media plates; seven of these colonies contained a prey fragment smaller than 
200 bp and were disregarded from further analysis. Interestingly, among these 
colonies there were the four colonies which grew white on TDO/X media and were 
unable to regrow in more stringent conditions. The remaining 21 prey fragments 
were sequenced and the outputs were analysed using online alignment tools. Out 
of 21 prey fragments, 13 contained sequences which aligned with protein coding 
fragments of genes (summarised in Table 3.8) whereas 8 of them aligned to either 
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intronic fragments or untranslated regions. The sequences of preys carrying 
coding sequences are summaries in Appendix G. 
 
Colony 
number 
Identified protein Expression Localisarion 
1 Homo sapiens nuclear factor I/A (NFIA) ubiquitous nucleus  
2 
Homo sapiens small EDRK-rich factor 2 
(SERF2) 
ubiquitous cytosol/nucleus 
4 
Homo sapiens eukaryotic translation initiation 
factor 3, subunit L (EIF3L) 
ubiquitous cytosol 
5 
Homo sapiens eukaryotic translation initiation 
factor 3, subunit L (EIF3L) 
ubiquitous cytosol 
9 Homo sapiens nuclear factor I/A (NFIA) ubiquitous cytosol/nucleus 
11 
Homo sapiens aryl hydrocarbon receptor 
interacting protein-like 1 (AIPL1) 
ubiquitous cytosol/nucleus 
12 Homo sapiens nuclear factor I/A (NFIA) ubiquitous cytosol/nucleus 
15 Palmitoyl-protein thioesterase 2 (PPT2) ubiquitous cytosol 
16 Homo sapiens fibulin 1 (FBLN1) ubiquitous 
extracellular 
matirx 
19 
Homo sapiens small EDRK-rich factor 2 
(SERF2) 
ubiquitous cytosol/nucleus 
22 
Homo sapiens eukaryotic translation initiation 
factor 3 
ubiquitous cytosol 
24 
Homo sapiens ubiquitin A-52 residue 
ribosomal protein fusion product 1 (UBA52) 
ubiquitous cytosol/nucleus 
26 
Homo sapiens cytochrome c oxidase subunit 
VIIc (COX7C), nuclear gene encoding 
mitochondrial protein 
ubiquitous 
mitochondrial 
inner 
membrane 
Table 3.8 Summary of prey fragments identified with bait 3. The table includes only prey 
fragments, which aligned to coding parts of the genome.  
 
All of the three colonies grown in screen 5 (using bait 6) carried prey 
fragments shorter than 200 bp and/or were identified within non-coding genomic 
sequences. A similar finding was made when analysing prey fragments identified 
in Y2H screens 6 and 7 (baits 8 and 7 respectively), all of which aligned to non-
coding genomic sequences (summarised in Appendix H).  
The analysis of prey fragments identified in the Y2H screening revealed that 
only bait 3 was able to pull out genuine potential interactants. However, not all of 
the identified proteins seemed to be likely to interact with EYS. It has been shown 
that the porcine orthologue of EYS localises to the photoreceptor outer segments 
and the Drosophila orthologue of EYS plays a role in the organisation of the 
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compound eye. Based on these findings, proteins such as nuclear factors or 
translation initiation factors were excluded from further analysis at this stage and 
a shortlist of preys subjected to post-screening control experiments is presented in 
Table 3.9. 
It is necessary to mention that none of the identified preys were cloned in 
frame with GAL4 activation domain and preys of interest would have to be 
re-cloned in frame and re-examined using bait 3. 
 
Colony 
number 
Prey identified 
Prey length 
(Full length) 
Expression Localisation 
2 
Homo sapiens small 
EDRK-rich factor 2 
(SERF2) 
442 bp (643 bp) ubiquitous cytosol/nucleus 
11 
Homo sapiens aryl 
hydrocarbon receptor 
interacting protein-like 1 
(AIPL1) 
595 bp (2959 
bp) 
ubiquitous cytosol/nucleus 
15 
Palmitoyl-protein 
thioesterase 2 (PPT2) 
327 bp (1759 
bp) 
ubiquitous cytosol 
16 
Homo sapiens fibulin 1 
(FBLN1) 
253 bp (11756 
bp) 
ubiquitous 
extracellular 
matrix 
24 
Homo sapiens ubiquitin 
A-52 residue ribosomal 
protein fusion product 1 
(UBA52) 
252 bp (508 bp) ubiquitous cytosol/nucleus 
26 
Homo sapiens 
cytochrome c oxidase 
subunit VIIc (COX7C) 
471 bp (1584 
bp) 
ubiquitous 
mitochondrial 
inner 
membrane 
Table 3.9 A shortlist of prey fragments identified with bait 3 and selected for analysis in 
post Y2H screening control experiments. 
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3.5 Confirmation of Positive Interaction 
The next stage of the data analysis was devoted to confirming whether the 
interactions identified by the Y2H screens are genuine and not false-positives. It 
could be that the preys identified interact with GAL4 DBD, which would result in 
expression of the reporter genes and obtaining false positive results and such a 
scenario needed to be excluded. Moreover, the Y2H results need to be reproducible 
in order to be considered genuine. In order to verify these two aspects, prey 
plasmids were isolated from yeast cells, amplified in competent bacteria and 
purified. The purified vectors were sequenced to confirm their integrity and 
transformed into Y187 yeast strain.  
In the first experiment it was established whether the identified 
interactions could be reproduced using freshly transformed yeast strains. To do 
that, small scale mating was performed using Y2HGold [pBD-DEST/bait 3] and 
Y187 yeast strain transformed with each of the tested prey constructs. Mated 
cultures were plated on a range of selective media allowing examination of 
whether the transformation and mating were successful, and if the reporter genes 
were activated. The results obtained are presented in Figure 3.13. As it can be 
observed, 2 out of 6 colonies were able to grow on the most restrictive media and 
activated all 4 of the reporter genes. The successful preys carried fragments of 
AIPL1 and FBLN1 genes and according to this experiment only these two 
interactants were genuine. The difference between the control experiment and a 
screen lies in the order of plating and exposing yeast colonies to different selective 
conditions. When screening, positive colonies were re-patched onto increasingly 
restrictive media in a sequential manner, i.e. colonies grown on one type of media 
were re-patched onto more stringent media once they were fully-grown. In 
contrast, for the post-screening control experiments, dilutions of mated culture 
were plated on the full-range of selective media simultaneously. This means that 
the positive diploid cells were required to activate the reporter genes immediately 
to be able to survive; in screening they would have had time to adjust to 
increasingly stringent conditions, which makes it easier for the revertant colonies 
to develop. In conclusion, only the interactions which were able to be reproduced 
in the post-screen control experiments can be considered genuine. 
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  Figure 3.13 Post-screening control experiment aiming to reproduce the interactions 
identified in screen 4 performed with bait 3. Numbers 1-7 represent different mated 
cultures. Each of the cultures was plated in three dilutions on a range of selective media. 
Only cultures 2 and 4, containing prey fragments of AIPL1 and FBLN1, were able to grow 
on all the media, which demonstrates that they are positive interactions. In this figure, 
prey gene names represent prey fragments of the genes and not full gene sequences. 
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In order to verify whether the prey fragments are able to interact with 
GAL4 DBD on its own, transformed Y187 yeast strains were mated with Y2HGold 
[pGBKT7-WT] that carried wild type GAL4 DBD. Serial dilutions of mated cultures 
were plated on a range of selective media, as shown in Figure 3.14. According to 
this experiment, the prey containing a fragment of FBLN1 gene was able to interact 
with GAL4 DBD and activate the expression of all reporter genes. This interaction 
had to be considered a false positive result and excluded from further analysis.  
In summary, out of the six putative interacting partners of EYS protein 
identified with bait 3, only one turned out to be genuine and the prey was found to 
be a fragment of AIPL1 gene. The remaining five candidate preys had to be 
disregarded as they were unable to reproduce the interaction or they showed 
interaction with GAL4 DBD rather than the bait fragment of EYS protein. 
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Figure 3.14 Post-screening control experiment aiming to verify whether the preys could 
interact with GAL4 DBD. Numbers 1-7 represent different mated cultures. Each of the 
cultures was plated in three dilutions on a range of selective media. The culture number 4, 
containing a prey fragment of FBLN1 gene grew blue which indicates that it interacted 
with the GAL4 DBD. For that reason, this interaction had to be regarded as false positive. 
In this figure, prey gene names represent prey fragments of the genes and not full gene 
sequences. 
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3.6 AIPL1 
Mutations in AIPL1 cause severe early-onset retinal degeneration called 
Leber’s congenital amaurosis (LCA), which is characterized by the loss of vision 
diagnosed at birth or within first months of life (LCA4; MIM 604393)(Sohocki et al., 
2000). In humans, AIPL1 is specifically expressed in the pineal gland and the 
photoreceptor cells, where it localises to the region spanning from the synapse to 
the inner segment with enrichment at the connecting cilium (Sohocki et al., 2000; 
van der Spuy et al., 2002). Moreover, AIPL1 is not only expressed in the adult 
photoreceptors but its expression has also been demonstrated to coincide with the 
development of both rods and cones (van der Spuy et al., 2003).  
The AIPL1 protein is composed of an N-terminal FKBP-like domain 
followed by three tetratricopeptide (TPR) repeats and a C-terminal proline-rich 
region (Figure 3.15) (Majumder et al., 2013; Sohocki et al., 2000). The FKBP-like 
domain of AIPL1 has been suggested to modulate interactions with farnesyl 
residues whereas the TPR domains can function as molecular scaffolds facilitating 
protein-protein interactions and assembly of higher order protein complexes. The 
role of the proline-rich C-terminal region has not been fully understood; however, 
it could participate in regulation of rapid protein exchange or recruitment in 
protein complexes (Majumder et al., 2013; van der Spuy, 2006). The domains 
which AIPL1 is composed of are commonly found in proteins with chaperoning 
activity and in fact, AIPL1 shares homology with AIP (aryl hydrocarbon receptor 
interacting protein) and FKBP51 and FKBP52 proteins, all of which belong to a 
group of co-chaperones interacting with chaperone Hsp90 via a TPR repeat 
domain (Scheufler et al., 2000; Sohocki et al., 2000). 
The function of AIPL1 in the human retina has been widely studied and a 
significant amount of knowledge of the biology of AIPL1 comes from studying its 
interactome.  The first identified interacting partner of AIPL1 was NUB1 (NEDD8 
Ultimate Buster 1), which is a negative regulator of NEDD8 and recruits NEDD8 
and its conjugates to the proteasome for degradation (Akey et al., 2002; Kamitani 
et al., 2001; Kito et al., 2001). Further research demonstrated that AIPL1 
modulates the translocation of NUB1 from the nucleus to the cytoplasm and acts in 
a chaperone-like manner to suppress formation of inclusions by NUB1 fragments 
(van der Spuy & Cheetham, 2004). 
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Figure 3.15 A schematic view of the predicted domain structure of AIPL1. The AIPL1 
protein is composed of an N-terminal FKBP-like domain followed by three 
tetratricopeptide (TPR) repeats and a C-terminal proline-rich region. 
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Moreover, AIPL1 can also interact with FAT10 and FAT10-modified proteins, and 
form ternary complexes with NUB1. FAT10 is a ubiquitin independent signal for 
degradation, which is promoted by binding with NUB1; it has been demonstrated 
that binding with AIPL1 has an inhibitory effect on the NUB1-mediated 
degradation of a FAT10-modified substrates (Bett et al., 2012). AIPL1 has also 
been shown to form heterocomplexes with Hsp70 and Hsp90 molecular 
chaperones that play essential role in photoreceptor proteostasis. Furthermore, it 
has been demonstrated that the cooperation of AIPL1 and Hsp70 supresses 
formation of NUB1 inclusions in a chaperone-like manner (Hidalgo-de-Quintana et 
al., 2008). 
Furthermore, Yeast 2-hybrid analysis has demonstrated that AIPL1 
interacts with and aids in farnesylation of proteins (Majumder et al., 2013; 
Ramamurthy et al., 2003). Protein farnesylation, a type of prenylation, is a lipid 
post-translational modification of proteins which have a C-terminal CaaX motif 
recognised by farnesyltransferase enzyme. Farnesylation of proteins enhances 
protein-membrane interactions and protein-protein interactions (Zhang & Casey, 
1996).  
The analysis of AIPL1 hypomorphic mouse models revealed decreased 
levels of rod cGMP phosphodiesterase (PDE), which is one of the major 
components of the phototransduction cascade. PDE has been shown to be a client 
protein of AIPL1, chaperoning activity of which is required for localisation of PDE 
in the photoreceptor outer segments (Liu et al., 2004b). Interestingly, PDE is a 
farnesylated protein and further studies have shown that AIPL1 interacts with the 
catalytic α-subunit of PDE and the interaction is essential for proper assembly of 
PDE (Kolandaivelu et al., 2009). 
In the most recent report, AIPL1 was demonstrated to interact and 
co-localise with EB proteins, which are microtubule plus-end tracking proteins 
that have an important function in microtubule dynamics. Co-localisation was 
detected at the photoreceptor connecting cilium but not in the cellular microtubule 
network or cilia of non-retinal cells, suggesting that the association of AIPL1 and 
EB proteins may have a specific function at the photoreceptor connecting cilium 
(Hidalgo-de-Quintana et al., 2015). 
The biology of AIPL1 has been extensively studied and there has been 
evidence provided that its disruption has significant implications for the 
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homeostasis of photoreceptor cells. Attempts of gene replacement therapy have 
been undertaken in murine models using AAV vectors. The rescue of a disease 
phenotype has been achieved, giving hope for the future clinical trials in humans 
(Sun et al., 2010; Tan et al., 2009). 
3.7 Analysis of AIPL1 as an Interacting Partner of EYS Using Y2H 
The prey fragment identified in Y2H screen performed with bait 3 aligned 
to the sequence of a human AIPL1 gene. The prey fragment of AIPL1 identified by 
the Y2H screen comprised of 103 amino acids, which constitutes approximately 
27 % of full length AIPL1, and covered a part of the third TPR domain and the 
C-terminal proline-rich region (Figure 3.16). 
The Y2H system provides not only a powerful tool for identifying novel 
interacting partners of a protein of interest but it is also useful for investigation of 
already known or putative interactions. In order to further analyse the interaction 
of EYS and AIPL1 using the Y2H system, the interaction of bait 3 and AIPL1 prey 
fragment was reproduced and compared to a number of controls. In the first 
instance, it was tested whether bait 3 is able to interact with the full length AIPL1 
prey. In addition to the positive and negative controls provided by the system 
manufacturer, a published and well characterised interaction of AIPL1 and NUB1 
was used as a further control (Akey et al., 2002). In this experiment NUB1 was 
cloned with GAL4 DBD and AIPL1 was fused with GAL4 AD. As it can be observed 
in Figure 3.17, the interaction of bait 3 and AIPL1 prey fragment could be 
reproduced (row 1); however, the bait was unable to interact with the full length 
AIPL1 (row 3). Furthermore, no blue colonies grew in the additional positive 
control culture containing NUB1 bait and AIPL1 prey (row 2). The interaction of 
AIPL1 and NUB1 was identified using the Y2H system, and well characterised in 
yeast as well as mammalian systems. It is, however, important to note that in the 
study, in which the interaction was discovered, a bovine sequence of AIPL1 was 
used as bait to screen a bovine retinal cDNA library. This means that, even though 
the interaction was proven to occur between human proteins, their bovine 
orthologues seem to be more likely to interact in yeast cells. This is an example of 
how complex the analysis of interactomes can be, especially when different species 
and systems are involved and mixed together.  
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Figure 3.16 Analysis of the prey fragment of AIPL1. (A) Alignment of full-length AIPL1 
with AIPL1 prey fragment identified in Y2H screen 4. The domain structure should be read 
as follows: the blue oval: FKBP-like domain, the green boxes: TPR domains and the purple 
box: primate-specific proline rich region. AIPL1 prey fragment overlapped a part of the 
third TPR domain and the proline-rich region of AIPL1. Numbers below the domains 
correspond to the amino acid residues of AIPL1 (B) Protein sequence of full length AIPL1 
(derived from Ensemble database, accessed on 12.03.2015). Amino acids in red font 
represent the sequence of the AIPL1 prey fragment.   
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Figure 3.17 Control experiment validating whether bait 3 can interact with full length 
AIPL1. An additional control using a known interaction between AIPL1 and NUB1 was 
used. Numbers 1-5 represent different cultures, each of which was plated on a range of 
selective media in three dilutions. Blue colour of the colonies indicates activation of 
reporter gene and digestion of X-α-gal added to the media. The interaction was 
demonstrated only for culture 1, which contained bait 3 and AIPL1 prey fragment. 
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Furthermore, one of the well-known drawbacks of Y2H is its low 
reproducibility between experiments and this could also explain why the 
interaction of AIPL1 and NUB1 was not reproduced (reviewed in Caufield et al., 
2012). 
 Another possible scenario could be that the assembly of fully functional 
GAL4 was impossible due to the incorrect conformation of the fusion proteins. To 
address that, in the next experiment the GAL4 tags were switched and AIPL1 was 
cloned with GAL4 DBD whereas NUB1 was cloned with GAL4 AD.  
Moreover, it must not be overlooked that the AIPL1 prey fragment, as well 
as the other prey fragments fished out in the Y2H screening, was not in frame with 
GAL4 AD. In spite of the fact that the nature of yeast cells allows them to tolerate 
frameshifts, skip stop codons and continue with translation, it was essential to 
verify whether the interaction of bait 3 and AIPL1 prey fragment can be 
reproduced when the prey fragment is cloned in frame with the GAL4 AD.  
Therefore, the next experiment addressed the aforementioned issues and 
the results are presented Figure 3.18. The interaction of bait 3 and AIPL1 prey 
fragment was consistently reproduced (row 1); however, when AIPL1 prey 
fragment was cloned in frame with GAL4 AD, no growth of colonies was observed 
on QDO/X/A media plate. Very little growth and very slightly blue colonies could 
be observed in undiluted culture on TDO/X media plates (row 2); nonetheless, it 
would be misleading to consider these colonies positive when compared to the 
original interaction and the controls. The interaction between AIPL1 and NUB1 
could not be reproduced in this experiment either, suggesting that human 
orthologues of the two proteins do not interact in yeasts equally abundantly to 
their bovine counterparts. 
In summary, the interaction of bait 3 and AIPL1 prey fragment was 
consistently reproduced in each of the control experiments. However, it was not 
possible to confirm whether the proteins interact when AIPL1 prey fragment was 
re-cloned in frame with the GAL4 AD domain. This observation could suggest that 
the result obtained in Y2H screening was a false positive interaction, occurring 
between bait 3 and the artefact protein synthesised on the template of the 
fragment of the AIPL1 gene, which had not been cloned in frame with the GAL4 AD. 
Nonetheless, due to the specific biology of yeast cells (they can tolerate 
frameshifts, skip stop codons and continue with translation) the interaction of   
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Figure 3.18 Control experiment verifying whether bait 3 is able to interact with AIPL1 
prey fragment when the latter is cloned in frame with GAL4 AD. The known interaction of 
AIPL1 and NUB1 was used as a control in addition to the controls provided in the Y2H kit. 
Numbers 1-5 represent different cultures, each of which was plated on a range of selective 
media in three dilutions. Apart from the positive control, only culture 1 was able to grow 
blue on all of the selective media, which was indicative of an interaction.  
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bait 3 and AIPL1 cannot be categorically disproved without provision of additional 
evidence.  
Furthermore, AIPL1 has been suggested to be a component of a 
chaperoning macromolecular heterocomplex that participates in protein 
biosynthesis and cellular translocation. It is, therefore, likely that EYS could be a 
client protein of AIPL1 and the interaction of EYS and AIPL1 could be essential for 
its proper folding and localisation. This purely theoretical assumption could be 
true but would require a significant amount of additional experimental data in its 
support.  
In light of the above, further analysis of the putative interaction of EYS and 
AIPL1 was carried out in spite of the ambiguous results of Y2H. This was necessary 
for completeness of the study and thorough validation of Y2H data. 
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3.8 Validation of Y2H Results in Mammalian Systems 
Any interaction identified by Y2H requires further experimental evidence 
confirming its authenticity. In this study, two validation methods were employed 
to verify the interaction of EYS and AIPL1: immunocytochemistry (ICC) and 
co-immunoprecipitation (Co-IP). ICC was performed in cultured mammalian cell 
lines and verified co-localisation of the two proteins of interest whereas Co-IP 
assays were conducted to establish whether the two proteins exist in one protein 
complex. 
For better understanding of the results presented in this section, it should 
be noted that the results obtained in the project are not chronologically presented 
in the thesis.  Some of the knowledge used to conduct and improve experiments 
described in this chapter was gained from experiments described further in the 
thesis. First of all, it should be taken into account that EYS is one of the largest 
genes discovered in the human retina thus far. The size of the gene has 
implications for feasibility of many standard procedures used in molecular biology 
such as cloning or transfections. Gateway technology used in the study allowed 
trouble-free cloning, however, transfection of the full length EYS vectors turned 
out to be extraordinarily challenging and successful only in very few attempts, as it 
will be described in more detail in the following Chapters 4 and 5. 
 Furthermore, detailed analysis of the genetic structure of EYS resulted in 
identification of two novel short isoforms of EYS expressed in the retina, annotated 
in UniProt as isoform 2 and isoform 3. This topic will be elaborated on in Chapter 4 
but it is necessary to explain here that the isoforms map to the N-terminal 
fragment of full length EYS isoform 1 and overlap with bait 3, constituting around 
40 % of its length. Therefore, these isoforms were included in the study for 
validation of the potential interaction with AIPL1 since they as well may interact 
with this putative binding partner. 
3.8.1 Co-localisation Studies of Putative EYS-AIPL1 Interaction 
Co-localisation studies of EYS and AIPL1 were performed in secondary cells 
lines. Both EYS and AIPL1 are photoreceptor specific proteins and the availability 
of cell lines endogenously expressing the two proteins is limited. In fact, there was 
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only one cell line available meeting this criterion, which was Y79 human 
retinoblastoma cell line. Y79 cells grow in suspension, are round in shape and have 
very little cytoplasm and membrane, which makes it challenging to properly 
distinguish their organelles under a light or confocal microscope. Therefore, 
protocols enabling attachment of Y79 cells to glass coverslips and outgrowth of 
protrusions had to be optimised prior to further experiments (see section 2.14.4 
Y79 Cell Attachment and Differentiation). When overexpressing the proteins of 
interest, a human epitheloid cervix carcinoma (HeLa) cell line was used. HeLa cells 
were chosen because the efficiency of transfections was higher than in other tested 
cell lines. 
3.8.1.1 Immunolabelling of EYS and AIPL1 in Y79 cells 
 In the first instance, endogenous expression patterns of EYS and AIPL1 
were investigated. Y79 cells were seeded on poly-L-lysine pre-coated coverslips, 
fixed and stained with anti-EYS3 goat and anti-AIPL1 rabbit antibodies. A confocal 
micrograph shown in Figure 3.19 depicts a cluster of immunolabelled Y79 cells in 
which a potential co-localisation of EYS and AIPL1 can be observed (yellow signal). 
It has previously been demonstrated that AIPL1 localises to the cytoplasm and to 
the nucleus (van der Spuy et al., 2002), and that expression pattern could be 
observed in this experiment. Nonetheless, the specific morphology of Y79 cells 
makes it difficult to assess whether the green signal coming from the anti-EYS3 
antibody is localised in the cytoplasm, cell membrane or both. In order to be able 
to look into this matter more deeply, overexpression of the proteins of interest was 
attempted. As it was mentioned previously, it was not possible to successfully 
transfect Y79 cells with tagged EYS construct due its size and therefore, Y79 cells 
were transfected only with myc-tagged AIPL1 and the proteins of interest were 
detected using anti-EYS1 rabbit and anti-myc mouse antibodies. A cluster of two 
Y79 cells overexpressing myc-AIPL1 is shown in Figure 3.20. As it can be seen in 
the micrograph, AIPL1 is characteristically localised to the cytoplasm and the 
nucleus. The green signal coming from anti-EYS1 antibody forms a ring around the 
nucleus, which overlaps with AIPL1. This suggests that EYS is localised to the 
cytoplasm; nonetheless, some of the signal could also be associated with the cell 
membrane.   
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Figure 3.19 Localisation of EYS and AIPL1 in a cluster of Y79 cells.  AIPL1 (red) localises 
to the cell cytoplasm and cell nucleus and EYS (green) overlaps with the cytoplasmic 
portion of the signal; co-localisation is indicated by yellow signal. The zoomed inserts 
represent the area demarcated by the white square in the images. The cells were 
immunolabelled with goat anti-EYS3 and rabbit anti-AIPL1 antibodies. Secondary 
antibodies were AlexaFluor 488 conjugated donkey anti-goat and Cyanine-3 conjugated 
donkey anti-rabbit antibodies. Nuclei are stained using DAPI (blue). Scale bar: 10 μm.   
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Figure 3.20 Localisation of EYS and myc-AIPL1 in a cluster of two Y79 cells. Myc-AIPL1 
(red) was detected in the nucleus and the cell cytoplasm and EYS (green) overlaps with 
the cytoplasmic portion of the signal; co-localisation is indicated by yellow signal. The 
zoomed inserts represent the area demarcated by the white square in the images. Rabbit 
anti-EYS1 and mouse anti-myc primary antibodies were used.  Secondary antibodies 
included AlexaFluor 488 conjugated goat anti-rabbit and AlexaFluor 633 conjugated goat 
anti-mouse antibodies. Nuclei are stained using DAPI (blue). Scale bar: 10 μm. 
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The merged signal in Figure 3.20 is only slightly yellow; however, it should 
be taken into account that the intensities of green and red signals differ depending 
on many factors, such as expression levels and affinity of the antibodies. It means 
that the strength of the yellow signal is variable and might not be equally apparent 
in all experiments. From the experiments performed on Y79 cells it could be 
concluded that EYS could co-localise with AIPL1, however, more detailed analysis 
would be required to fully validate this hypothesis. Notably, the existence of EYS 
short isoforms 2 and 3 came to our knowledge later in the project and this finding 
complicated the analysis of the Y2H results as these could also interact with AIPL1. 
As it will be described in the next chapter, anti-EYS1 antibody is only able to detect 
EYS isoforms 1 and 4 and therefore, the results obtained in Y79 cells presented in 
this section can only be related to the large EYS isoforms 1 and 4.  
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3.8.1.2 Analysis of Exogenously Expressed AIPL1 and EYS  
Investigation of exogenous expression patterns of the proteins of interest 
was performed in HeLa cells and the vector constructs were introduced into the 
cells using transfection. The large size of full length EYS isoform 1 made it 
impossible to successfully transfect HeLa cells and therefore, tagged AIPL1 
constructs were co-transfected with tagged constructs of shorter fragments of EYS. 
The fragments used in this set of experiments included V5 tagged AIPL1, GFP 
tagged N-terminal fragment EYS (1-1635 aa), GFP tagged EYS isoform 2 and GFP 
tagged EYS isoform 3; GFP empty vector was used as a control. The N-terminal 
fragment of EYS was chosen because it encompasses the sequence of bait 3 used in 
Y2H and it contains EYS signal peptide which may be necessary for its proper 
localisation. The schematic overview of the fragments is presented in Figure 3.21. 
Figure 3.22-Figure 3.25 depict the expression patterns of the analysed 
proteins. V5 tagged AIPL1 characteristically localised to the cytoplasm and to the 
nucleus in all of the experiments. EYS N-terminal fragment and EYS isoforms 2 
and 3 localised mainly to the cytoplasm. In some context, this observation could 
relate to Y2H in that the complexes of bait and prey need to be transported back to 
nucleus in order to activate the expression of reporter genes. As it can be seen in 
the micrographs presented here, EYS N-terminal fragment localised almost 
exclusively to the cytoplasm, which could explain the low efficiency of Y2H screens.  
Upon examination of the confocal micrographs, it can be concluded that 
AIPL1 co-localises with EYS N-terminal fragment as well as isoform 2 and 3, which 
is indicative of a potential interaction. To validate these interactions, further 
analysis by Co-IP was performed. 
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Figure 3.21 Schematic overview of protein fragments used in the localisation studies of 
EYS N-terminal fragment and EYS isoforms 2 and 3. In the experiment the fragments were 
tagged with GFP at the N-terminus and their expression patterns were compared to the 
expression pattern of V5 tagged AIPL1. 
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Figure 3.22 Localisation of GFP tagged EYS N-terminal fragment and V5 tagged AIPL1 in 
co-transfected HeLa cells.  GFP tagged EYS N-terminal fragment localises to the cytoplasm 
whereas V5 tagged AIPL1 resides in the cytoplasm and the nucleus. Any co-localisation is 
indicated by the yellow/orange signal. The zoomed inserts represent the area demarcated 
by the white square in the images. Anti-V5 primary and Cyanine 3 conjugated donkey anti-
goat secondary antibodies were used. Nuclei are stained using DAPI (blue). Scale 
bar: 10 μm. 
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Figure 3.23 Localisation of GFP tagged EYS isoform 2 and V5 tagged AIPL1 in 
co-transfected HeLa cells.  GFP tagged EYS isoform 2 localises to the cytoplasm whereas 
V5 tagged AIPL1 resides in the cytoplasm and the nucleus. Any co-localisation is indicated 
by the yellow/orange signal. The zoomed inserts represent the area demarcated by the 
white square in the images. Anti-V5 primary and Cyanine 3 conjugated donkey anti-goat 
secondary antibodies were used. Nuclei are stained using DAPI (blue). Scale bar: 10 μm.  
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Figure 3.24 Localisation of GFP tagged EYS isoform 3 and V5 tagged AIPL1 in co-
transfected HeLa cells.  GFP tagged EYS isoform 3 localises to the cytoplasm whereas V5 
tagged AIPL1 resides in the cytoplasm and the nucleus. Any co-localisation is indicated by 
the yellow/orange signal. The zoomed inserts represent the area demarcated by the white 
square in the images. Anti-V5 primary and Cyanine 3 conjugated donkey anti-goat 
secondary antibodies were used. Nuclei are stained using DAPI (blue). Scale bar: 10 μm. 
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Figure 3.25 Localisation of GFP wild type and V5 tagged AIPL1 in co-transfected HeLa 
cells.  GFP wild type as well as V5 tagged AIPL1 localises to the cytoplasm and the nucleus. 
Any co-localisation is indicated by the yellow/orange signal. The zoomed inserts represent 
the area demarcated by the white square in the images. Anti-V5 primary and Cyanine 3 
conjugated donkey anti-goat secondary antibodies were used. Nuclei are stained using 
DAPI (blue). Scale bar: 10 μm.  
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3.8.2 Validation of Y2H Data by Co-Immunoprecipitation 
Co-IP is one of the methods used to authenticate Y2H data by verifying 
whether the two proteins of interest form complexes together. In order to perform 
a successful Co-IP it is necessary to possess antibodies raised against the desired 
epitopes. One antibody is used to pull down the complex of proteins from the cell 
lysate and another is used in immunoblotting to verify the presence of a potential 
interacting partner. In this project, there were bespoke antibodies available raised 
against EYS and AIPL1, and both of them were produced in rabbit. In principle, the 
two antibodies used for Co-IP assay should be obtained in two different animals in 
order to avoid false positive results. This made it impossible to perform Co-IP 
assays using the custom made anti-EYS and anti-AIPL1 antibodies and wild type 
protein extract from Y79 cells. The correct selection of antibodies was especially 
important in this project since the size of AIPL1, which is approximately 50 kDa, is 
the same as that of the heavy chains of most antibodies. This means that if the 
anti-EYS rabbit antibody was used for pulling down the complex and anti-AIPL1 
rabbit is used for immunoblotting, the band appearing at the size of 50 kDa could 
come from AIPL1 or the heavy chains of the anti-EYS rabbit antibody – anti rabbit 
HRP conjugated antibody could bind to both of them. In light of this, attempts to 
examine the potential interaction of full length EYS and AIPL1 in Y79 cells were not 
undertaken.  
Instead, it was decided to carry out Co-IPs using tagged AIPL1 and EYS 
isoforms 2 and 3 as well as EYS N-terminal fragment corresponding to 1-1635 aa. 
Using tagged proteins resolved issues concerning protein specific antibodies; 
AIPL1 was cloned with a V5 tag whereas EYS proteins were fused with a 3XFLAG 
tag. For each of the experiments, the constructs were co-transfected into HeLa cells 
and cell lysates were freshly prepared before each Co-IP assay to avoid protein 
degradation during freeze-thaw cycles.  
Co-IP experiments require a number of controls to confirm the specificity of 
the method and such controls were performed along with each Co-IP assay. 
Controls marked as ‘Input’ were total protein extracts prepared from cells 
co-transfected and single transfected with the used constructs. Since the same 
extracts were used in IP experiments, it was an important quality control 
demonstrating that the desired tagged proteins were present in the samples. As a 
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negative control, cell lysate from untransfected HeLa cells was used. Protein 
extracts from co-transfected cells were used to perform Co-IP verifying whether 
the two proteins of interest interact. It was also used in the negative control for IP, 
which was performed with goat unspecific IgG antibody (isotype control; marked 
as ‘IgG’) and it checked whether the antibodies raised in goat non-specifically bind 
any proteins present in the extract from co-transfected HeLa cells. Control IPs 
were performed using extracts form cells transfected with either 3XFLAG tagged 
construct or V5 tagged AIPL1. These samples aimed to control whether the V5 
antibody used pulls down the V5 tagged protein only or whether it is also able to 
non-specifically bind overexpressed 3XFLAG tagged constructs. The presence of a 
tagged protein in a cell lysate used for preparation of a given sample is indicated at 
the bottom of each Co-IP figure, where ‘+’ indicates the presence and ‘-‘ the absence 
of the fusion protein in the lysate.  
In the first Co-IP experiment it was examined whether V5-AIPL1 interacts 
with EYS isoforms 2. Protein complexes were precipitated from the cell extract 
using anti-V5 antibody and immunoblotting was performed using anti-FLAG and 
anti-AIPL1 antibodies. The results are shown in Figure 3.26, where blot ‘A’ 
represents the membrane immunolabelled with anti-FLAG antibody and blot ‘B’ is 
a control blot immunolabelled with anti-AIPL1 antibody.  
In the input lanes of blot ‘A’, there can be bands observed corresponding to 
the size of FLAG-EYS isoform 2 (~72 kDa; green asterisks) and no band is visible in 
the negative control (extract from untransfected HeLa cells). The bands were 
detected in lanes corresponding to co-transfected and single transfected cells, 
confirming that the fusion proteins were synthesised in the transfected cells. The 
negative IP control was free of any protein bands, demonstrating the specificity of 
the anti-V5 antibody used. The positive IP samples were performed using anti-V5 
antibody and extracts from co-transfected and single transfected cells. The band 
marked with the red asterisk corresponds to the size of 3XFLAG-EYS isoform 2 and 
it confirms that it interacts with V5-AIPL1 as the extracts used in this sample 
contained both of the proteins. The specificity of IP is confirmed by the lack of 
protein band in the next lane which represents the IP performed with anti-V5 
antibody and extract containing 3XFLAG-EYS isoform 2.  
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Figure 3.26 Co-immunoprecipitation assay demonstrating interaction between 3xFLAG 
tagged EYS isoform 2 and V5 tagged AIPL1. Blot ‘A’ represents membrane probed with 
anti-FLAG antibody. The presence of a protein band in the Co-IP lane (red asterisk) 
confirms the interaction. IP performed with non-specific goat IgG was used as an IP 
negative control (IgG). Input refers to extracts from co-transfected and single transfected 
HeLa cells. The IB negative control (-ve control) was protein extract from untransfected 
HeLa cells. Blot ‘B’ is a control blot probed with anti-AIPL1 antibody and it demonstrates 
specificity of the assay. Loading was normalised using a BCA assay and the samples were 
resolved by denaturing SDS-PAGE. Secondary antibodies were HRP conjugated goat anti-
mouse and goat anti-rabbit antibodies. The presence of each construct in the loaded 
sample is denoted by ‘+’ and the absence by ‘-‘. Expected band sizes: 3xFLAG-EYS isoform 
2 – ~72 kDa, V5-AIPL1 - ~50 kDa. IB – immunoblotting, IP – immunoprecipitation. 
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The control blot ‘B’ is a replica of blot ‘A’ but instead, it was immuno-
labelled with anti-AIPL1 antibody. As expected, V5-AIPL1 was detected in the input 
lanes as well as IP lanes at the size of approximately ~50 kDa, confirming that the 
Co-IP assay was specific. However, the IP negative control performed with non-
specific goat IgG antibody resulted in detection of a band at the size of around 
50 kDa. As it can be seen, this band has slightly lower molecular mass than 
V5-AIPL1 and it most likely corresponds to the IgG antibody heavy chains which 
were non-specifically detected by the HRP conjugated goat anti-rabbit secondary 
antibody. The non-specific band is a lot more abundant than bands corresponding 
to V5-AIPL1 and the same amounts of extracts were used for each sample; if that 
band corresponded to V5-AIPL1, it would be expected that it is of the same 
intensity as other V5-AIPL1. Furthermore, since the same control was clean in blot 
’A’, the presence of this band does not question the obtained results and it can be 
considered as an artefact, which resulted from the limitations of the method. In the 
Co-IP protocol, magnetic beads are incubated with the desired antibody, rinsed 
and incubated with the cell lysate. Even though stringent washes were a routine 
procedure, some contamination with the unbound antibody might have happened. 
Also, in order to elute the complex from the magnetic beads, the sample was 
incubated at 70 ˚C and during that time some of the antibodies bound to the beads 
could have detached. Immunoglobulins are composed of heavy and light chains 
connected via disulphide bonds, which are broken when exposed to reducing 
agents. Therefore, any antibodies present in the Co-IP eluate may appear on the 
blot at the size of either ~50 kDa (heavy chains) or ~25 kDa (light chains). In 
practice, however, it happens that secondary antibodies raised against a particular 
animal non-specifically detect antibodies raised in another animal and this is what 
probably occurred in the experiments presented herein.  
In the next experiment, the interaction between 3XFLAG-EYS isoform 3 and 
V5-AIPL1 was tested. The obtained results are presented in Figure 3.27 and the 
order of samples is the same as for the previous experiment. As it can be seen in 
blot ‘A’, protein bands corresponding 3XFLAG-EYS isoform 3 are observed in the 
input lanes (~69 kDa; green asterisks) and the IP lane (red asterisk) 
demonstrating that the interaction between the two tested took place.  
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Figure 3.27 Co-immunoprecipitation assay demonstrating interaction between 3xFLAG 
tagged EYS isoform 3 and V5 tagged AIPL1. Blot ‘A’ represents membrane probed with 
anti-FLAG antibody. The presence of a protein band in the Co-IP lane (red asterisk) 
confirms the interaction. IP performed with non-specific goat IgG was used as an IP 
negative control (IgG). Input refers to extracts from co-transfected and single transfected 
HeLa cells. The IB negative control (-ve control) was protein extract from untransfected 
HeLa cells. Blot ‘B’ is a control blot probed with anti-AIPL1 antibody and it demonstrates 
specificity of the assay. Loading was normalised using a BCA assay and the samples were 
resolved by denaturing SDS-PAGE. Secondary antibodies were HRP conjugated goat anti-
mouse and goat anti-rabbit antibodies. The presence of each construct in the loaded 
sample is denoted by ‘+’ and the absence by ‘-‘.Expected band sizes: 3xFLAG-EYS isoform 3 
– ~69 kDa, V5-AIPL1 - ~50 kDa. IB – immunoblotting, IP – immunoprecipitation.  
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The negative control lanes on blot ‘A’ were clean and the control blot ‘B’ confirmed 
that the assay was properly conducted.  
Interestingly, overexpressed EYS isoforms 2 and 3 were consistently 
detected with an accompanying band detected at around 100 kDa. It suggests that 
some portions of the protein is either more heavily modified, e.g. glycosylated, or it 
could be a result of EYS isoforms 2 and 3 forming dimers. This observation would 
need to be addressed experimentally in the future to fully understand it. 
 In the next Co-IP assay it was verified whether 3XFLAG-EYS N-terminal 
fragment (1-1635 aa), overlapping Y2H EYS bait 3, can interact with V5-AIPL1 
(Figure 3.28). As shown in blot ‘A’, the interaction did occur, which is indicated by 
the band detected in the IP lane at approximately 180 kDa (red asterisks). Bands of 
the expected size were also seen in the input lanes (green asterisks) and the 
control samples as well the control blot worked as expected, confirming the 
specificity of the assay.  
 Altogether, Co-IP assays performed to validate the Y2H results 
demonstrated that EYS isoforms 2 and 3 as well as EYS N-terminal fragment 
(1-1635 aa) can physically bind AIPL1. These experiments enhance the data 
obtained from ICC experiments and complete the validation of Y2H results, making 
AIPL1 a true binding partner of the tested EYS proteins. 
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Figure 3.28 Co-immunoprecipitation assay demonstrating interaction between 3xFLAG 
tagged EYS N-terminal fragment (1-1635 aa) and V5 tagged AIPL1. Blot ‘A’ represents 
membrane probed with anti-FLAG antibody. The presence of a protein band in the Co-IP 
lane (red asterisk) confirms the interaction. IP performed with non-specific goat IgG was 
used as an IP negative control (IgG). Input refers to extracts from co-transfected and single 
transfected HeLa cells. The IB negative control (-ve control) was protein extract from 
untransfected HeLa cells. Blot ‘B’ is a control blot probed with anti-AIPL1 antibody and it 
demonstrates specificity of the assay. Loading was normalised using a BCA assay and the 
samples were resolved by denaturing SDS-PAGE. Secondary antibodies were HRP 
conjugated goat anti-mouse and goat anti-rabbit antibodies. The presence of each 
construct in the loaded sample is denoted by ‘+’ and the absence by ‘-‘. Expected band 
sizes: 3xFLAG-N-terminal fragment (1-1635 aa) – ~182 kDa, V5-AIPL1 - ~50 kDa. IB – 
immunoblotting, IP – immunoprecipitation. 
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3.9 Discussion of Chapter 3 
The EYS gene was identified at the RP25 locus and it was described as the 
largest gene known to be expressed in the retina (Abd El-Aziz et al., 2008; Collin et 
al., 2008). Mutations in EYS have been demonstrated to cause autosomal recessive 
retinitis pigmentosa (arRP) with the prevalence ranging from 5-23.5 % depending 
on population, making it a major gene for arRP (Abd El-Aziz et al., 2010; Arai et al., 
2015; Audo et al., 2010; Bandah-Rozenfeld et al., 2010; Hosono et al., 2012; 
Iwanami et al., 2012). EYS has been demonstrated to localise to the photoreceptor 
outer segments in the porcine retina (Abd El-Aziz et al., 2008) and to play a role in 
the organisation of Drosophila rhabdomeric photoreceptors (Zelhof et al., 2006). 
Nevertheless, little is known about the role of EYS in the human retina and 
broadening that knowledge would be undoubtedly advantageous for 
understanding the molecular basis of arRP and for the development of potential 
therapeutic approaches.  
A common approach to study a function of a newly discovered protein is to 
investigate its interactome. Proteins do not function as single entities; they form 
stable or transient complexes and are part of dynamic and carefully regulated 
machinery. By looking into interacting partners of a given protein, it is possible to 
determine what processes it is involved in and what role it might play in the 
network of interactions (Ngounou Wetie et al., 2014). In the case of EYS, 
knowledge of its binding partners would provide vital clues to what function it 
may have in human photoreceptors and why its role is required for the 
homeostasis of the retina.  
In this project, the Y2H system was chosen due to its relative simplicity and 
low cost. Another advantage was that Y2H is well adapted to high throughput 
screening aimed at identification of binary protein-protein interactions in a certain 
type of tissue, here the human retina. Furthermore, Y2H can not only be used for 
screening of DNA or cDNA libraries, but also for exploration of known interactions 
between two putative binding partners such as mapping interaction sites (Ivanov 
et al., 2011).  
EYS full-length isoform 1 protein comprises 3144 aa and has a complex 
domain structure.  To allow more comprehensive Y2H screening, nine bait 
fragments were designed including the full-length EYS protein. The main purpose 
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of using protein fragments in addition to full-length EYS was to further 
characterise and map any interactions identified with the full length protein. 
However, using full length EYS did not yield positive results and the failure could 
have been caused by a number of factors. The most striking feature of EYS is its 
size and its impact on Y2H performance is not without significance. The expression 
level of such a large bait may have been low and not efficient enough to for 
detection by Western blot analysis, let alone activation of the reporter genes. 
Moreover, in Y2H the interacting bait and prey need to translocate to the nucleus 
in order to activate reporters and this may not be possible for large proteins that 
do not naturally reside in the nucleus. Consideration should also be given to the 
signal peptide present at the N-terminus of EYS, which could have caused the 
protein to be secreted out of the yeast cells or to localise to the membranous 
organelles of the cell. To verify if this might be the case, the next screen was 
performed with bait 7, which encompasses the full length of EYS apart from the 
signal peptide. The failure of this screen suggested that the signal peptide was not 
the main factor preventing the system from working.  
To reduce the bait size but retain the natural domain order of EYS, bait 8 
was used; however, this screen did not yield positive results either. The Y2H 
system manufactured by Clontech is characterised by its high stringency enforced 
by the use of AbA as one of the reporters. It is an advantageous modification of the 
system; however, it may cause weaker or transient interactions to be missed. In 
order to test whether this was the limitation in the previous Y2H screens, the 
conditions of screening were modified and the stringency was lowered by 
replacing the AbA reporter with the nutritional reporter (HIS3; histidine) in the 
media used for the initial plating of the mated culture. Indeed, this modification 
made a difference and positive colonies were observed in some of the screens. It 
was still not possible to screen the library using the full-length EYS; however, 
screens performed with bait 3, 6, 7 and 8 resulted in obtaining positive colonies.  
This result addressed another very important question of whether the bait 
fragments were truly expressed in yeast cells. The control bait expression 
experiment did not decisively confirm the presence of bait proteins in the yeast 
protein extracts, although, the lack of protein bands may have been caused by 
protein degradation or low expression levels. Successful screening, resulting in 
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obtaining positive blue yeast colonies, supported this hypothesis and suggested 
that the bait constructs were expressed in yeast.   
In all of the Y2H screens performed altogether, 41 colonies were obtained 
on the lowest stringency media (TDO/X) and out of these 35 colonies were able to 
grow on the highest stringency media (QDO/X/A). The sequence analysis of the 
prey fragments revealed that only 13 contained sequenced aligning with exonic 
sequences of the human genome. Interestingly, all 13 prey fragments were 
identified using bait 3, corresponding to the N-terminal part of EYS protein 
(23 - 1635 aa). This group of 13 prey fragments included nuclear and translation 
initiation factors which were excluded from further analysis. These could be 
returned to at later stages of the project; nevertheless, from what is known about 
the domain structure of human EYS and the role of the Drosophila orthologue of 
EYS in the rhabdomeric photoreceptors, it is unlikely that the excluded proteins 
interact with EYS in vivo. The final shortlist of prey fragments included six 
potential interacting partners that were subjected to further analysis using the 
Y2H system. The post-screening control experiments revealed that only one prey 
fragment provided reproducible results and the remaining five had to be classified 
as false positive results; four of them were most likely the result of revertant 
colonies formation and one was demonstrated to non-specifically activate 
expression of the reporter genes.  
The remaining prey was identified to be a fragment of the AIPL1 gene, 
implicated in Leber congenital amaurosis, a severe early onset retinal 
degeneration (Sohocki et al., 2000). Importantly, the AIPL1 fragment identified in 
the screening was not cloned in frame with the GAL4 AD and the interaction could 
not be reproduced when the frame was reinstated. The presence of such prey 
fragments in the cDNA library was a serious limitation of the system; however, the 
result was not categorically disregarded as AIPL1 appeared to be a strong 
candidate for a true interacting partner of EYS.  
Furthermore, from the previous experience in the Bhattacharya laboratory, 
it was known that prey fragments with disrupted frame could provide true 
interacting partners of the protein of interest (personal communication). In light of 
this, further validation of the potential interaction of EYS and AIPL1 was pursued 
using mammalian cell lines employing ICC and Co-IP methods. 
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ICC was performed in Y79 and HeLa cell lines. Y79 cells were chosen since 
they endogenously express both EYS and AIPL1; however, these cells grow in 
suspension and so they have moderately developed morphology, which makes it 
challenging to perform accurate analyses of subcellular localisation of the proteins 
of interest. Even though yellow signal indicating co-localisation was observed, it 
was not possible to verify whether the signal comes from the cytoplasm, cell 
membrane or both, due to the characteristic large nucleus and little surrounding 
cytoplasm of Y79 cells. Transfection of suspension cell lines is challenging and Y79 
cells are not an exception, therefore, overexpression studies of EYS were not 
possible using Y79 cells. Even though transfection with tagged AIPL1 was 
successful, the results did not provide sufficient clarity to substantiate whether the 
two proteins co-localise. Therefore, the analysis of exogenous expression patterns 
of tagged protein constructs was conducted in HeLa cells, which were chosen for 
their ease of transfection. The large size of EYS full-length protein made it 
impossible to successfully co-transfect HeLa cells with tagged constructs of EYS 
and AIPL1; however, a thorough analysis using EYS short isoforms and fragments 
was carried out. The results of immunolabelling experiments clearly showed that 
AIPL1 co-localizes in the cytoplasm with EYS isoforms 2 and 3 as well as 
N-terminal fragment of the protein, which is indicative of a potential interaction.  
One of the biggest limitations in the project was the difficulty of 
overexpressing EYS in cell lines, which hindered much of the analysis of the 
expression patterns. The issue could be resolved by employing induced pluripotent 
stem cells (iPSC) which increasingly gain popularity as disease models and 
potential cell therapy tools (Ross & Akimov, 2014; Tucker et al., 2014) . iPSCs could 
be differentiated into a cell line endogenously expressing EYS and AIPL1 and such 
a strategy would allow for greater accuracy when performing co-localization 
studies of EYS and AIPL1. It would also be invaluable to obtain iPSCs from patients 
carrying mutations in EYS and/or AIPL1 and look into the differences in 
localisation of the two proteins of interest.  
ICC provided useful insights into the subcellular localisation in which the 
proteins of interest function; however, the method did not validate whether they 
are able to bind each other. Therefore, immunofluorescence experiments were 
supplemented with Co-IP, which aimed to test if AIPL1 and EYS proteins form 
complexes together. Once more, the interaction between EYS isoform 1 and AIPL1 
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could not have been verified due to the lack of suitable reagents, i.e. antibodies 
raised in two different animals. The experiments were conducted using 3XFLAG 
tagged EYS isoforms 2 and 3 and EYS N-terminal fragment (1-1635 aa), and 
V5 tagged AIPL1. The experiments confirmed that the interaction between AIPL1 
and tested EYS proteins does occur.  
The Co-IP results provided additional evidence in support of the hypothesis 
that EYS proteins interact with AIPL1. The fact that EYS N-terminal fragment, 
which overlaps with the sequence of Y2H bait 3, interacted with AIPL1 in 
mammalian cells confirms that Y2H results were genuine. Moreover, the 
interaction with EYS isoforms 2 and 3 could suggest that the binding site maps to 
the portion of EYS encompassing the first five EGF-like domains, which are 
uniform in all of the tested EYS proteins. Further research would be required to 
narrow down and characterise the binding site. It would also be interesting to 
verify whether AIPL1 can interact with any of the C-terminal domains of EYS and 
whether disease causing mutations in EYS and AIPL1 disrupt the interaction; such 
analysis was not undertaken in this project due to time constrictions. 
AIPL1 is a multifunctional photoreceptor specific protein; it has been 
demonstrated to be a part of a chaperoning heterocomplex and to be able to 
interact with and aid in processing of farnesylated proteins such as PDE6 (Hidalgo-
de-Quintana et al., 2008; Ramamurthy et al., 2003). Since AIPL1 is a molecular 
chaperone, it is within its nature to bind to many proteins that require its 
assistance in biosynthesis. The identified interaction does not provide information 
on what the role of EYS may be; however, it is still an exciting and novel discovery. 
Both AIPL1 and EYS are important for the homeostasis of the retina and the 
molecular mechanisms they are involved in may be interconnected. EYS lacks a 
C-terminal CaaX box required for farnesylation; however, AIPL1 could still be 
necessary for its folding and/or trafficking to the final subcellular localisation. 
These processes occur to be important enough to cause degeneration of 
photoreceptor cells when disrupted. Further research will be required to 
investigate whether AIPL1 can also interact with full length EYS isoform 1. To do 
this, it would be necessary to obtain anti-EYS or anti-AIPL1 antibodies raised in an 
animal other than rabbit or to elaborate an efficient method of introducing EYS 
isoform 1 cDNA into the cell lines. It should be noted that the goat anti-EYS 
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antibody (named anti-EYS3 in this study) did not work in immunoblotting and, 
therefore, it could not have been used for Co-IP (Appendix I). 
Investigation of the EYS interactome turned out to be a lot more challenging 
than expected. Y2H screening resulted in identification of only one potential 
binding partner. The low yield of results provided by Y2H is not meaningless and 
suggests that something must have had a disadvantageous effect on the screening. 
Numerous controls were performed in the Y2H screening and all of them proved 
that the system was functional and was used properly. Also, the experiments in 
mammalian cells using EYS proteins were not straightforward to perform and the 
analysis of the obtained results was similarly complicated.  
In light of this, it was concluded that difficulties in experimental procedures 
must have been related to some features of EYS and/or EYS bait fragments. 
Domain structure of EYS would suggest that it could be protein associated with the 
cell membrane or secreted to the extracellular matrix. If that is the issue for EYS, 
many interactions could have been missed due to bait and/or prey proteins being 
unable to enter the nucleus and activate expression of reporters (false negatives). 
Another possibility is that EYS is post-translationally modified in a manner that is 
crucial for its interactions and cannot be replicated in yeast cells. Further 
fundamental information regarding EYS would be crucial to redesigning the 
project: if EYS was a known membrane associated protein, it would be possible to 
use a Y2H system especially designed for detection of membrane proteins, e.g. 
Split-Ubiquitin Based Membrane Yeast Two-Hybrid (MYTH). If, on the other hand, 
EYS was known to be an extracellular protein, a SCINEX-P (screening for 
interactions between extracellular proteins) system could be employed (reviewed 
in Brückner et al., 2009). One could argue that a different system examining 
protein-protein interactions could have been chosen for investigating of the 
interactome of EYS; however, there was no experimental data available to support 
the choice of one system over another. The likelihood that a modification of the 
Y2H system would have worked better was unpredictable, especially for a protein 
of unknown function that is as large as EYS.  
Another option could be employing mass spectrometry (MS), which is a 
powerful method in proteomic research enabling investigation of the whole 
protein complexes that the protein of interest in incorporated in.  To perform MS, a 
good source of protein extract, coming from either a cell line or a tissue, would be a 
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major requirement. Y79 cells are the only cells endogenously expressing EYS and 
they could be used, although, practically they are challenging to work with and the 
majority of the cell volume is due to the nucleus, where EYS is unlikely to reside. 
Proteins extracts could also be obtained from retinal tissue, however, it needs to be 
noted that EYS is not expressed in rodents which would make it more complicated 
to obtain a desired amount of tissue that would come from an animal closely 
related to human or form human directly. MS could be preceded by affinity 
purification (AP/MS); however, any method requiring transfection with tagged 
EYS is, at the current state of art, prone to failure.   
In conclusion, the interactome of EYS could be analysed using alternative 
methods; however, an informed decision about the correct methodology to employ 
will not be possible until more is known about EYS localisation and/or function. 
This knowledge would greatly improve the relevance of methods chosen to study 
EYS and, therefore, the next stage of the thesis will be devoted to further 
investigating the nature of EYS. 
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Chapter 4: Characterisation of EYS  
The EYS gene is one of the largest genes known to be expressed in the 
human retina and since its discovery more than one hundred fifty disease causing 
mutations have been identified in individuals suffering from arRP. In spite of an 
extensive knowledge of the clinical phenotype of affected individuals, little is 
known about EYS protein and its role in the human retina. Upon commencement of 
the project, it was recognised that EYS localises to the photoreceptor outer 
segments of porcine retina and that it is involved in the organisation of the 
Drosophila rhabdomeric photoreceptors. One approach to investigate the role of 
EYS was to perform Y2H screening and identify its interacting partners, which 
would provide an invaluable source of information regarding the molecular 
processes that EYS is involved in. As described in Chapter 3, Y2H screening 
identified only one potential interacting partner of EYS which did not provide 
enough data to make compelling conclusions regarding the putative function of the 
protein of interest. Reasons for such an outcome may have been many but most 
likely they were related to some characteristics of EYS such as size and/or 
localisation. Results obtained in Y2H screening highlighted the need for 
broadening the knowledge of EYS localisation, which would be crucial to 
redesigning the strategy and improving the methodology used to identify retinal 
interacting partners of EYS. Characterisation of EYS was the objective of the 
experimental work presented in this chapter. 
4.1 EYS and Its Isoforms 
The EYS gene was identified at the RP25 locus by two research groups 
independently (Abd El-Aziz et al., 2008; Collin et al., 2008). In the study published 
by Abd El-Aziz and colleagues, EYS was reported to be composed of 43 exons 
whereas Collin et al. identified a 44 exon gene. The facultative 42nd exon 
comprises 63 bp and lies just prior to the sequence encoding the fourth LamG 
domain. By performing RT-PCR analysis and immunohistochemistry studies, both 
groups demonstrated that EYS has a retina specific expression pattern. When 
browsing online genomic databases, it cannot be overlooked that there have been 
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more than two EYS isoforms annotated. GenBank database reports the existence of 
four EYS isoforms which is consistent with the data annotated in Ensembl and 
UCSC genome browsers as well as UniProt protein database. UniProt database, 
however, provides nomenclature of EYS isoforms which is different to the 
nomenclature provided in NCBI and UCSC databases. In this study, nomenclature 
from the latter was followed and, for clarity, details of EYS isoforms are 
summarised in Table 4.1. 
 
Isoform 
cDNA 
[bp] 
Protein 
[aa] 
RefSeq (GenBank) 
Variation with respect to the 
canonical isoform 4 
Isoform 1 10589 3144 
NM_001142800.1,  
NP_001136272 
2691-2711 aa: Missing 
Isoform 2 5450 619 
NM_001142801.1,  
NP_001136273 
595-3165 aa: Missing 
590-594 aa: CSCSL → 
RILNTVIPHQIQQHIERFIQHDQVGFIVRI 
Isoform 3 2168 594 
NM_198283.1,  
NP_938024 
595-3165 aa: Missing 
590-594 aa: CSCSL → YLCII 
Isoform 4 10485 3165 
NM_001292009.1,  
NP_001278938 
canonical 
Table 4.1 An overview of human EYS isoforms based on the information derived from the 
GenBank and UniProt databases (accessed on 14.04.2015). NM numbers refer to transcript 
whereas NP numbers to protein variants.  
 
EYS isoform 4 was described as canonical by UniProt as it is the longest of 
all the variants. EYS isoform 1 lacks the 42nd exon; however, this change does not 
seem to affect the domain structure of the protein as both of the groups who 
identified EYS reported identical order of domains. This was also confirmed by 
scanning the sequence of EYS isoforms 1 and 4 using the Prosite database of 
protein domains (http://prosite.expasy.org/; de Castro et al., 2006). The domain 
structure of EYS isoforms 2 and 3 had not been examined before and therefore, the 
same tool was used to investigate the potential structure of the short variants of 
EYS. Both of the isoforms were predicted to be composed of five EGF-like domains, 
with a variable length and amino acid composition of the C-terminal ends of the 
protein. Since the first 589 aa of all of the EYS isoforms are identical, it is expected 
that EYS isoforms 2 and 3 also possess the N-terminal signal peptide which may be 
essential for their final localisation. The genetic and protein domain structure of 
EYS isoforms is shown in Figure 4.1. 
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Figure 4.1 An overview of human EYS transcripts variants. A: a schematic view of EYS 
transcript variants; green perpendicular bars represent protein coding exons, lanes 
represent introns and arrows indicate the transcriptional direction (data from NCBI Gene 
database accessed on 14.04.2015; http://www.ncbi.nlm.nih.gov/gene/346007) B: 
Predicted protein domain structure of EYS isoforms; domain order of EYS isoforms 1 and 4 
is presented as previously published (Barragan et al., 2010) whereas the domain structure 
of EYS isoforms 2 and 3 were predicated using the Prosite ExPasy database 
(http://prosite.expasy.org/, accessed on 14.04.2015). 
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4.1.1 Characterisation of EYS Isoforms 1 and 4  
Many of the disease-causing mutations in EYS affect the sequence encoding 
EYS isoforms 1 and 4. It is, therefore, of paramount importance to understand the 
role of these isoforms in the retina. To better characterise the EYS long variants, a 
set of experiments was performed aiming to investigate their localisation and 
expression patterns. EYS isoforms 1 and 4 seem to have an identical domain 
structure and in this study, the cDNA of EYS isoform 1 was available and used for 
experiments. Also, the difference in size between EYS isoforms 1 and 4 is 
undistinguishable via immunoblotting and therefore, some of the data presented in 
this section can concern both of the variants.  
In the first instance, immunoblotting was performed in order to verify the 
presence of EYS isoforms 1 and 4 in the protein extracts prepared form cell lines 
available in the project, which were Y79, SK-N-SH, ARPE-19 and HeLa cell lines. 
The result of immunoblotting with anti-EYS1 antibody is shown in Figure 4.2, 
where it can be observed that there is a thin band visible in the Y79 lane at the size 
of approximately 350 kDa (indicated by a red asterisk). This band corresponds to 
EYS isoforms 1 and 4 and it was only detected protein extract from Y79 cells; this 
result is consistent with published RT-PCR analyses (Abd El-Aziz et al., 2008). 
Apart from the band at ~350 kDa, there are also multiple bands visible at 
lower molecular weights in all of the lanes. The protein bands detected between 
the sizes of 55 – 71 kDa in all lanes could correspond to EYS isoforms 2 and 3; 
especially that the anti-EYS1 antibody was raised against an epitope common for 
all four of EYS isoforms. The immunoblotting control experiments, however, 
demonstrated that anti-EYS1 antibody is unable to detect EYS isoforms 2 and 3 
(Appendix I); this means that the bands were most probably non-specifically 
detected by either the primary or secondary antibodies used. Since EYS isoforms 1 
and 4 are large proteins, they are prone to degradation when performing 
experiments and it is also plausible that bands visible in Y79 lane at lower sizes 
were degradation products.  
Together, these observations suggest that bands detected below 350 kDa 
are most likely proteins non-specifically detected by the primary or secondary 
antibodies.  
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Figure 4.2 Western blot analysis of expression of EYS isoforms 1 and 4 in selected cell 
lines. The expected size of EYS isoform 1/4 is 350 kDa. A positive band was detected in 
protein extracts from wild type Y79 cells and is marked with a red asterisk. HiMark 
Protein standard was used to assess the size of protein bands. Loading was normalised 
using BCA assay; approximately 30 µg of protein was loaded in each lane. Immunoblotting 
was performed with anti-EYS1 rabbit and HRP conjugated goat anti-rabbit antibodies. Y79 
– a human retinoblastoma cell line; SK-N-SH – a human neuroblastoma cell line; ARPE-19 
– a human retinal pigment epithelial cell line; HeLa – a human epitheloid cervix carcinoma 
cell line. 
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The next stage of the analysis was to investigate the subcellular localisation 
of EYS isoforms 1 and 4. In order to look at the endogenous expression patterns, 
immunofluorescence experiments were performed on Y79 cells, which had been 
grown on poly-L-lysine coated coverslips. A cluster of Y79 cells stained with 
anti-EYS1 antibody is shown in Figure 4.3. As it can be observed, EYS is 
concentrated in the area most likely corresponding to the cytoplasm; however, it is 
also possible that some of the protein localises to the cell membrane. 
To better understand the subcellular localisation of EYS in Y79 cells, 
immunofluorescence experiments were performed using a range of cellular 
markers allowing visualisation of certain structures of the cells. The first marker 
used was acetylated α-tubulin, which is a component of microtubules and allows 
visualisation of acetylated cytoskeletal structures present in the cytoplasm. A cell 
co-stained with anti-acetylated-α-tubulin and anti-EYS1 antibodies is shown in 
Figure 4.4. The signal generated by anti-EYS1 antibody forms a ring around the 
nucleus and is surrounding the cytoplasm highlighted by staining of 
acetylated-α-tubulin. This suggests that EYS could be associated with the plasma 
membrane; nevertheless, the signal was also detected in the cytoplasm. 
To look into the membrane localisation of EYS, a fluorophore-conjugated 
wheat germ agglutinin (WGA) stain was used. WGA is a lectin that binds to 
N-acetyl-D-glucosamine and sialic acid residues found on the surface of cell 
membranes. The co-staining performed with fluorophore-conjugated WGA and 
anti-EYS1 antibody is shown in Figure 4.5; some co-localisation of EYS with WGA is 
visible, however, the overlap of signals is not thorough and some EYS signal could 
still come from the cytoplasm. As Y79 cells grow in suspension, they are spherical 
in shape and have low volume of the cytoplasm. These features make it challenging 
to make accurate observations regarding subcellular localisation of EYS, and 
therefore the yellow signal observed in co-staining with WGA could be random, 
especially in such a small and round cell body. 
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Figure 4.3 Localisation of EYS in a cluster of wild type Y79 cells. EYS (green) is 
concentrated in the area corresponding to the cytoplasm; however, it is also possible that 
some of the protein localises to the cell membrane. The zoomed inserts represent the 
areas demarcated by the white squares in the images. Immunostaining was performed 
with anti-EYS1 rabbit antibody. Secondary antibody was Alexa Fluor 488 conjugated goat 
anti-rabbit. Nuclei were stained with DAPI (blue). Scale bar: 10 μm. 
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Figure 4.4 Localisation of EYS and α-tubulin in Y79 cell line. EYS (green) forms a ring 
around the nucleus and is surrounding the cytoplasm highlighted by staining of 
acetylated-α-tubulin (red). The zoomed inserts represent the areas demarcated by the 
white squares in the images. Immunolabelling was performed with anti-EYS1 rabbit and 
anti-acetylated-α-tubulin mouse antibodies. Secondary antibodies were Alexa Fluor 488 
conjugated goat anti-rabbit and Cyanine 3 conjugated goat anti-mouse. Nuclei were 
stained with DAPI (blue). Scale bar: 10 μm. 
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Figure 4.5 Localisation of EYS in Y79 cell s stained with a membrane marker, WGA. EYS 
(green) is present in the cell cytoplasm and some portion of the signal overlaps with the 
cell membrane stained with WGA (red). Co-localisation is indicated by a yellow signal.  The 
zoomed inserts represent the areas demarcated by the white squares in the images. 
Immunolabelling was performed with anti-EYS1 rabbit antibody and AlexaFluor 
488-conjugated wheat germ agglutinin (WGA) stain. Secondary antibody was Alexa Fluor 
633 conjugated goat anti-rabbit. Nuclei were stained with DAPI (blue). Scale bar: 10 μm. 
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In order to encourage morphological differentiation, Y79 cells were seeded 
on coated coverslips and treated with dibutyryl-cAMP, according to a protocol 
optimised for the needs of the project.  Figure 4.6 depicts a cluster of Y79 cells 
treated with dibutyryl-cAMP and stained with anti-EYS1 and 
anti acetylated-α-tubulin antibodies. Microtubules can be seen throughout the 
cytoplasm and one long membrane protrusion is visible, which most likely 
corresponds to the primary cilium. EYS was detected as speckled signal distributed 
in the areas that could correspond to the cytoplasm or the cell membrane.  
To further analyse the subcellular localisation of EYS, the cells were stained 
with phalloidin conjugated with a fluorescent dye. Phalloidin specifically binds 
filamentous actin (F-actin) molecules which form actin filaments that are abundant 
throughout the cell but also present beneath the plasma membrane and in 
actin-based microvilli. As shown in Figure 4.7, F-actin is concentrated under the 
cell membrane and present in the membrane protrusions whereas EYS is mostly 
concentrated in the main cell body, in the areas that most likely represent the 
cytoplasm; very little signal is present in the protrusions and the two proteins 
seem to have distinctly separate localisation patterns. 
Y79 cells are not the most convenient tool for studying localisation of 
proteins and it would have been undoubtedly advantageous to investigate the 
exogenous expression patterns of EYS isoform 1 and 4 in adherent cell lines. The 
size of vector constructs made it extraordinarily challenging to transfect full sized 
EYS isoform 1 constructs into cell lines and it was successful only on a few 
occasions, which will be referred to further in Chapter 5. To gain a better idea of 
how full length EYS could localise in adherent cell lines, N-terminal (1-1635 aa) 
and C-terminal (1880-3144 aa) fragments of EYS isoform 1 were cloned with a GFP 
tag and transfected into HeLa cells. This particular cell line was chosen as it was 
found at many stages of the project that it transfects with the highest efficiency. 
Transfected cells were afterwards stained with fluorophore-conjugated WGA stain 
to visualise the cell membrane and the result is presented in Figure 4.8. As shown, 
both N-terminal and C-terminal fragments of EYS isoform 1 appear to localise to 
the cytoplasm and no co-localisation was observed at the cell membrane or 
microvilli. This would suggest that EYS isoform 1 has a cytoplasmic localisation; 
however, the full length protein would need to be examined to verify this 
hypothesis. 
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Figure 4.6 Localisation of EYS and acetylated-α-tubulin in a cluster of Y79 cells treated 
with dibutyryl-cAMP. EYS (green) was detected in the cell cytoplasm whereas 
microtubules (red) were seen throughout the cytoplasm and one long membrane 
protrusion is visible, which most likely corresponds to the primary cilium. The zoomed 
inserts represent the areas demarcated by the white squares in the images. 
Immunolabelling was performed with anti-EYS1 rabbit and anti-acetylated-α-tubulin 
mouse antibodies. Secondary antibodies were Alexa Fluor 488 conjugated goat anti-rabbit 
and Cyanine 3 conjugated goat anti-mouse. Nuclei were stained with DAPI (blue). Scale 
bar: 10 μm. 
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Figure 4.7 Localisation of EYS and F-actin in a cluster of Y79 cells treated with 
dibutyryl-cAMP. F-actin (red) was concentrated under the cell membrane and present in 
the membrane protrusions whereas EYS was mostly concentrated in the main cell body, in 
the areas that most likely represent the cytoplasm; very little signal is present in the 
protrusions and the two proteins seem to have distinctly separate localisation patterns. 
The zoomed inserts represent the areas demarcated by the white squares in the images. 
The cells were immunolabelled with anti-EYS1 rabbit antibody and stained with 
AlexaFluor 594-conjugated phalloidin dye. A secondary antibody was Alexa Fluor 488 
conjugated goat anti-rabbit. Nuclei were stained with DAPI (blue). Scale bar: 10 μm. 
 
  
Characterisation of EYS 
192 
 
 
 
Figure 4.8 Localisation of GFP tagged EYS N-terminal and C-terminal fragments in HeLa 
cells stained with a membrane marker WGA.  EYS N- and C-terminal fragments (green) 
localise to the cytoplasm and he signal does not overlap with WGA (red). GFP wild type 
(empty vector) was used as a control. The zoomed inserts represent the areas demarcated 
by the white squares in the images. Transfected cells were stained with TexasRed 
conjugated wheat germ agglutinin (WGA) stain. Nuclei were stained with DAPI (blue). 
Scale bar: 10 μm. 
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Altogether, the immunofluorescence experiments performed in Y79 and 
HeLa cell lines demonstrated that EYS could localise to the cytoplasm and possibly 
to the cell membrane. Variable localisation could be caused by presence of the 
shorter EYS isoforms 2 and 3; however, anti-EYS1 antibody was demonstrated to 
only detect EYS isoforms 1 and 4. Therefore, the results obtained in this section 
can be considered specific for large EYS isoforms 1 and 4. 
4.1.2 Characterisation of EYS Isoforms 2 and 3 
Since the expression of EYS isoforms 2 and 3 had not previously been 
addressed experimentally, RT-PCR analysis was performed on a panel of cDNA 
samples derived from a number of different adult human tissues and cultured cell 
lines. In the first experiment, full length sequences of EYS isoforms 2 and 3 were 
sought for in the panel of tissue specific cDNAs and the obtained results are 
presented in Figure 4.9. The analysis demonstrated that EYS isoforms 2 and 3 are 
exclusively expressed in the retina and testis and, interestingly, more than one 
band could be observed in the testis lane for EYS isoform 2, suggesting that there 
are more EYS variants expressed in this tissue.  
When it comes to the cell lines, the analysis demonstrated that EYS isoforms 
2 and 3 are expressed in Y79 cells but not in the other tested cell lines, which were 
SK-N-SH, ARPE-19 and HeLa (Figure 4.10). The lack of expression in SK-N-SH and 
ARPE-19 cell lines (derived from human neuroblastoma and the RPE respectively) 
could suggest that the presence of the short EYS variants is restricted to the neural 
retina. 
EYS isoforms 2 and 3 are significantly different in size and domain structure 
from the other two variants of EYS; therefore, it is not unlikely that EYS isoforms 
have variable activities in the human body. All of the variants share the same signal 
peptide which could suggest that they go through similar post-translational 
processing and localise to the same compartment of the cell.  
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Figure 4.9 RT-PCR analysis of expression of EYS isoforms 2 and 3 in a panel of cDNA 
sampled derived from human tissues. Primers were designed to cover the entire coding 
sequence of both isoforms. The predicted sizes of EYS isoform 2 and 3 are 1882 bp and 
1796 bp respectively. Positive bands demonstrating presence of the transcripts were 
observed for both of the isoforms in cDNA derived from the retina and testis. PCR mix 
without cDNA was used as negative control. A 150 bp fragment of ubiquitously expressed 
hypoxanthine phosphoribosyltransferase 1 gene (HPRT1) was used as a quality control. 
Promega 1 kb and 100 bp PCR markers were used to assess sizes of the bands.  
 
 
 
 
Characterisation of EYS 
195 
 
 
Figure 4.10 RT-PCR analysis of expression of EYS isoforms 2 and 3 in the panel of cDNA 
derived from four human cell lines. Primers were designed to cover the entire coding 
sequence of both isoforms. The predicted sizes of EYS isoform 2 and 3 are 1882 bp and 
1796 bp respectively. Positive bands demonstrating presence of the transcripts were 
observed for both isoforms in probes derived from Y79 cells. PCR mix without cDNA was 
used as negative control. A 150 bp fragment of ubiquitously expressed hypoxanthine 
phosphoribosyltransferase 1 gene (HPRT1) was used as a quality control. Promega 1 kb 
and 100 bp PCR markers were used to assess sizes of the bands. Cell lines used in the 
experiment: ARPE-19 – a human retinal pigment epithelial cell line; HeLa – a human 
epitheloid cervix carcinoma cell line; SK-N-SH – a human neuroblastoma cell line; Y79 – 
a human retinoblastoma cell line. 
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In order to look into the subcellular localisation of EYS isoforms 2 and 3, 
immunocytochemistry experiments were performed. Y79 cells were shown to 
express all four EYS isoforms endogenously; nonetheless, the available anti-EYS1 
antibody was only able to detect EYS isoforms 1 and 4, as described in the previous 
section. For this reason and in order to ensure that the analysis is specifically 
focused on EYS isoforms 2 and 3, ectopic expression of GFP tagged constructs was 
analysed. In the first instance, Y79 cells were investigated as they provide a retina 
specific environment for the synthesis of EYS proteins. Y79 cells were attached to 
the glass coverslips and transfected with GFP tagged EYS isoforms 2 and 3; GFP 
empty vector was used as a control. The results of the experiment are presented in 
Figure 4.11 and, as it can be observed, GFP tagged EYS isoforms 2 and 3 appear to 
have an identical expression pattern and localise to the cytoplasm. As expected, the 
signal from the GFP wild type tag was diffused across the cytoplasm and the 
nucleus. The subcellular localisation of GFP tagged EYS isoforms 2 and 3 could also 
overlap with the cell membrane; however, their distribution is similar to the one of 
GFP wild type which strengthens the hypothesis of the cytoplasmic localisation.  
Taking into account the previously mentioned drawbacks to using the Y79 
cell line, and that the transfection method for these cells is technically demanding 
and the efficiency usually low, the GFP tagged constructs were transfected into the 
HeLa cell line in order to characterise the expression pattern of EYS isoforms with 
more accuracy. The panel presented in Figure 4.12 shows successfully 
overexpressed GFP tagged EYS isoforms 2 and 3, and wild type GFP, which was 
used as a control. The vast majority of the overexpressed EYS isoforms localised to 
the cytoplasm; however, there was also some signal detected in the cell nuclei. The 
nuclear localisation was also detected in other experiments; however, it was not a 
consistently repeated pattern. This would suggest that it can be a result of 
overexpression or that the localisation of EYS isoforms 2 and 3 is dynamic and 
modulated by an unknown mechanism. Moreover, there are some stronger green 
speckles and aggregate-like structures visible for both of the isoforms, which could 
correspond to transporting vesicles or organelles such as Golgi apparatus; they 
could also manifest protein degradation. 
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Figure 4.11 Localisation of GFP tagged EYS isoforms 2 and 3 in Y79 cells. Both of the 
isoforms localised to the cell cytoplasm of transfected Y79 cells.  GFP wild type (empty 
vector) was used as a control of the fluorescent tag. The zoomed inserts represent the 
areas demarcated by the white squares in the images. Nuclei were stained using DAPI 
(blue). Scale bar: 10 µm.  
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Figure 4.12 Localisation of GFP tagged EYS isoforms 2 and 3 in HeLa cells. EYS isoform 2 
localised to the cytoplasm whereas EYS isoform 3 localised to the cytoplasm and the 
nucleus of transfected HeLa cells.  GFP wild type (empty vector) was used as a control of 
the fluorescent tag. The zoomed inserts represent the areas demarcated by the white 
squares in the images. Nuclei were stained using DAPI (blue). Scale bar: 10 µm. 
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To confirm specificity of the experiment, protein extracts were prepared 
from HeLa cells transfected with GFP tagged EYS isoforms 2 and 3, and the GFP 
empty vector. Immunoblotting was performed using anti-GFP mouse antibody and 
as shown in Figure 4.13, protein bands at expected sizes were detected, confirming 
that tagged EYS isoforms 2 and 3 were successfully overexpressed in HeLa cells. 
To delineate the subcellular localisation of EYS isoforms 2 and 3 more 
accurately, cells transfected with the GFP tagged variants were compared with 
markers of the particular cellular compartments. In order to highlight the 
structures present in the cytoplasm, F-actin filaments were stained with 
fluorophore-conjugated phalloidin and microtubules were immuno-labelled with 
anti α-tubulin antibody. The cell membrane was stained with a fluorophore-
conjugated WGA stain and in order to highlight the Golgi apparatus, immuno-
staining with α-giantin antibody was performed.  
The panel presented in Figure 4.14 shows the expression pattern of EYS 
isoform 2 compared with the aforementioned cellular markers. From the staining 
with phalloidin, it can be concluded that GFP tagged EYS isoform 2 localises to the 
cytoplasm with the signal being spread up to the cell boundary; no signal was 
detected in the plasma membrane protrusions. 
 The cytoplasmic localisation of EYS isoform 2 was re-confirmed by the 
speckled co-localisation with microtubules, which is indicated by the yellow signal. 
To check whether EYS isoform 2 resides in the cell membrane, transfected cells 
were stained with fluorophore-conjugated WGA dye. As it can be seen, EYS 
isoform 2 does not appear to be present in the cell membrane or the nuclear 
membrane. To test whether the speckled and aggregate-like signal observed in 
Figure 4.12 was a result of localisation to the Golgi apparatus, co-labelling with 
anti-giantin antibody was performed. Co-localisation was not observed, suggesting 
that the aggregates observed may have been the result of overexpression and/or 
the protein degradation. 
Figure 4.15 presents a panel demonstrating subcellular localisation of EYS 
isoform 3 compared with the previously described markers. Similarly to EYS 
isoform 2, EYS isoform 3 localised across the cytoplasm and partially overlapped 
with actin filaments and microtubules but was not found to reside in the cell 
membrane, microvilli or the Golgi apparatus. GFP tag expressed on its own is 
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shown in a panel presented in Figure 4.16 and, as expected, it was found to be 
diffused across the cytoplasm and the nucleus.  
Overall, immunocytochemistry experiments demonstrated that EYS 
isoforms 2 and 3 localise to the cytoplasm and, occasionally, to the cell nucleus. 
Neither of the variants was found in the cell membrane, microvilli or the Golgi 
apparatus.  
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Figure 4.13 Western blot analysis of GFP tagged EYS isoforms 2 and 3. Expected band 
sizes: GFP-EYS isoform 3 – 94 kDa, GFP-EYS isoform 2 – 97 kDa, GFP wild type – 27 kDa, 
Protein extract from wild type HeLa cells was used as negative control. Loading was 
normalised using BCA assay; approximately 30 µg of protein was loaded in each lane. 
Bio-Rad Precision Plus Protein Standard was used to assess the band size. Anti-GFP mouse 
primary antibody and HRP conjugated goat anti-mouse secondary antibody were used. IB 
– immunoblotting. 
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Figure 4.14 Localisation of GFP tagged EYS isoform 2 and a panel of cellular markers in 
transfected HeLa cells. EYS isoform 2 (green) localised to the cell cytoplasm and 
occasionally the cell nucleus. The cellular makers (red) were the following organelles: 
F-actin filaments visualised via staining with AlexaFluor 594-conjugated phalloidin, 
microtubules stained with anti-α-tubulin mouse antibody, the cell membrane stained with 
TexasRed conjugated WGA dye and the Golgi apparauts was highlighted by staining with 
anti-giantin mouse antibody. The zoomed inserts represent the areas demarcated by the 
white squares in the images. Nuclei were stained with DAPI (blue). Scale bar: 10 μm. 
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Figure 4.15 Localisation of GFP tagged EYS isoform 3 and a panel of cellular markers in 
transfected HeLa cells. EYS isoform 3 (green) localised to the cell cytoplasm and 
occasionally the cell nucleus. The cellular makers (red) were the following organelles: 
F-actin filaments visualised via staining with AlexaFluor 594-conjugated phalloidin, 
microtubules stained with anti-α-tubulin mouse antibody, the cell membrane stained with 
TexasRed conjugated WGA dye and the Golgi apparauts was highlighted by staining with 
anti-giantin mouse antibody. The zoomed inserts represent the areas demarcated by the 
white squares in the images. Nuclei were stained with DAPI (blue). Scale bar: 10 μm. 
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Figure 4.16 Localisation of GFP wild type tag (empty GFP vector) and a panel of cellular 
markers in transfected HeLa cells. GFP wild type localised to the cell cytoplasm and to the 
cell nucleus. The cellular makers (red) were the following organelles: F-actin filaments 
visualised via staining with AlexaFluor 594-conjugated phalloidin, microtubules stained 
with anti-α-tubulin mouse antibody, the cell membrane stained with TexasRed conjugated 
WGA dye and the Golgi apparauts was highlighted by staining with anti-giantin mouse 
antibody. The zoomed inserts represent the areas demarcated by the white squares in the 
images. Nuclei were stained with DAPI (blue). Scale bar: 10 μm.  
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4.2 Ex Vivo Characterisation of EYS Expression 
To investigate the cellular localisation of EYS in a more illustrative model, 
immunohistochemistry (ICH) experiments were performed. In the first published 
immunohistochemistry experiment, EYS was reported to localise to the 
photoreceptor outer segments of the porcine retina (Abd El-Aziz et al., 2008).  
In this study, it was aimed to investigate the localisation of EYS more deeply 
and assess its localisation in the retina derived from an organism more closely 
related to humans. The best available alternative to human tissue was material 
explanted from adult crab-eating macaques (Macaca fascicularis). To improve 
credibility of the results, specimens from two different animals were used. 
In the first experiment, a single immunostaining was performed to examine 
the expression pattern of EYS in the monkey retina. Anti-EYS2 antibody was 
selected as it was raised against an epitope conserved in the genomes of human 
and crab-eating macaque. As shown in Figure 4.17, EYS was detected in all layers 
of the retina; however, the strongest signal was detected in the layer 
corresponding to the connecting cilium and the base of the photoreceptor outer 
segments. There is also strong signal visible in the lower half of the outer plexiform 
layer, suggesting that EYS could additionally localise to the synaptic area of 
photoreceptors or retinal interneurons, and in the ganglion cell layer.  
In order to further investigate the potential ciliary localisation of EYS, 
co-staining with anti-EYS2 and anti-acetylated-α-tubulin antibodies was 
performed. Acetylated α-tubulin is a component of microtubules and it is 
commonly used as a marker of the connecting cilium and the ciliary axoneme. 
Photoreceptor connecting cilium is a structure bridging the inner and outer 
segments of photoreceptor cells. All proteins residing in the outer segment are 
synthesised in the inner segment so they must traverse through the connecting 
cilium to reach their destination. Directly below the connecting cilium, there is the 
basal body which acts as an organising centre for nucleation of microtubules. The 
microtubules extend from the basal body to form the axonemal structure that 
reaches at least half the length of the outer segment (reviewed in Pearring et al., 
2013). The micrograph presented in Figure 4.18 suggests that EYS has a similar 
expression pattern to acetylated α-tubulin, observed as thin whip-like signal 
extending from the connecting cilium to the photoreceptor outer segment.  
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Figure 4.17 Localisation of EYS in the macaque retina. EYS (green) was detected in all 
layers of the retina; however, significantly stronger signal is visible in the areas 
corresponding to the connecting cilium and some part of photoreceptor outer segments 
and outer plexiform layer. The zoomed images (Zoom) are demarcated by the white 
square in the images. Anti-EYS2 rabbit primary antibody and AlexaFluor488 conjugated 
goat anti-rabbit secondary antibody were used. DAPI was used to stain cell nuclei (blue). 
Scale bar: 20 µm. RPE – retinal pigment epithelium, OS – outer segment, CC – connecting 
cilium, IS – inner segment, OPL – outer plexiform layer, ONL – outer nuclear layer, INL – 
inner nuclear layer, GCL – ganglion cell layer. Negative control was a specimen labelled 
with AlexaFluor488 conjugated goat anti-rabbit antibody and DAPI.   
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Figure 4.18 Localisation of EYS and acetylated α-tubulin in the macaque.  EYS (green) 
has a similar expression pattern to acetylated α-tubulin (red), observed as thin 
whip-like signal extending from the connecting cilium to the photoreceptor outer 
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segment. Acetylated α-tubulin is a structural component and therefore a marker of 
the photoreceptor ciliary axoneme.  Any co-localisation is indicated by 
yellow/orange signal. The zoomed images (Zoom) are demarcated by the white 
square in the images. Anti-EYS2 rabbit and anti-acetylated α-tubulin mouse primary 
antibodies and AlexaFluor488 conjugated goat anti-rabbit and Cyanine 3 conjugated 
donkey anti-mouse secondary antibodies were used. DAPI was used to stain cell nuclei 
(blue). Scale bar: 10 µm. RPE – retinal pigment epithelium, OS – outer segment, CC – 
connecting cilium, IS – inner segment. 
 
This suggests that EYS follows the ciliary axoneme and could be a protein 
associated with this particular structure.  
 To ascertain whether EYS localised to the photoreceptor outer segments in 
the monkey retina, its expression pattern was compared to arrestin that is an outer 
segment specific protein present in light adapted rod and cone photoreceptors. 
The micrograph presented in Figure 4.19 shows a co-staining performed with 
anti-EYS2 (green) and anti-arrestin (red) antibodies. As previously, the EYS signal 
was detected across the retina with a distinct pattern of thin long fibrils observed 
in the region of the connecting cilium whereas the staining of arrestin highlighted 
the layer of the photoreceptor outer segments. The overlap has been observed 
confirming that EYS localises to the photoreceptor outer segments. Figure 4.20 
shows a piece of the same specimen at higher magnification. Here, it can be seen 
more clearly that the green whip-like signal is present in the region of the 
connecting cilium and extending above into the outer segment, giving impression 
that it could overlap with the photoreceptor axoneme. 
Since arRP is a condition affecting primarily rods, it was expected that EYS 
would predominantly localise to this type of photoreceptors. This, however, cannot 
be determined without performing the analysis utilising rod and cone specific 
markers.  
To confirm whether EYS is present in rods, retinal sections were immuno-
labelled with an anti-EYS2 antibody and fluorophore-conjugated WGA stain, 
specifically binding to rod associated matrix proteins. A micrograph of a stained 
retina section is presented in Figure 4.21, in which WGA is shown in red and EYS is 
shown in green. The staining re-confirmed that EYS localises to the region of the 
connecting cilium and the rod photoreceptor outer segment.  
To further examine the co-localisation of EYS and WGA, an image was taken 
at higher magnification. As shown in Figure 4.22, EYS was detected as thin fibrils 
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which appear to follow the ciliary axoneme. It also overlapped with the red signal 
of WGA stain, confirming that EYS is expressed in rods.  
To test if EYS is also expressed in cones, co-staining with fluorophore-
conjugated PNA, which binds to cone specific matrix proteins, was performed. The 
result presented in Figure 4.23 demonstrates that EYS is not only associated with 
rods but it is also present in the cone photoreceptor outer segments. Strikingly, the 
signal coming from the anti-EYS2 antibody had a very distinct pattern; it is not 
distributed throughout the outer segments but concentrated on one side of the cell. 
To verify that observation using a marker that can be immuno-labelled, co-staining 
of EYS and s-opsin was performed. S-opsin is a protein specifically localising to the 
s-cone outer segments and in this experiment it was used to highlight that 
particular structure. The micrograph presented in Figure 4.24 shows an s-cone 
outer segment highlighted in green and EYS highlighted in red. The expression 
pattern of EYS is indeed consistent with the previous experiments and it appears 
as a whip-like structure extending from the connecting cilium into the outer 
segment.  
Immunocytochemistry experiments conducted on monkey retinal sections 
revealed that EYS could be a ciliary associated protein in both rods and cones. 
Based on that observation, it can be suggested that EYS may be involved in 
processes such as maintaining the structure of the ciliary axoneme, intraflagellar 
transport or signalling pathways. Further research would be required to fully 
determine the role EYS in photoreceptor cells.  
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Figure 4.19 Localisation of EYS and arrestin in the macaque retina. The whip-like 
signal of EYS (green) was detected in the area corresponding to the connecting cilium and 
outer segments whereas arrestin (red) is specifically localised to the photoreceptor 
outer segment. The zoomed images (Zoom) are demarcated by the white square in 
the images. Anti-EYS2 rabbit and anti-arrestin mouse primary antibodies and 
AlexaFluor488 conjugated goat anti-rabbit and Cyanine 3 conjugated donkey anti-mouse 
secondary antibodies were used. DAPI was used to stain cell nuclei (blue). Scale bar: 20 
µm. RPE – retinal pigment epithelium, OS – outer segment, CC – connecting cilium, IS – 
inner segment, ONL – outer nuclear layer, INL – inner nuclear layer, GCL – ganglion cell 
layer. 
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Figure 4.20 Localisation of EYS and arrestin in the macaque retina – a high magnification 
image. The whip-like signal of EYS (green) was detected in the area corresponding to the 
connecting cilium and outer segments whereas arrestin (red) is specifically localised to 
the photoreceptor outer segment. The zoomed images (Zoom) are demarcated by the 
white square in the images. Anti-EYS2 rabbit and anti-arrestin mouse primary antibodies 
and AlexaFluor488 conjugated goat anti-rabbit and Cyanine 3 conjugated donkey anti-
mouse secondary antibodies were used. DAPI was used to stain cell nuclei (blue). Scale 
bar: 20 µm. RPE – retinal pigment epithelium, OS – outer segment, CC – connecting cilium, 
IS – inner segment, ONL – outer nuclear layer. 
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Figure 4.21 Localisation of EYS in the retina stained with the rod specific dye, WGA. EYS 
(green) was detected in the region of the photoreceptor ciliary axoneme and overlapped 
with WGA (red). Anti-EYS2 primary antibody (green) and AlexaFluor488 conjugated goat 
anti-rabbit secondary antibody were used. TexasRed-X-conjugated WGA was used to stain 
rod associated matrix proteins and DAPI was used to stain cell nuclei (blue). The zoomed 
images (Zoom) are demarcated by the white square in the images. Scale bar: 20 µm. RPE – 
retinal pigment epithelium, OS – outer segment, CC – connecting cilium, IS – inner 
segment, ONL – outer nuclear layer, INL – inner nuclear layer, GCL – ganglion cell layer. 
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Figure 4.22 Localisation of EYS in the macaque retina stained with the rod specific dye, 
WGA – a high magnification image. EYS (green) was detected in the region of the 
photoreceptor ciliary axoneme and overlapped with WGA (red). The zoomed images 
(Zoom) are demarcated by the white square in the images. Anti-EYS2 primary antibody 
and AlexaFluor488 conjugated goat anti-rabbit secondary antibody were used. TexasRed-
X-conjugated WGA was used to stain rod associated matrix proteins and DAPI was used to 
stain cell nuclei (blue). Scale bar: 20 µm. RPE – retinal pigment epithelium, OS – outer 
segment, CC – connecting cilium, IS – inner segment, ONL – outer nuclear layer.  
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Figure 4.23 Localisation of EYS in the macaque retina stained with a cone specific dye, 
PNA - a high magnification image . EYS (green) was detected in the region of the 
photoreceptor ciliary axoneme and it was distinctively concentrated on one side of cone 
cells, which were highlighted by PNA (red). The zoomed images (Zoom) are demarcated 
by the white square in the images. Anti-EYS2 primary antibody and AlexaFluor488 
conjugated goat anti-rabbit secondary antibody were used. TexasRed-X-conjugated PNA 
was used to stain cone associated matrix proteins and DAPI was used to stain cell nuclei 
(blue). Scale bar: 20 µm. RPE – retinal pigment epithelium, OS – outer segment, CC – 
connecting cilium, IS – inner segment, ONL – outer nuclear layer.  
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Figure 4.24 Localisation of EYS and S-opsin in the macaque retina. EYS (red) was detected 
in the region of the photoreceptor ciliary axoneme and the signal was distinctively 
concentrated on one side of the cone cell and overlapped with the localisation of S-opsin 
(green), which is a protein specifically localised to the cone outer segments. The zoomed 
images (Zoom) are demarcated by the white square in the images. Anti-EYS2 and anti-s-
opsin primary antibodies and cyanine 3 conjugated donkey anti-goat and AlexaFluor488 
conjugated donkey anti-mouse secondary antibodies were used. Scale bar: 10 µm. OS – 
outer segment, CC – connecting cilium, IS – inner segment.  
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4.3 Discussion of Chapter 4 
The role of EYS protein in the human retina is unquestionably essential for 
its homeostasis; however, the function it has in the photoreceptor cells is still not 
fully understood. The experimental work presented in Chapter 4 aimed to expand 
the fundamental knowledge of EYS and such characterisation was necessary to 
better understand its significance for human health. 
In the first instance, the analysis of online genomic and proteomic 
databases was performed. In studies published in 2008, EYS was described to be 
specifically expressed in the retina and EYS gene was reported to have either 43 or 
44 exons (isoform 1 and 4 respectively). Online databases, however, predicted 
there can be more than two splicing variants of EYS and surprisingly, the two 
additional isoforms (isoform 2 and 3) significantly differ in size and domain 
structure from the canonical protein (Figure 4.1).  
Alternative splicing is a dynamically regulated process that contributes to 
the proteomic diversity and it is especially common for the genes expressed in the 
nervous system where the synthesis of protein variants determines properties of 
different types of neurons (reviewed in Li et al., 2007). Therefore, it could be that 
function and levels of expression of EYS isoforms vary depending on the 
developmental and/or physiological condition of an organism. In order to 
supplement previously published expression studies, RT-PCR analysis of short EYS 
isoforms 2 and 3 was performed. Data obtained demonstrated that full length 
transcripts of EYS isoforms 2 and 3 are present in the retina and testis, and Y79 
cell line. Furthermore, amplification of EYS isoforms 2 from the testicular cDNA 
resulted in obtaining multiple bands, which could suggest that there are further 
EYS splicing variants expressed in the testis.  
These results are consistent with data published by Collin et al., who aimed 
to verify expression of EYS isoform 4 in human tissues by amplification of 
fragments of the gene; such a strategy was most likely undertaken due to the large 
size of EYS and difficulties with amplification of the full length gene. The group was 
able to amplify most of the coding exons of EYS isoform 4 in the retina and 
observed two clearly separated bands in a fragment encompassing exons 41-44, 
which confirmed the existence of EYS isoform 1. Interestingly, the analysis 
presented in the paper also included amplification of a fragment spanning exons 
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9-12, whose sequence is conserved in all EYS isoforms. It resulted in identification 
of a DNA band in the retina and testis, which implied that EYS isoforms may also be 
expressed in the testis; however, the presence of this band was not referred to by 
the authors of the study (Collin et al., 2008).  
It should also be mentioned that EYS has been identified by a genome wide 
association study (GWAS) study as a gene potentially implicated in severe statin 
induced myopathy, a common side effect of the treatment of hypercholesterolemia 
(Isackson et al., 2011). The group suggested that there is an EYS isoform 
specifically expressed in the spinal cord, which comprises of 45 exons and 3196 aa. 
The published RT-PCR analysis was focused on fragments spanning over exons 27-
45 and performed on cDNA samples from the retina, skeletal muscle, brain and 
spinal cord. The EYS transcripts were suggested to be expressed in all of the tested 
tissues; however, the longest 45 exon isoform was claimed to be spinal cord 
specific. The published data is not consistent with the RT-PCR analyses performed 
by Abd El-Aziz et al. and Collin et al. who reported EYS to be a retina specific gene 
(Abd El-Aziz et al., 2008; Collin et al., 2008). EYS is a large gene and it may well 
have multiple isoforms that have variable functions in many tissues of the human 
body; nevertheless, the spinal cord isoform of EYS has not been annotated in any of 
the databases and its sequence is not available. Therefore, this isoform has not 
been included in the study presented herein.  
Immunofluorescence experiments were performed in cultured cell lines in 
order to investigate the subcellular localisation of EYS proteins. In the first 
instance, localisation of EYS isoforms 1 and 4 was explored. Endogenous patterns 
of localisation were investigated in Y79 cells, the only cell line known to express 
EYS proteins. Y79 cells are a suspension cell line, where the cell is mostly made up 
of a large nucleus with relatively little surrounding cytoplasm. The cells grow in 
clusters and their organelles are tightly packed around the nucleus, hindering 
analysis of localisation studies. Cell attachment protocols were successfully 
optimised and used in the study, although the morphology of Y79 cells does not 
change much when they are attached to the culture dish. Therefore, cells were 
treated with dibutyryl-cAMP which encourages differentiation in cells and in the 
case of Y79s, enhanced the outgrowth of processes and improved visualisation of 
the cell structures. To better understand the origin of the signal coming from the 
anti-EYS1 antibody, a selection of markers highlighting different cell structures 
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were used. The analysis demonstrated that EYS isoform 1 most likely localises to 
the cytoplasm but could as well reside in the cell membrane. Further research 
would need to be carried out to fully determine the localisation of EYS in cell lines. 
One of the directions could be overexpression of full length EYS isoforms 1 and 4 in 
adherent cell lines, an approach that was attempted in this study and did not yield 
positive results. This was most likely due to the large size of EYS isoform 1 
constructs which were as big as 16 kb and the technology available in the project 
could not suffice for transfecting with such large plasmids. To have an overview of 
where EYS domains could localise, N-terminal and C-terminal fragments of EYS 
were cloned with GFP tag and transfected into HeLa cells. Both of the fragments 
localised in the cytoplasm and were not present in the cell membrane. This implies 
that EYS is likely to have cytoplasmic localisation; nonetheless, such hypothesis 
could only be fully validated by performing research on the full sized protein.   
Investigation of subcellular localisation of EYS isoforms 2 and 3 was less 
demanding. EYS isoforms 2 and 3 are significantly smaller that EYS isoforms 1 and 
4 and therefore, it was possible to clone them into tagged vectors and overexpress 
them in cell lines. Overexpression in the Y79 cell line enabled localisation of the 
isoforms in the environment that they are naturally synthesised in. Their 
localisation appeared to be identical to that of EYS isoforms 1 and 4 and the signal 
was mostly concentrated in the cytoplasm. To better visualise the subcellular 
localisation of EYS isoforms 2 and 3, they were overexpressed in HeLa cells and 
compared to a range of markers. These experiments demonstrated that GFP tagged 
EYS isoforms 2 and 3 localise to the cytoplasm and sporadically to the nucleus; the 
nuclear localisation was inconsistent between experiments and could imply that 
EYS isoform 3 has a dynamic localisation and/or function. Another scenario could 
be that the variable expression pattern is an artefact caused by the protein being 
overexpressed.  
In the previous reports, EYS has been demonstrated to co-localise with 
rhodopsin in the porcine retina (Abd El-Aziz et al., 2008). Experiments conducted 
in this project aimed to look into the localisation of EYS more deeply, using retinal 
tissue sections derived from an animal more closely related to humans. The retinal 
tissue sections available in this study were explanted from adult crab-eating 
macaques (Macaca fascicularis). In the first instance, single immuno-staining was 
performed in order to optimise experimental conditions for the anti-EYS2 antibody 
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and to establish the localisation pattern of EYS in the monkey retina. Signal that 
was detected highlighted a whip-like structure that appeared in the area 
corresponding to the connecting cilium and the ciliary axoneme. Signal coming 
from the anti-EYS2 antibody was also detected in all other layers of the retina; 
however, it was diffused and significantly weaker, except for the outer plexiform 
layer and the ganglion cell layer where equally strong signal was detected. It could 
imply that EYS is expressed in other retinal neurons, which could be investigated 
in the future.   
In order to accurately establish the localisation of EYS in the monkey retina, 
double immuno-labelling with well characterised cellular markers was performed. 
Markers used in the study were selected so that it can be assessed whether EYS 
may be associated with the ciliary axoneme and if it is present in rods, cones or 
both. The obtained results provided evidence supporting the hypothesis that EYS is 
likely to be associated with the ciliary axoneme in both rods and cones. This is 
consistent with the observations made in the porcine retina and re-enforced the 
previously published hypothesis that EYS resides in the photoreceptor outer 
segments (Abd El-Aziz et al., 2008). 
Altogether, the data presented in this chapter provided additional 
information regarding EYS genetic structure and localisation in the retina. 
Expression of EYS isoforms 2 and 3 was for the first time fully characterised by 
RT-PCR and immunofluorescence studies. Further analysis of EYS isoforms 
provided evidence implying that EYS is expressed in both rod and cone 
photoreceptors and it is most likely associated with the ciliary axoneme, where it 
could be involved in signalling, intraflagellar transport or have a structural role. 
EYS is an undoubtedly essential component of the human retina and its disruption 
is associated with arRP; nonetheless, a Japanese patient suffering from a cone-rod 
dystrophy was reported, carrying  a truncating compound heterozygous mutation 
in EYS (Katagiri et al., 2014). This supports the hypothesis that EYS is not only 
crucial for the functioning of rods but it is also important for the stability of cones. 
In the future, it would be of paramount importance to conduct similar experiments 
on human specimens to fully characterise the human orthologue of EYS. 
Furthermore, the existence of EYS splicing variants should not be underrated and 
the future research should also focus on their significance in the retina and address 
their expression and function in the testis. 
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Another important conclusion can be made regarding the signal peptide of 
EYS. It has previously been suggested that the N-terminal signal peptide of EYS 
could direct it to a secretory pathway, making EYS an extracellular protein. Data 
presented in this chapter imply that EYS is not secreted but resides in the 
photoreceptor outer segments. Therefore, it could be suggested that the signal 
peptide is responsible for targeting EYS to the photoreceptor outer segment by, for 
example, means of vesicular trafficking (reviewed in Pearring et al., 2013).  
Overall, a significant amount of data regarding EYS was obtained which not 
only contributes to better understanding of EYS but also opens new avenues for 
the design of future research projects. 
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Chapter 5: Characterisation of the Relationship between EYS and 
Prominin-1 
An intriguing phenomenon in the biology of EYS is its unusual course of 
evolution, in which the expression of EYS was lost in several lineages of mammals, 
including rodents. EYS, however, has been discovered to be an orthologue of a 
Drosophila protein called spam or spacemaker (Abd El-Aziz et al., 2008; Collin et 
al., 2008). It has been demonstrated that spam is a secreted extracellular protein, 
which is a member of network of interactions critical to the formation of the 
inter-rhabdomeral space (IRS) in the Drosophila ommatidium (Husain et al., 2006; 
Zelhof et al., 2006). Zelhof et al. have also suggested that spam interacts with 
prominin to counteract the adhesive force of chaoptin during the IRS formation. 
The group also investigated the relationship of spam and prominin in the 
Drosophila cell line and showed that prominin is required for the localisation of 
spam to the surface of the cell membrane (Zelhof et al., 2006). Phenotypic analysis 
of Drosophila mutants suggested that the interaction of prominin and spam was 
required for proper formation of the rhabdomeric photoreceptors, and their 
human orthologues rescued the mutant phenotype and enabled formation of the 
IRS when introduced into the Drosophila model. This led the authors to suggest 
that the interaction of spam and prominin may be conserved in humans (Nie et al., 
2012). In another study, Drosophila spam has been found to be expressed in the 
mechanoreceptor neurons and it has been shown to protect the neurons from 
environmental insult by preservation of the cell shape enforced by stiffening of the 
cell membrane (Cook et al., 2008). 
The human orthologue of prominin, Prominin-1, is a pentaspan 
transmembrane protein that has been shown to be involved in the photoreceptor 
membranous disk formation, and mutations in PROM1 gene cause retinal 
degeneration (see Introduction, section 1.5).  
Prominin-1 has been widely studied in vertebrates. It has been shown that 
in murine photoreceptors it localises to the membrane extensions that give rise to 
the membrane discs of the outer segments (Maw et al., 2000). It has also been 
reported that knocking out prominin-1 in mice leads to progressive degeneration 
of photoreceptors (Zacchigna et al., 2009). In Xenopus laevis, prominin-1 has been 
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demonstrated to be present at the basal disks of rod outer segments and at the 
outer rims of open disk lamellae of cone outer segments (Han et al., 2012). The 
known interactome of human Prominin-1 includes Protocadherin-21, a protein 
involved in the disk membrane morphogenesis, and actin, which is a well-known 
component of the cytoskeleton (Yang et al., 2008). 
In light of the literature data-mining, Prominin-1 is a strong candidate for 
being an interacting partner of EYS. It is likely that the interaction of the two 
proteins is conserved in humans and crucial for the proper functioning of human 
photoreceptors.  Prominin-1 was not found to be an interacting partner of EYS in 
the Y2H screens performed in this study. This, however, does not mean that the 
interaction does not occur as Prominin-1 is a protein specifically localising to the 
cell membrane protrusions and, therefore, it is highly likely that it could not have 
been detected using the GAL4 based Y2H system used in this study.  
Since there is strong evidence in support of the interaction taking place in 
Drosophila, the relationship between human orthologues of EYS and Prominin-1 
was investigated in this study.  
5.1 Immunocytochemistry Studies of EYS and Prominin-1 
The first approach to characterise the potential interaction of EYS and 
Prominin-1 was to analyse their subcellular localisation. To begin with, Y79 cell 
line was examined as it was known to endogenously express EYS.  
To confirm the expression of PROM1 in Y79 cells, RT-PCR analysis was 
performed and the result is shown in Figure 5.1. The positive result of the analysis 
enabled investigation of endogenous expression of Prominin-1 and EYS; however, 
the first immunofluorescence experiments demonstrated that Prominin-1 is not 
abundantly expressed in Y79 cells. This may be due to the lack of elaborate 
membranous structure present in Y79 cells, or due to inefficient binding of the 
available anti-Prominin-1 antibodies, although, the former scenario should not be 
the case in light of the immuno-stainings of Y79 cells presented in Chapter 4. 
Consequently, the endogenous expression of EYS was compared to the ectopic 
expression of DsRed tagged Prominin-1. Figure 5.2 depicts a cluster of seven Y79 
cells, two of which were successfully transfected with DsRed-Prominin-1.  
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Figure 5.1 RT-PCR analysis of expression of Prominin-1 in cDNA derived from Y79 cells. 
Primers were designed to cover a fragment of PROM1 cDNA encompassing exons 20-28 
with the expected size of 672 bp. PCR mix without cDNA was used as negative control. A 
150 bp fragment of ubiquitously expressed hypoxanthine phosphoribosyltransferase 1 
gene (HPRT1) was used as a quality control. Bioline Hyperladder I was used to assess sizes 
of the bands. Y79 – a human retinoblastoma cell line. 
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Figure 5.2 Localisation of EYS and DsRed-Prominin-1 in Y79 cells. EYS (green) localised to 
the cell cytoplasm whereas DS-Red-Prominin-1 localised to the cell membrane microvilli. 
Co-localisation of the proteins was not been observed. The zoomed inserts represent the 
area demarcated by the white square in the images. Anti-EYS1 primary and AlexaFluor 
488 conjugated goat anti-rabbit secondary antibodies were used. Nuclei were stained with 
DAPI (blue). Scale bar: 10 μm. 
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As the micrograph shows, DsRed-Prominin-1 characteristically localised to the cell 
membrane protrusions whereas EYS was detected as a speckled signal present in 
the areas that probably correspond to the cytoplasm; it was not detected in the 
microvilli and co-localisation with Prominin-1 was not observed.  
A micrograph of another cell taken at higher magnification is shown in 
Figure 5.3. The image was taken so that the cell membrane localisation of 
Prominin-1 is detailed and microvilli of the cell are not well visible here. The 
micrograph shows that the two examined proteins are unlikely to share the 
localisation pattern. There is some yellow signal visible in the merged picture that 
could indicate co-localisation in the area of the cell membrane; however, in such 
poorly developed cell morphology it could also be random.  
The immunocytochemistry experiments presented in Chapter 4 suggested 
that EYS proteins mainly localise to the cytoplasm and it is known that Prominin-1 
has strong preference for the membrane microvilli. One could argue that based on 
this knowledge it could already be concluded that EYS and Prominin-1 do not 
co-localise together. However, the experiments performed in the Drosophila model 
demonstrated that spam decorates the surface of the cell membrane only in the 
presence of prominin, which might participate in recruiting spam to its final 
destination. A similar phenomenon could be occurring between the human 
orthologues and the co-expression of Prominin-1 and EYS together could amend 
the cytoplasmic localisation of EYS proteins.  
In order to better understand the subcellular localisation of EYS proteins 
and Prominin-1, an overexpression approach was undertaken. To begin with, V5 
tagged EYS isoform 1 and DsRed tagged Prominin-1 constructs were 
co-transfected into HeLa cells.  It needs to be explained here, that the V5-EYS 
isoform 1 construct was approximately 16 kb and transfection with such a large 
plasmid vector, let alone co-transfection with another construct, was 
extraordinarily challenging. The optimisation of this experiment involved testing 
several cell lines and numerous commercially available transfection reagents. Most 
of the tested reagents were liposome based; however, calcium phosphate based 
methods and electroporation were also attempted with no success.   
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Figure 5.3 Localisation of EYS and DsRed-Prominin-1 in a cluster of two Y79 cells. EYS 
(green) localised to the cell cytoplasm whereas DS-Red-Prominin-1 I concentrated in the 
cell membrane. Any co-localisation of the two proteins in indicated by yellow signal. The 
zoomed inserts represent the area demarcated by the white square in the images. Anti-
EYS1 primary and AlexaFluor 488 conjugated goat anti-rabbit secondary antibodies were 
used. Nuclei were stained with DAPI (blue). Scale bar: 10 μm. 
Characterisation of the Relationship between EYS and Prominin-1  
227 
 
The only reagent which yielded positive results was Effectene (Qiagen, The 
Netherlands); nevertheless, the efficiency of the co-transfection was very low with 
only a few positively co-transfected cells observed altogether. From the cell lines 
tested, HeLa cells were transfected with highest efficiency and, therefore, that 
particular cell line was used in the experiments. An example of a co-transfected 
HeLa cell is shown in Figure 5.4. As it can be seen, Prominin-1 localised to the cell 
membrane and cell membrane protrusions. EYS was not found to localise in the 
microvilli and the majority of the signal seemed to localise to the cytoplasm; 
however, there is some yellow signal present that could indicate co-localisation in 
the cell membrane. More detailed analysis of the co-localisation is difficult as the 
cells were compromised by the strict conditions of co-transfection which probably 
had an adverse effect on their structure.  
The large size of EYS isoform 1 construct hindered the progress of 
immunocytochemistry experiments aiming to investigate its relationship with 
Prominin-1. However, in light of the results described in Chapter 4, it is likely that 
EYS isoforms 2 and 3 could also interact with Prominin-1. To address this issue, 
GFP tagged EYS isoforms 2 and 3 were co-transfected with V5-tagged Prominin-1 
into HeLa cells. As shown in Figure 5.5 and Figure 5.6, EYS isoforms 2 and 3 share 
the localisation pattern and both of them localised to the cytoplasm whereas 
Prominin-1 was specifically detected in the cell membrane, especially in the cell 
membrane protrusions. There is very little yellow signal visible that could indicate 
co-localisation, nonetheless, the localisation pattern of EYS isoforms 2 and 3 is 
undoubtedly distinct from the pattern of Prominin-1. 
Figure 5.7 represents a control performed with a GFP empty vector, where 
it can be observed that GFP on its own has diffused localisation throughout the 
nucleus and cytoplasm, and is also observed in the microvilli of the cell. 
Immunocytochemistry experiments investigating the ectopic expression of 
EYS proteins and Prominin-1 demonstrated that the proteins of interest do not 
co-localise in mammalian cell lines. The cytoplasmic localisation of EYS isoforms 
does not appear to be modulated by the presence of overexpressed Prominin-1. 
This data show that the phenomenon of prominin recruiting spam to the cell 
membrane in a Drosophila cell line is not observed between the human proteins. 
The obtained results also imply that the examined proteins do not exist in 
proximity which means that they are unlikely to physically interact. 
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Figure 5.4 Localisation of V5 tagged EYS and DsRed tagged Prominin-1 in HeLa cells. V5-
EYS (green) was detected in the cell cytoplasm whereas DsRed-Prominin-1 localised to the 
cell membrane and cell membrane microvilli. Any potential co-localisation is indicated by 
the yellow/orange signal. The zoomed inserts represent the area demarcated by the white 
square in the images. Goat anti-V5 primary and Alexa Fluor 488 conjugated donkey anti-
goat secondary antibodies were used. Nuclei were stained with DAPI (blue). Scale 
bar: 10 μm.  
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Figure 5.5 Localisation of GFP tagged EYS isoform 2 and V5 tagged Prominin-1 in Hela 
cells. GFP-EYS isoform 2 localised predominantly to the cell cytoplasm whereas 
V5-Prominin-1 was concentrated in the cell membrane microvilli. Any potential 
co-localisation is indicated by the yellow/orange signal. The zoomed inserts represent the 
area demarcated by the white square in the images. Goat anti-V5 primary and Alexa Fluor 
594 conjugated donkey anti-goat secondary antibodies were used. Nuclei were stained 
with DAPI (blue). Scale bar: 10 μm.  
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Figure 5.6 Localisation of GFP tagged EYS isoform 3 and V5 tagged Prominin-1 in Hela 
cells. GFP-EYS isoform 3 localised predominantly to the cell cytoplasm whereas V5-
Prominin-1 was concentrated in the cell membrane microvilli. Any potential co-
localisation is indicated by the yellow/orange signal. The zoomed inserts represent the 
area demarcated by the white square in the images. Goat anti-V5 primary and Alexa Fluor 
594 conjugated donkey anti-goat secondary antibodies were used. Nuclei were stained 
with DAPI (blue). Scale bar: 10 μm.  
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Figure 5.7 Localisation of wild type GFP tag and V5 tagged Prominin-1 in Hela cells. Wild 
type GFP localised the cell cytoplasm and the nucleus whereas V5-Prominin-1 was 
concentrated in the cell membrane microvilli. Any potential co-localisation is indicated by 
the yellow/orange signal. The zoomed inserts represent the area demarcated by the white 
square in the images. Goat anti-V5 primary and Alexa Fluor 594 conjugated donkey 
anti-goat secondary antibodies were used. Nuclei were stained with DAPI (blue). Scale 
bar: 10 μm.  
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5.2 Ex Vivo Analysis of EYS and Prominin-1 Localisation 
Data collected from immunocytochemistry experiments demonstrated that 
human EYS and Prominin-1 do not share the subcellular localisation. In order to 
have a better understanding of where EYS and Prominin-1 reside in the retina, 
immunohistochemistry experiments were performed. 
The localisation of EYS in the monkey retina was described in Chapter 4 
where it was demonstrated that EYS is likely to be a protein associated with the 
photoreceptor ciliary axoneme. The localisation of Prominin-1 was widely studied 
and it has been shown that murine prominin-1 localises to the evaginations of the 
plasma membrane at the base of rod photoreceptor outer segments, where the 
nascent membranous disks are formed (Maw et al., 2000; Zacchigna et al., 2009). 
Similar results were obtained when studying the localisation of an orthologue of 
Prominin-1 in Xenopus laevis, where it was found that it localises to the basal disks 
of rod outer segments and the outer rims of open disk lamellae of cone outer 
segments (Han et al., 2012). 
This data taken together would suggest that EYS and Prominin-1 are not 
present in the same compartment of the photoreceptor cell; however, such a 
conclusion would be made based on results coming from different species and 
could therefore be misleading. To address the co-localisation of EYS and 
Prominin-1 in a specimen derived from one animal, immunohistochemistry 
experiments were conducted on retinal tissue sections from adult Macaca 
fascicularis.  
Figure 5.8 shows a piece of a retinal section co-labelled with anti-EYS2 and 
anti-Prominin-1 antibodies. Consistently with observations described in Chapter 4, 
EYS was detected as a whip-like signal present in the region of the connecting 
cilium and above, which most likely corresponds to the ciliary axoneme.  
The red signal coming from the anti-Prominin-1 antibody appeared to be 
detected in both types of photoreceptor cells and had a characteristic pattern in 
each of them. The white arrow indicates a rod cell, in which Prominin-1 was 
detected as red dots present at the base of the outer segments. This is consistent 
with the published data demonstrating that prominin localises to the membrane 
protrusions that are destined to become rod outer segment membranous disks in 
the mouse retina (Han et al., 2012; Maw et al., 2000).  
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Figure 5.8 Localisation of EYS and Prominin-1 in the macaque retina. The white arrow 
indicates a rod cell whereas the white arrow head indicates a cone cell. EYS (green) was 
detected in rods and cones as a whip-like signal in the region of a photoreceptor ciliary 
axoneme whereas Prominin-1 (red) was detected at the base of the rod outer segments 
and along the edge of the cone outer segments opposite to the signal of EYS. Co-
localisation of the two proteins was not observed. The zoomed images (Zoom) correspond 
to the areas demarcated by the white square in the images. Anti-EYS2 rabbit and anti-
Prominin-1 mouse primary antibodies and AlexaFluor488 conjugated goat anti-rabbit and 
Cyanine 3 conjugated goat anti-mouse secondary antibodies were used. DAPI was used to 
stain cell nuclei (blue). Scale bar: 20 µm. OS- outer segment, CC – connecting cilium, IS – 
inner segment, ONL – outer nuclear layer. 
  
Characterisation of the Relationship between EYS and Prominin-1  
234 
 
Yellow signal, indicative of co-localisation of the two proteins, was not detected; 
the red dots identified as Prominin-1 localise clearly just below the green fibril of 
EYS.  
An example of a cone cell illustrating the relationship of EYS and 
Prominin-1 is indicated by a white arrowhead. As it can be seen, the red signal 
corresponding to Prominin-1 is concentrated on one side of the indicated cell and 
such localisation pattern was described by others in a Xenopus laevis model; this 
suggests that the red signal indicates the tips the open disks lamellae (Han et al., 
2012). The green signal of EYS is located on the opposite side of the cone outer 
segment, which is consistent with the observations described in Chapter 4. Such 
arrangement would suggest that the green signal marks the structure residing 
opposite to the edges of cone open disks, which could be the ciliary axoneme.    
However, the aforementioned localisation pattern was not the only one 
observed. Figure 5.9 shows two more cone cells photographed at higher 
magnification. In both of the cells shown, the green fibril of EYS signal is 
surrounded from both sides by the red signal representing Prominin-1. Such 
arrangement of the two proteins could be an artefact resulted from sectioning of 
the retina; the outer segment is conical in shape and Prominin-1 is localised at the 
tip of the membranous disks whereas EYS is expected to reside in the area of the 
ciliary axoneme, therefore, cutting of the cell through the tip of the disk could 
result in a pattern observed in Figure 5.9. Another scenario could be that 
Prominin-1 localises not only to the cone outer segment but also to the calyceal 
processes that form a collar around the base of the outer segments of both rod and 
cone photoreceptors. This hypothesis would need to be verified experimentally, 
nevertheless, calyceal process have been shown to be present in macaque and 
human photoreceptor cells, where they house USH1 protein family implicated in 
Usher syndrome type 1 (USH1)(Sahly et al., 2012). Likewise in rod cells, EYS and 
Prominin-1 do not seem to share the localisation pattern in cones, which implies 
they do not exist in proximity in the monkey retina. 
Altogether, immunohistochemistry experiments lead to the conclusion that 
EYS and Prominin-1 do not co-localise in the monkey retina, which suggests that 
the two proteins do not directly interact. 
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Figure 5.9 Localisation of EYS and Prominin-1 in the macaque retina. The white arrows 
indicate the analysed cone cells. Prominin-1 (red) was detected along the edges of the 
cone outer segments whereas EYS (green) was detected in between as a whip-like signal 
in the region of a photoreceptor ciliary axoneme. The zoomed images (Zoom) correspond 
to the areas demarcated by the white square in the images. Anti-EYS2 rabbit and anti-
Prominin-1 mouse primary antibodies and AlexaFluor488 conjugated goat anti-rabbit and 
Cyanine 3 conjugated goat anti-mouse secondary antibodies were used. DAPI was used to 
stain cell nuclei (blue). Scale bar: 20 µm.  
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5.3 Co-immunoprecipitation of Prominin-1 and EYS Proteins 
To fully address the question of whether human orthologues of EYS and 
Prominin-1 are binding partners, co-immunoprecipitation (Co-IP) assays were 
performed. Immunofluorescence studies suggested that the two proteins do not 
co-localise in the tested cell lines and in the monkey retina; however, it could be 
that the interaction is dynamic and/or takes place only at certain stages of protein 
trafficking or the retina development.  
In the first instance, it was aimed to verify whether Prominin-1 is able to 
interact with EYS isoforms 1 and 4. As described previously, overexpression of EYS 
isoform 1 was extremely demanding and therefore, it was not possible to 
overexpress the two proteins for the purpose of Co-IP assays. To circumvent this 
issue, Co-IP assay was performed on a protein extract prepared from Y79 cells. For 
immunoprecipitation of the protein complex, anti-Prominin-1 antibody was used 
and the presence of EYS was tested by probing the membrane with anti-EYS1 
antibody. As shown in Figure 5.10, EYS was detected in the input lane at the 
expected size of approximately 350 kDa (blot A, red asterisk). Protein bands 
detected below that size in the same lane might have been a result of protein 
degradation or non-specific binding of the secondary antibody used. The lanes 
labelled as ‘α-Prom-1’ represent the eluted sample from the magnetic beads that 
had been incubated with anti-Prominin-1 antibody. The lack of a protein band at 
the size of EYS (~350 kDa) demonstrated the lack of interaction between EYS and 
Prominin-1. The lanes labelled as ‘-ve IP’ represent a negative control performed 
by incubation of protein extracts with magnetic beads without a primary antibody. 
This aimed to test whether protein G attached to the magnetic beads is able to non-
specifically bind to the proteins of interest. Blot ‘B’ represents the same 
arrangement of samples but it was probed with anti-Prominin-1 antibody. The 
band marked with a green asterisk in the ‘IP α-Prom-1’ lane corresponds to the 
size of Prominin-1 (~100 kDa) and demonstrates that the antibody used in the 
Co-IP experiments is binding its epitope specifically. It also shows that Prominin-1 
was present in the protein extract prepared from Y79 cells. The band, however, is 
smeared and there is another thin band visible slightly on top of it. This may be 
due to Prominin-1 being glycosylated, which makes proteins appear as smears  
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Figure 5.10 Co-immunoprecipitation assay demonstrating lack of interaction between 
EYS with Prominin-1 in wild type Y79 cells. Blot ‘A’ represents membrane probed with 
anti-EYS1 antibody. The absence of a protein band in the Co-IP lane confirms the lack of 
interaction. Immunoprecipitation (IP) was performed with mouse anti-Prominin-1 
antibody (α-Prom-1). IP performed without an antibody was used as a negative control 
(-ve IP). Input refers to an extract from wild type Y79 cells and the red asterisk marks the 
band of EYS isoforms 1 and 4. Blot ‘B’ is a control blot probed with anti-Prominin-1 
antibody and it demonstrates specificity of the assay; the green asterisk marks the band of 
Prominin-1 whereas the blue asterisks indicate the antibody heavy and light chains. 
Loading was normalised using a BCA assay and the samples were resolved by denaturing 
SDS-PAGE. Secondary antibodies were HRP conjugated goat anti-mouse and goat anti-
rabbit antibodies. Expected band sizes: EYS – 350 kDa, Prominin-1 - ~50 kDa. IB – 
immunoblotting, IP – immunoprecipitation. 
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rather than sharp bands in immunoblotting; the higher band may correspond to 
the more heavily glycosylated portion of the protein. Protein bands marked with 
blue asterisks correspond to the IP antibody heavy chains (~50 kDa) and light 
chains (~25 kDa). The presence of degraded IP antibody is a result of the elution 
procedure which is a part of the Co-IP assay protocol. In order to elute samples, 
magnetic beads are incubated at 70 ˚C in a reducing environment and during that 
time some of the antibodies bound to the beads may detach. Strikingly, Prominin-1 
was not detected in the ‘input’ lane which was disadvantageous since the ‘input’ 
lanes meant to serve as a positive control of the protein size. This suggests that 
Prominin-1 is not abundantly expressed in Y79 cells but there is enough protein to 
perform immunoprecipitation assays as it was pulled down by the antibody. 
Results obtained in Co-IP assays performed on protein extracts from wild type Y79 
cells suggest that EYS isoform 1 and 4 do not physically interact with Prominin-1. 
The next step was to test whether Prominin-1 is an interacting partner of 
EYS isoforms 2 and 3. In the case of these two isoforms, advantage was taken of 
their more convenient size and Co-IP assays were conducted using tagged proteins 
that were overexpressed in HeLa cells. The experiments were performed using 
GFP tagged EYS isoforms 2 and 3 and V5 tagged Prominin-1; protein extract from 
wild type HeLa cells was used as a negative control. Co-IP assays were carried 
using anti-V5 antibody to pull down protein complexes of overexpressed 
Prominin-1. Figure 5.11 presents results obtained from Co-IP testing the 
interaction of EYS isoform 2 and Prominin-1. Blot ‘A’ represents immunoblotting 
performed with anti-GFP antibody. The red asterisk in the ‘input’ lane marks the 
protein band corresponding to GFP tagged EYS isoform 2; bands of the same size 
were not detected in the IP lanes and the negative control.  Blot ‘B’ was a control 
blot containing the same samples but probed using the anti-V5 antibody. The green 
asterisk marks the band of the pulled down V5-Prominin-1 and blue asterisks 
correspond to the antibody heavy and light chains. The band corresponding to 
V5-Prominin-1 detected in the input lane is marked with a purple asterisk. Results 
of the Co-IP assay implied that V5-Prominin-1 does not physically interact with 
EYS isoform 2, which is indicated by the lack of a protein band at expected size in 
the ‘α-V5 IP’ lane. 
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Figure 5.11 Co-immunoprecipitation assay demonstrating lack of interaction between of 
GFP tagged EYS isoform 2 and V5 tagged Prominin-1 in co-transfected HeLa cells. Blot ‘A’ 
represents the membrane probed with anti-GFP antibody. Immunoprecipitation (IP) was 
performed with goat anti-V5 antibody. IP performed without an antibody was used as IP 
negative control (-ve IP). Input refers to an extract from co-transfected HeLa cells whereas 
the negative control (-ve control) was protein extract from transfected HeLa cells. The red 
asterisk marks the band of GFP-EYS isoforms 2 in the input lane. The absence of a protein 
band in the Co-IP lane confirms the lack of interaction. Blot ‘B’ is a control blot probed 
with anti-V5 antibody and it demonstrates specificity of the assay. The green asterisk 
marks the band of V5-Prominin-1 in the Co-IP lane, the purple asterisks marks the band of 
v5-Prominin-1 in the input and the blue asterisks indicate the antibody heavy and light 
chains. Loading was normalised using a BCA assay and the samples were resolved by 
denaturing SDS-PAGE. Secondary antibodies were HRP conjugated goat anti-mouse and 
rabbit anti-goat antibodies. The presence of each construct in the loaded sample is 
denoted by ‘+’ and the absence by ‘-‘. Expected band sizes: GFP-EYS isoform 2 – ~97 kDa, 
V5-Prominin-1 – ~ 100 kDa. IB – immunoblotting, IP – immunoprecipitation. 
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Co-IP assay were also performed to test whether EYS isoform 3 is able to 
interact with Prominin-1. Similarly to EYS isoform 2, HeLa cells were 
co-transfected with GFP tagged EYS isoform 3 and V5 tagged Prominin-1. Co-IP 
was performed with anti-V5 antibody and the membranes were probed with 
anti-GFP and anti-V5 antibodies. As shown in Figure 5.12, interaction between EYS 
isoform 3 and V5-Prominin was not detected, which can be concluded from the 
lack of band corresponding to EYS isoform 3 in the IP lane of blot A. The band of 
EYS isoform 3 is indicated by the red asterisk in the input lane. Blot B was a control 
blot, where it was shown that anti-V5 antibody binds to V5-Prominin-1; the green 
asterisk marks the band of V5-Prominin-1, the blue asterisks indicate the antibody 
heavy and light chains whereas the band of V5-Prominin-1 in the input lane is 
marked with a violet asterisk.  
Altogether, Co-IP assays performed in this study demonstrated that EYS 
proteins do not complex with Prominin-1, which means that they are unlikely to be 
interacting partners in humans. However, it could be that the interaction between 
Prominin-1 and EYS proteins is transient and, therefore, it could not have been 
detected using the methodology applied in the study.   
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Figure 5.12 Co-immunoprecipitation assay demonstrating lack of interaction between of 
GFP tagged EYS isoform 3 and V5 tagged Prominin-1 in co-transfected HeLa cells. Blot ‘A’ 
represents the membrane probed with anti-GFP antibody. Immunoprecipitation (IP) was 
performed with goat anti-V5 antibody. IP performed without an antibody was used as IP 
negative control (-ve IP). Input refers to an extract from co-transfected HeLa cells whereas 
the negative control (-ve control) was protein extract from transfected HeLa cells. The red 
asterisk marks the band of GFP-EYS isoforms 2 in the input lane. The absence of a protein 
band in the Co-IP lane confirms the lack of interaction. Blot ‘B’ is a control blot probed 
with anti-V5 antibody and it demonstrates specificity of the assay. The green asterisk 
marks the band of V5-Prominin-1 in the Co-IP lane, the purple asterisks marks the band of 
v5-Prominin-1 in the input and the blue asterisks indicate the antibody heavy and light 
chains. Loading was normalised using a BCA assay and the samples were resolved by 
denaturing SDS-PAGE. Secondary antibodies were HRP conjugated goat anti-mouse and 
rabbit anti-goat antibodies. The presence of each construct in the loaded sample is 
denoted by ‘+’ and the absence by ‘-‘. Expected band sizes: GFP-EYS isoform 3 – ~94 kDa, 
V5-Prominin-1 – ~ 100 kDa. IB – immunoblotting, IP – immunoprecipitation. 
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5.4 Discussion of Chapter 5 
Prominin-1 is a protein implicated in retinal degenerations and it has been 
suggested that it may be an interacting partner of EYS. The functional link between 
EYS and Prominin-1 was implied based on extensive research conducted on their 
Drosophila orthologues, spam and prominin. It has been shown that spam is a 
secreted protein expressed only in the eyes of insects with open rhabdom system, 
where it interacts with prominin to counteract the adhesive force of chaoptin. This 
mechanism is a necessary step in the partitioning of the rhabdomeres and creation 
of the IRS. Moreover, it has been demonstrated that the loss of spam converts the 
open rhabdom system to the closed system whereas its targeted expression in 
closed system markedly reorganises the architecture so that it resembles the open 
system (Husain et al., 2006; Zelhof et al., 2006). 
The analysis of Drosophila mutant models revealed that presence of human 
orthologues of spam and prominin is sufficient for the formation of the IRS. Based 
on this observation, authors of the study suggested that the functional interaction 
between the two proteins may be conserved in humans and causing retinal 
degeneration when disrupted (Nie et al., 2012).  
Given that the aim of the project was to investigate the interactome of EYS, 
Prominin-1 was tested as its potential interacting partner. The first approach was 
to look into the co-localisation of the two proteins in cell lines. EYS proteins and 
Prominin-1 are endogenously expressed in Y79 cells and therefore, this cell line 
was looked into in the first instance. The expression of Prominin-1 turned out to be 
relatively low, to the extent that microvilli, where it normally resides, could not be 
visualised. To resolve this issue, Y79 cells were transfected with DsRed-Prominin-1 
and labelled with anti-EYS1 antibody. The experiment demonstrated that 
Prominin-1 localises to the cell membrane microvilli present on the surface of Y79 
cells whereas EYS does not follow the same pattern of expression; the speckled 
signal was observed in the regions that could correspond to the cytoplasm and the 
cell membrane but not cell membrane protrusions. Some yellow signal could be 
seen at the cytoplasm-cell membrane interface; however, in such modestly 
developed cell structure, artefacts of immunofluorescence could be mistaken for 
genuine results. 
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To better understand the subcellular localisation of the two proteins, an 
overexpression approach in adherent cells was undertaken. In the first instance, it 
was attempted to co-transfect HeLa cells with full length EYS isoform 1 and 
Prominin-1. As it was mentioned previously, transfection with EYS isoform 1 alone 
is technically challenging and the co-transfection was expected to be even more 
demanding. Time-consuming and labour intensive optimisation of transfection 
procedures were conducted, which eventually resulted in obtaining positively 
co-transfected cells. The efficiency, however, was very low and observations of 
immuno-localisation of EYS isoform 1 and Prominin-1 could only be made in a few 
cells. Based on that, it was concluded that EYS isoform 1 and Prominin-1 most 
likely do not share the same pattern of localisation; however, these observation 
cannot be considered certain due to the low number of representative cells. 
The analysis of co-localisation was also performed for EYS isoforms 2 and 3. 
The localisation pattern for both of the isoforms was the same, with Prominin-1 
residing in the microvilli and EYS fragments being diffused throughout the 
cytoplasm. No yellow signal was observed at the membrane or at the contact zone 
of the cell membrane and the cytoplasm, indicating that there is no co-localisation 
in that subcellular compartment.  
The analysis of subcellular co-localisation of proteins is a useful approach to 
investigate whether the two proteins of interest interact, assuming that the 
proximity of the two proteins implies interaction. With that borne in mind, it 
would be reasonable to conclude that Prominin-1 is not an interacting partner of 
any of the isoforms of EYS. However, the interaction investigated here could be 
transient and taking place only at some stages of the cell cycle. One certain 
conclusion that can be made is that none of the EYS isoforms localises to the cell 
membrane protrusions. It means that the phenomenon of prominin recruiting 
spam to the surface of the cell membrane of the Drosophila cell line does not occur 
between their human orthologues. 
For full verification of the potential co-localisation of EYS and Prominin-1, 
immunohistochemistry experiments were performed on monkey retinal sections. 
From experimental work presented in Chapter 4, it was known that EYS may be 
associated with the ciliary axoneme whereas Prominin-1 was demonstrated to 
localise to the base of the rod outer segments and outer rims of the cone open 
disks lamellae in the murine and Xenopus laevis models (Han et al., 2012; Maw et 
Characterisation of the Relationship between EYS and Prominin-1  
244 
 
al., 2000). In this study, immunohistochemistry experiments were carried out in 
the adult monkey retinal sections. As expected, EYS was detected in the region 
corresponding to the ciliary axoneme in rods and cones whereas the signal 
generated by the anti-Prominin-1 antibody differed between the two types of 
photoreceptors. In the rod cells, Prominin-1 appeared as speckles localised below 
the green signal of EYS, which implies that it is localised at the apical region of the 
rods inner segments. In cones, the red signal was detected either on one side of the 
cone opposite to the signal of EYS or on both sides of the cell with EYS localising in 
the middle. In any of the cases, EYS did not appear to co-localise with Prominin-1 
which re-enforces the outcomes of the immunocytochemistry experiments. 
Notably, these results were obtained in the macaque tissue and to fully validate the 
interaction of EYS and Prominin-1 in humans, it would be necessary to experiment 
on human retinal specimens, which were not available in this project.  
Immunofluorescence experiments indicated that EYS and Prominin-1 do 
not co-localise together in cell lines and retinal sections. This, however, does not 
exclude the possibility that the two proteins are capable of binding each other and 
interact in development or at some stages of trafficking pathways.  
To investigate this issue further, Co-IP assays were performed. The 
interaction between Prominin- 1 and EYS isoforms 1 and 4 was examined in the 
protein extract prepared from Y79 cells. This strategy was undertaken due to the 
difficulties with introducing EYS isoform 1 constructs into the cells via 
transfection. Since both of the proteins of interest are endogenously expressed in 
Y79 cells, they were considered to be suitable material for conducting Co-IP assays.  
The obtained results demonstrated that EYS isoform 1 and 4 do not interact 
with Prominin-1. Issues were encountered when trying to detect the presence of 
Prominin-1 in the input control lane containing Y79 lysate, nevertheless, the 
protein was pulled down by the anti-Prominin-1 antibody attached to the magnetic 
beads, proving that Prominin-1 was present in the extract. This meant that the 
expression of Prominin-1 in Y79 cells is not abundant but sufficient for conducting 
Co-IP assays. Examination of the potential interaction between Prominin-1 and 
EYS isoforms 2 and 3 was carried out using tagged proteins that were 
overexpressed in HeLa cells. These experiments demonstrated that neither EYS 
isoform 2 nor 3 interact with Prominin-1.  
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Co-IP assay yielded results consistent with the observations made in 
immunofluorescence experiments and implied that the human orthologues of EYS 
and Prominin-1 are not interacting partners. An alternative scenario could be that 
EYS proteins interact with Prominin-1 transiently and such interaction could not 
have been detected using Co-IP assay that is biased towards stable protein-protein 
interactions.  
Functional interaction between the Drosophila orthologues of EYS and 
Prominin-1 was shown to be essential for the homeostasis of the Drosophila 
photoreceptors. The interaction was suggested to be conserved in humans, making 
Prominin-1 an interesting candidate for a binding partner of EYS. This was 
addressed in the study presented herein by performing a range of experiments 
including immunocytochemistry, immunohistochemistry and 
co-immunoprecipitation assays. The outcomes of the experiments confirmed that 
none of the isoforms of EYS co-localise or physically bind Prominin-1. This implies 
that the two proteins of interest are not strong interacting partners; however, the 
interaction could still be happening transiently and be a part of a dynamic process 
taking place during retinal development or protein trafficking. This aspect could be 
looked into more deeply using advanced methods such as live cell imaging. 
Furthermore, even if EYS and Prominin-1 do not interact directly, they could still 
be members of the same multi-protein complex and there could still be a functional 
link between them. Multi-protein complexes in which EYS and Prominin-1 are 
potentially involved in could be analysed using mass spectrometry which would 
reveal proteins that could act as intermediate binding partners of EYS and 
Prominin-1. Additionally, the problem could be addressed by analysis of animal 
mutant models checking whether EYS localises properly in PROM1 mutants and 
the other way around. This would be a challenging task, mostly because of the 
absence of EYS in the rodent retina, however, disease modelling using induced 
pluripotent stem cells could be an alternative.  
In spite of the fact the mechanisms taking place in the Drosophila model do 
not seem to be conserved in humans, the research devoted to investigation of EYS 
and Prominin-1 addressed a very important and previously unexplored area of 
EYS biology, leading to the exclusion of Prominin-1 from the group of potential 
binding partners of EYS in humans. 
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Chapter 6: Mutation Screening of PROM1 Gene in a Cohort of arRP 
Patients 
Prominin-1 was proposed to be an interacting partner of EYS, the protein of 
interest in this study. Both Prominin-1 and EYS are vital for the homeostasis of the 
human retina and mutations in PROM1 and EYS genes lead to retinal degeneration. 
At the commencement of the project, there had been nearly one hundred disease 
causing mutations reported in EYS and only eight mutations had been reported in 
PROM1. Mutations in PROM1 have been shown to cause severe retinal 
degenerations and the phenotype is heterogeneous. The majority of individuals 
carrying PROM1 mutations suffer from autosomal recessive RP; however, 
recessively inherited cone-rod dystrophy and macular degeneration have also 
been reported. Moreover, one mutation, p.R373C, has been reported to cause 
autosomal dominant macular degeneration and it has been shown to disrupt 
morphogenesis of photoreceptor membranous disks in a mouse model (see 
Introduction, section 1.5). 
In the era of next generation sequencing and whole exome sequencing, the 
number of identified mutations in genes commonly compromised in retinal 
dystrophies keeps increasing; there are now more than 150 mutations reported in 
EYS and 19 mutations identified in PROM1 thus far (Appendix A). There is a great 
discrepancy between the numbers of mutations reported in each of the genes of 
interest and, therefore, PROM1 was screened for novel mutations in this study. 
6.1 Mutation screening of PROM1 gene 
The panel subjected to screening in this project involved 96 unrelated 
patients of Caucasian origin, diagnosed with arRP with unidentified causative 
mutation(s). Sequencing primers were anchored in the intronic sequences to 
ensure that the splice sites and full exonic sequences are covered. The reference 
sequence of PROM1 was derived from Ensembl database; transcript ID 
ENST00000510224. Analysis of sequence electropherograms revealed seven 
previously unannotated heterozygous variations present in six unrelated patients 
(Figure 6.1). Four of the newly identified variants potentially affect the coding 
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sequence, three of which map to the extracellular domains and one to the 
transmembrane domain (Figure 6.2). Two of the variations were found in UTR 
sequences and one at the acceptor splice site. None of the variations was observed 
in 192 samples of the Human Random Control DNA Panels 1 and 2 (HRC-1 and 
HRC-2 Caucasian control panels). The obtained results are summarised in Table 
6.1.  
Substitutions c.181A>G and c.1604A>G alter the amino acid composition of 
the protein. Potential pathogenicity of substitutions was assessed using software 
available online (Polyphen-2 and SIFT), although, it needs to be noted that 
bioinformatics predictions are based on mathematical algorithms and 
pathogenicity of any mutation needs to be verified by functional experiments. The 
c.181A>G change is predicted to be non-pathogenic and c.1604A>G is probably 
damaging according to Polyphen-2, however, both are tolerated according to SIFT, 
which exemplifies the need for wet-bench experiments to verify potential effects of 
the mutations.  
Deletion c.(620-622)delA causes a frame shift starting at codon 208 and 
ending at codon 231 where a stop codon is gained after the addition of 22 novel 
amino acids. A similar effect is caused by the insertion c.(1348-1352)insT which 
results in a frame shift beginning at codon 452 and gaining a stop codon 12 amino 
acids further downstream. A premature stop codon can result in the transcript 
being directed to nonsense mediated decay (NMD), which is an mRNA quality 
control process preventing production of C-terminally truncated proteins. This 
could lead to a decrease in the natural expression level of the protein (reviewed in 
Schweingruber et al., 2013). If the transcript is able to escape NMD, a truncated 
protein would be synthesised, which could interfere with protein folding and/or 
affect its function. 
Interestingly, the patient carrying the deletion c.(620-622)delA was found 
to have another mutation in the 5’ UTR, c.-307G>A, that could have an impact on 
the regulation of expression of PROM1.  It is possible that these mutations have a 
combined effect on the patient leading to a disease phenotype and form a 
compound heterozygote; however, it may also be that they reside in the same allele 
and in this case another variation would have to be identified to explain the 
recessive inheritance. 
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Figure 6.1 Sequence chromatograms showing newly identified variations in PROM1 in 
individuals diagnosed with arRP. All of the changes were found in a heterozygous state. 
Sequence variants were annotated following recommendations of Human Genome 
Variation Society (HGVS). Red arrows indicate the amended nucleotide or, in case of the 
insertions and deletion, the first amended nucleotide. WT – ‘wild type’ refers to a 
reference sequence derived from Ensembl database.  
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Figure 6.2 Schematic view of Prominin-1 domain structure with the view of distribution 
of variations identified in the coding sequence of PROM1. UTR and splice site variations 
are not included in this depiction. 
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Table 6.1 Summary of variations identified in PROM1 in this study. A cohort of arRP 
patients was screened for novel mutations resulting in identification of seven novel 
variants in six unrelated patients. All variants were found in a heterozygous state. 
Polyphen2 and SIFT software was used to assess pathogenicity of substitutions affecting 
the coding sequence. NMD refers to nonsense mediated decay of mRNA. 
  
Patient 
number
Position
Nucleotide 
Change
Amino Acid 
Change
State Polyphen2 Sift Possible effect
1
Exon1 
(5'UTR)
c.-307G>A N/A
hetero-
zygous
N/A N/A
change might have 
an impact on 
regulation of gene 
expression
1 Exon 6
c.(620-
622)delA
p.T208Lfs*23
hetero-
zygous
N/A N/A
transcript may 
undergo NMD or 
truncated protein 
may be produced
2 Exon 2 c.181A>G p.I61V
hetero-
zygous
benign
tolerated 
(0.5)
possible protein 
function 
impairment
3
Intron 6-
7
c.630-2A>G N/A
hetero-
zygous
N/A N/A
splice acceptor site 
may be affected - 
impaired splicing
4 Exon 13
c.(1348-
1352)insT
p.Y452Lfs*13
hetero-
zygous
N/A N/A
transcript may 
undergo NMD or a 
truncated protein 
may be produced - 
mutation was 
previously 
published in 
homozygous state 
(Pras et al., 2009)
5 Exon 15 c.1604A>G p.N535S
hetero-
zygous
probably 
damaging
tolerated 
(0.47)
possible protein 
function 
impairment
6
Exon 28 
(3'UTR)
c.*189A>G N/A
hetero-
zygous
N/A N/A
change might have 
an impact on 
regulation of gene 
expression
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The insertion c.(1348-1352)insT was previously reported in 
a consanguineous Arab family (Pras et al., 2009). In the published study, three 
siblings diagnosed with cone-rod dystrophy were found to be homozygous carriers 
of c.(1348-1352)insT and the parents were unaffected heterozygous carriers (Pras 
et al., 2009). Variation c.*189A>G was found in the 3’ UTR and it could affect 
regulatory processes of gene expression. The c.630-2A>G substitution found at the 
splice acceptor site, which could interrupt the normal splicing of the exons, e.g. an 
exon could be removed or an intron retained, leading to production of a shorter or 
structurally altered protein.  
All of the variations identified in this screen were heterozygous and the 
panel tested comprised of individuals with recessively inherited retinitis 
pigmentosa. The mode of inheritance was confirmed in the clinics; however, the 
DNA samples derived from family members were unavailable to confirm it by 
direct sequencing. In light of this, it is highly unlikely that the identified mutations 
are pathogenic; however, the examined individuals may carry other unidentified 
mutations present in PROM1, which could form a compound heterozygote together 
with the change identified in this study. These could include copy number 
variations and insertions/deletions of exon(s) and such variations could not have 
been detected via direct sequencing used in this project. Further research would 
be required to find a causative genetic variation for the individuals involved in the 
study. 
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6.2 Discussion of Chapter 6 
Understanding the genetic cause of retinal degenerations is the first step 
towards understanding the disease and development of potential therapies. One of 
the genes implicated in retinal dystrophies is PROM1, which has been found to be 
mutated in individuals suffering from arRP, macular degeneration and cone-rod 
dystrophy. Of note, there could be a functional link between Prominin-1 and EYS 
proteins, investigation of which was described in Chapter 5.  
In this study, a cohort of 96 individuals diagnosed with recessively 
inherited RP was screened for novel mutations in the PROM1 gene. The screening 
resulted in identification of seven previously unidentified changes in six unrelated 
individuals. Among the identified variations there were five substitutions, one 
deletion and one insertion. Substitutions identified in the protein coding sequence 
(c.181A>G and c.1604A>G) were predicted to be most likely tolerated by the 
bioinformatics software available online. Together with the two other 
substitutions found in the UTR regions (c.-307G>A and c.*189A>G), these could be 
rare polymorphisms which can have no effect on the health of the carriers.  
However, substitutions found in the coding sequence could affect protein folding 
whereas changes in the UTR regions could have a negative impact on the 
regulation of gene expression. The substitution affecting a splice acceptor site 
(c.630-2A>G) may have more serious implications on protein synthesis as it could 
result in an intron being retained or exon being skipped, which could affect protein 
folding and function. The identified deletion and insertion (c.(620-622)delA and 
c.(1348-1352)insT) result in a frameshift leading to introduction of a premature 
stop codon, which may induce NMD or result in the production of a truncated 
protein. Notably, the individual carrying deletion c.(620-622)delA was also found 
to have a change in the 5’ UTR, c.-307G>A, and these variants could act together in 
the disease pathogenesis. More research would be required to verify the effect of 
the two changes on the biosynthesis of Prominin-1 in vivo. 
All of the changes identified in the coding sequence of PROM1 could affect 
protein folding. This may lead to accumulation of misfolded or unfolded proteins in 
the endoplasmic reticulum (ER), which in turn could cause a cellular condition 
known as ER stress resulting in cell death by apoptosis (reviewed in Athanasiou 
et al., 2013).  
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Furthermore, all of the variations found in this study are heterozygous and 
the individuals examined inherited the disease in a recessive manner. Therefore, it 
cannot be concluded that the identified variations are pathogenic. However, it is 
likely that the identified changes are loss-of-function mutations and a second allele 
would have to be mutated to cause the disease; the second undetected genetic 
variation in PROM1 would form a compound heterozygote together with the 
identified change. The second unidentified change could be a copy number 
variation (CNV), e.g. deletion or insertion of a whole exon, and such a change could 
not have been identified using direct sequencing method applied in this study. This 
could be resolved by performing comparative genomic hybridisation (CGH) or 
employing Next Generation Sequencing (NGS). Once a second variation is found, 
functional studies of each variation will be required to fully delineate the effect 
each of them can have on the protein first, and eventually on the homeostasis of 
photoreceptors. Another possible scenario is that heterozygous mutations in 
PROM1 are only pathogenic when inherited together with a variation in another 
gene, causing a digenic form of RP. The digenic mode of inheritance is not common 
in photoreceptor degeneration, although there is one report showing that RP can 
be caused by co-inherited heterozygous mutations in genes encoding Peripherin-2 
and Rom-1 (Kajiwara et al., 1994). Extra attention should be drawn to the patient 1 
who carries deletion c.(620-622)delA and substitution c.-307G>A in the 5’ UTR. 
The deletion has a truncating effect on the transcript, which undoubtedly affects 
conformation of the protein or induces NMD. The substitution c.-307G>A could be 
a non-pathogenic polymorphism but it as well could affect regulatory processes of 
gene expression. This could be addressed experimentally and if it has an adverse 
effect on gene expression the two changes could be considered a compound 
heterozygote, given that it can be shown that they reside in two separate alleles.  
Interestingly, PROM1 is a gene expressed in many tissues including the 
retina, pancreas, placenta, kidney, liver, lung, brain and heart (Yu et al., 2002); yet, 
mutations in PROM1 have only been linked to retinal degeneration and no other 
obvious pathological signs have been reported. This issue was addressed by 
Fargeas and colleagues who identified a paralog of PROM1 gene, PROM2. The 
amino acid identity between Prominin-1 and Prominin-2 has been shown to be less 
than 30 %; nevertheless, both of the proteins exhibit characteristic structure and 
strong preference to plasma membrane protrusions. PROM2, however, has been 
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discovered not to be expressed in the eye and this phenomenon was suggested to 
explain the ocular specific phenotype of PROM1 mutants; the presence of 
Prominin-2 could compensate for the absence of Prominin-1 (Fargeas et al., 2003).   
Altogether, seven previously unidentified genetic variations were found in 
the examined cohort of individuals. Since the changes were heterozygous, they 
cannot be considered as potentially causative of retinal dystrophies. Further 
research would be required to verify whether the individuals carry more changes 
in PROM1 or other parts of their genomes. 
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Chapter 7: Discussion and Future Perspectives 
Retinitis pigmentosa (RP) is a group of retinal degenerative diseases 
characterised by significant clinical and genetic heterogeneity, with an incidence of 
approximately 1 in 4000 for a total of more than one million individuals affected 
worldwide (Hartong et al., 2006). Loss of vision has a devastating effect on quality 
of life and imposes serious socio-economic burden for patients and their families 
(Köberlein et al., 2013). Yet, an effective approach to treat photoreceptor 
degeneration, including RP, has not been developed; the current treatment options 
are limited to slowing down the progress of the condition. To date, mutations in 84 
genes have been  identified to be causative of RP by affecting functions such as 
phototransduction, biosynthesis of proteins or lipid metabolism (RetNet database; 
https://sph.uth.edu/retnet/home.htm)(Wright et al., 2010). In the era of 
high-throughput sequencing of individual human genomes, the number of 
identified disease causing genetic variants is only set to rise. This is invaluable for 
diagnostic purposes; however, the long term goal towards the development of 
therapy of blinding diseases can only be achieved via identification of physiological 
functions of retinopathy associated proteins.  
EYS gene was identified at the RP25 locus on chromosome 6q12, a major 
locus for autosomal recessive RP. Spanning over 2 Mb, EYS is one of the largest 
genes expressed in the retina (Abd El-Aziz et al., 2008; Collin et al., 2008). 
Immunofluorescence experiments demonstrated that EYS localises to the 
photoreceptor outer segments in the porcine retina where it co-localised with 
rhodopsin (Abd El-Aziz et al., 2008). Interestingly, in the course of mammalian 
evolution, EYS has been lost from several lineages including the armadillo, little 
brown bat and ruminant lineages. Importantly, EYS is not expressed in three 
rodents: mouse, rat and guinea pig (Abd El-Aziz et al., 2008) commonly used for 
research purposes in the laboratory. However, it is well conserved in Drosophila 
melanogaster and research conducted in this model revealed that the Drosophila 
orthologue of EYS (eys) is involved in the modelling of the photoreceptor 
architecture, and that it is a member of a network of interactions necessary for the 
proper formation of inter-rhabdomeral space (IRS) in the ommatidium. 
Furthermore, it has been demonstrated that the formation of IRS depends on the 
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interaction of eys with another well-conserved protein, prominin, and disruption 
of this interaction causes disorganisation of the rhabdom. It has also been 
suggested that this interaction may be conserved in humans and be essential for 
photoreceptor homeostasis (Nie et al., 2012; Zelhof et al., 2006).  Studying of eys in 
the Drosophila model also resulted in identification of the role of eys in 
preservation of the cell shape of the mechanoreceptor neurons  by stiffening of the 
cell membrane (Cook et al., 2008). 
Since the discovery of EYS, more than 150 mutations have been identified in 
individuals suffering from autosomal recessive form of RP, making it the major 
gene implicated in this disease. In spite of the vast knowledge of EYS related 
disease phenotype, the role of EYS protein in the human retina has remained a 
mystery. The project presented herein aimed to delineate the role of EYS in the 
human photoreceptors, which is a key point towards undertsanding the 
mechanisms of RP. Once the role of EYS in pathophysiology of RP is known, it will 
be possible to investigate whether it can be targeted by gene therapy, drug 
development or other therapeutical approaches.  
7.1 Identification and Characterisation of Interacting Partners of EYS 
 The approach undertaken to investigate the role of EYS in the retina was to 
study its interactome. Identification of interacting partners of a protein of interest 
allows to hypothesise its potential function and opens avenues for further 
functional research (reviewed in De Las Rivas & Fontanillo, 2010).  
The method chosen to identify novel protein-protein interactions (PPIs) in 
this project was Yeast 2-hybrid (Y2H). Y2H is a genetic screen for the detection of 
PPIs and the system used in this study was based on the GAL4 transcription 
activator. Y2H screening was performed using EYS protein bait fragments and a 
human retinal cDNA library that was previously prepared in the laboratory. Many 
technical issues had to be dealt with when utilising the system and the difficulties 
were most likely caused by the large size of EYS and/or its conformation. Extensive 
screening of the retinal cDNA library resulted in identification of one potential 
interacting partner, AIPL1. The interaction was detected using an N-terminal 
fragment of EYS (154-1635 aa) and the prey fragment of AIPL1 mapped to its 
C-terminal part (281-384 aa). The putative interaction was validated via 
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immunocytochemistry (ICC) and co-immunoprecipitation (Co-IP) experiments. 
Validation was performed using the same EYS isoform 1 N-terminal bait fragment 
(154-1635 aa) and EYS isoforms 2 and 3, which were cloned and characterised at a 
later stage of the project. EYS isoform 1 (the canonical/full-length protein) could 
not have been used in the validating experiments due its size, which caused major 
difficulties with achieving successful overexpression of the tagged protein. Y79 
cells, which endogenously express EYS and AIPL1, were not a reliable system for 
immuno-localisation studies due their poorly developed morphology and they 
could not have been used as a source of protein for Co-IP due to unavailability of 
compatible anti-EYS and anti-AIPL1 antibodies; both antibodies available were 
raised in rabbit. Nonetheless, AIPL1 was demonstrated to co-localise and 
immunoprecipitate together with EYS isoform 2 and 3 as well as EYS N-terminal 
bait fragment (bait 3). These results implied that AIPL1 is a novel binding partner 
of EYS isoforms 2 and 3 and may also be able to interact with EYS isoform 1.  
AIPL1 is also implicated in retinal degeneration: mutations in AIPL1 cause 
severe early-onset retinal degeneration known as Leber’s congenital amaurosis 
(LCA) (Sohocki et al., 2000). The role of AIPL1 in photoreceptor cells has not been 
fully understood; however, there is evidence to suggest that it may function as a 
photoreceptor specific molecular chaperone (Hidalgo-de-Quintana et al., 2008). 
Furthermore, it has been demonstrated that AIPL1 interacts with and aids in 
processing of prenylated proteins (Ramamurthy et al., 2003). One such protein is 
rod cGMP phosphodiesterase (PDE6) which is a critical enzyme in 
phototransduction; the biosynthesis of a PDE6 heterotetramer requires 
prenylation of its catalytic subunits and its proper assembly is reliant upon the 
interaction with AIPL1 (Kolandaivelu et al., 2009). While PDE6 is a protein 
localising to the photoreceptor outer segment, AIPL1 was demonstrated to reside 
in the region spanning from the connecting cilium to the synapse (van der Spuy 
et al., 2002). In this study, it has been shown that EYS is likely to associate to the 
photoreceptor ciliary axoneme, which makes EYS another example of a protein 
localising to the photoreceptor outer segment and interacting with AIPL1. Even 
though EYS is unlikely to be prenylated, it is possible that it is a substrate protein 
of AIPL1 and requires its chaperoning activity to properly fold and/or localise to 
its final destination. Interestingly, in the most recent study, AIPL1 has been 
demonstrated to co-localise at the photoreceptor connecting cilium with EB 
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proteins, a microtubule binding family of proteins important in the microtubule 
dynamics, suggesting that the heterocomplex AIPL1-Hsp90 may function at this 
subcellular compartment (Hidalgo-de-Quintana et al., 2015).  
Both EYS and AIPL1 have been shown to be implicated in retinal 
degenerations and, therefore, it is possible that the two proteins are components 
of photoreceptor specific pathways that are essential for the homeostasis of the 
retina, e.g. AIPL1 could assist with the biosynthesis of EYS and the trafficking to the 
outer segment. The interaction of EYS proteins and AIPL1 has not been 
investigated by immunohistochemistry and it will be important to carry out such 
analysis in the future. It would be of best value to perform immunohistochemistry 
on human specimens which could also be used as a source of protein for Co-IP. 
These experiments, however, would require obtaining custom made anti-EYS or 
anti-AIPL1 antibodies raised in an animal other than rabbit; commercially 
available antibodies have not met the needs of the project due to the questionable 
specificity.  
The identification of AIPL1 as a novel interacting protein partner of EYS did 
not provide any insights into the specific function that might EYS plays in the 
photoreceptor outer segments. This triggered the design of further experiments 
aiming to better characterise EYS, which could help understand what specific role 
it plays in the retina once it has been fully assembled and trafficked to its final 
destination. 
Another approach to study the interactome of the protein of interest can be 
investigation of candidate binding partners selected based on the published 
literature. One such candidate for an interacting partner of EYS was Prominin-1. 
Prominin-1 is a pentaspan transmembrane protein known to have a strong 
preference for plasma membrane protrusions and is implicated in retinal 
degeneration (Maw et al., 2000; Weigmann et al., 1997). Extensive research 
conducted in a Drosophila model suggested that the functional link between the 
orthologues of EYS and Prominin-1 could be conserved in humans and is vital for 
the homeostasis of photoreceptor cells (Nie et al., 2012; Zelhof et al., 2006). One of 
the aims of this study was to verify whether this was the case. The methodology 
included immunofluorescence used to compare the localisation patterns of the two 
proteins and Co-IP to verify whether the two proteins associate with each other. 
ICC and IHC experiments demonstrated that EYS proteins do not co-localise with 
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Prominin-1 and furthermore, Co-IP assays demonstrated that these two proteins 
do not complex together.  
These results have suggested that the interaction of EYS and Prominin-1 is 
most likely not conserved in humans; however, it could be that the interaction is 
transient and/or takes place at certain stages of development. This could be a valid 
point since the studies of Drosophila models revealed that both eys and prominin 
are expressed at the beginning of rhabdomere formation during the puparium 
stage of the Drosophila development (Zelhof et al., 2006). It is also possible that the 
functional link between EYS and Prominin-1 exists in fully developed 
photoreceptors and there are unidentified intermediate interacting partners 
involved. These aspects remain to be addressed in future research.   
As Prominin-1 was considered a potential interacting partner of EYS and 
the number of disease causing mutations is much lower in PROM1 than in EYS, 
mutation screening of PROM1 in a panel of arRP patients was carried out. The 
screening resulted in identification of seven previously unidentified heterozygous 
changes in six unrelated patients. Since the patients examined were confirmed to 
inherit the disease in a recessive manner, none of the newly found variations can 
be considered pathogenic. It could be that the changes are benign or that there are 
other unidentified variations present in PROM1 or another gene. In light of this, the 
genetic background of arRP diagnosed in the panel of patients involved requires 
further research, preferably by using high throughput methods such as next 
generation sequencing.  
Altogether, identification of novel interacting partners of EYS led to the 
conclusion that EYS proteins can interact with AIPL1, which may assist with the 
biosynthesis of EYS in photoreceptor cells. Furthermore, the potential interaction 
of EYS and Prominin-1 was examined and evidence was provided against the 
hypothesis that the two proteins interact in adult primates.   
Overall, the analysis of EYS interacting partners provided useful insights 
into its biology; nonetheless, drawing conclusions regarding its possible role in the 
retina has not been possible and further research would be required to investigate 
the interactome of EYS more deeply. 
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7.2 Characterisation of EYS  
Elucidating the role of EYS protein in the human retina is vital for 
understanding mechanisms underlying RP. Experimental efforts to further 
characterise EYS were necessitated by multiple technical difficulties encountered 
in Y2H and the resulting low efficiency of the screening. The in-depth analysis of 
EYS genetic structure as well as subcellular localisation aimed to bring us closer to 
understanding its function in the retina and ease the design of future studies.  
The analysis of genomic online databases followed by RT-PCR analysis 
resulted in identification of EYS isoforms 2 and 3 which were confirmed to be 
expressed in the human retina and testis as well as the Y79 cell line. Altogether, 
there are currently four recognised EYS isoforms: EYS isoform 1 and 4 comprising 
of 3144 aa and 3165 aa respectively, and two shorter splicing variants, EYS 
isoforms 2 and 3 made up of 619 aa and 594 aa respectively. The testicular 
expression of EYS isoforms 2 and 3 is yet to be investigated; however, testes 
related phenotype has not thus far been reported in males carrying mutations in 
EYS.  
The subcellular localisation of EYS isoforms was investigated by performing 
ICC studies. Overexpressed GFP tagged EYS isoforms 2 and 3 were found to localise 
mostly to the cytoplasm and occasionally to the cell nucleus. The nuclear 
expression could be an artefact of transfection and over-expression of the proteins, 
or it could indicate a potential signalling or transporting type of role for the short 
EYS isoforms, where they shuttle in between the cytoplasm and nucleus in 
response to cellular changes. This would be an interesting aspect to address, 
especially with respect to the interaction with AIPL1, which has previously been 
shown to modulate the nuclear translocation of NUB1, a protein involved in 
NEDD8 mediated proteasomal degradation (van der Spuy & Cheetham, 2004). 
Therefore, it could be that AIPL1 is involved in the translocation of EYS isoforms 2 
and 3 between the nucleus and the cytoplasm, as these were shown to associate. 
The analysis of EYS isoforms 1 and 4 was challenging due their size and was 
limited to investigation of endogenous localisation patterns in Y79 cells. This 
resulted in the conclusion that EYS isoforms 1 and 4 probably localise to the cell 
cytoplasm and possibly to the cell membrane. The analysis of overexpressed GFP 
tagged EYS protein fragments suggested their cytoplasmic localisation. 
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Immunohistochemistry experiments were performed in the Macaca 
fascicularis retinal sections and showed that EYS may be associated with the 
photoreceptor ciliary axoneme, which is a microtubular structure that plays a role 
in the structural integrity of photoreceptor outer segments and intraflagellar 
transport (IFT). It could, therefore, be that EYS plays a role in maintaining the 
structure of the photoreceptor outer segments by, for example, being a component 
of the ciliary scaffold. This would be in line with the study published by Cook et al., 
where it was demonstrated that EYS stiffens the cell membrane of the Drosophila 
cell line (Cook et al., 2008). Another hypothesis can be that EYS is a member of the 
IFT machinery, which is of central importance for both assembly and maintenance 
of the cilium. Photoreceptor outer segments do not house the protein synthesis 
machinery; therefore, the proteins residing in that compartment need to be 
transported from the inner segment via connecting cilium by means of IFT 
(Taschner et al., 2012). It could be that EYS is a component of multi-protein motor 
assemblies, which take part in the very dynamic process of IFT.  
The experimental work undertaken to characterise EYS provided further 
insights into the subcellular localisation of EYS and its genetic structure. This was 
an important aspect of the project which provided invaluable information on EYS; 
nonetheless, many questions have remained unanswered. The role of EYS in the 
human photoreceptors needs to be more deeply investigated to fully understand 
its importance. More advanced methods such as electron microscopy would have 
to be employed to research the localisation of EYS in more detail. Furthermore, 
characterisation and cloning of EYS isoforms 2 and 3 greatly contributed to the 
analysis of the potential interactions with AIPL1 and Prominin-1; however, the 
specific role of the short variants of EYS has not yet been addressed. The isoforms 
of EYS may be multifunctional proteins localising to more than one subcellular 
compartment. This makes EYS a very challenging protein to investigate and a 
significant amount of carefully designed research would be required to fully 
decipher its function in the human body. 
7.3 Future Perspectives 
The project presented herein involved broad analysis of the biological 
features of EYS and a few approaches were undertaken: (i) new interacting 
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partners of EYS were sought for using Y2H, (ii) putative interacting partners 
identified by Y2H (AIPL1) and by a candidate gene approach (Prominin-1) were 
characterised by immunofluorescence and Co-IP assays, (iii) subcellular 
localisation of EYS was better characterised and (iv) mutation screening of PROM1 
in a cohort of arRP patients was conducted. Each stage of the study yielded exciting 
results and each of them can be elaborated on in the future research projects. 
The network of interactions that EYS is involved in has not been fully 
investigated. Multiple technical issues were encountered which hindered the 
efficient Y2H screening and in the future, an alternative approach could be 
undertaken to investigate the interactome of EYS. From the number of available 
methods, Y2H is one of the most convenient and cost effective methods of high-
throughput searching for novel interactions. However, from the project presented 
herein, it can be concluded that the GAL4 based Y2H is not the most suitable 
system to study EYS; this is most likely due to its size and/or localisation in yeast 
cells that prevent the bait-prey complex to travel to the nucleus.  As an alternative, 
a modification of Y2H could be used but this will only be possible if the exact 
localisation of EYS is known, e.g. membrane split-ubiquitin Y2H (MbY2H) system 
could be used for the detection of interactions between membrane bound proteins 
(Brückner et al., 2009). An alternative approach could be to employ affinity 
purification in tandem with mass spectrometry (AP-MS). The advantage of the 
method is that it allows identification of PPIs under native conditions, i.e. using 
mammalian cells, the multicomponent complexes are pulled down allowing 
investigation of the network of interaction more comprehensively by mass 
spectrometry (Ngounou Wetie et al., 2014). The method, however, requires 
transfection and expression of the tagged protein of interest in the cell line. This 
imposes serious limitations since transfection with tagged EYS isoform 1 was 
challenging using standard laboratory protocols. Transfection using commercially 
available reagents as well as electroporation did not bring satisfactory results; 
however, the solution could be to work on tagged EYS protein fragments. 
Alternatively, it could be attempted to find a method of efficient introduction of 
such large plasmids into the cell lines of interest, for example, by employing viral 
vectors that are capable of carrying large DNA constructs (Waehler et al., 2007). 
The bottleneck in this approach can be the transfection of viral constructs carrying 
a gene of interest into the packaging cell line, which could be hindered by the size 
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of EYS.  This issue could be addressed by using the recently developed dual AVV 
vectors which are capable of efficient transduction of large genes in smaller 
fragments that are then reconstituted into full sized genes (Trapani et al., 2014). 
Construction of viral vectors for EYS would not only contribute to the AP-MS 
approach but would also enable more detailed characterisation of the localisation 
pattern of overexpressed EYS isoform 1 and could be a starting point for working 
on gene therapy approach to treat arRP. 
Furthermore, since AP-MS makes it possible to look into to the protein 
complexes, it could also be used to verify whether EYS complexes with Prominin-1. 
This would address part of the question of whether there is a functional link 
between the two proteins; whether the two associate in development remains to 
be investigated once a suitable and viable option for an animal model becomes 
available for investigating endogenous expression of EYS.  
Prominin-1 has been considered as a potential interacting partner of EYS 
based on previously published literature and there is rationale for some other 
proteins to be potential interacting partners of EYS. In this study, co-localisation of 
EYS and acetylated α-tubulin has been shown. This interaction could be examined 
using immunohistochemistry to see if they also co-localise in human tissue and 
Co-IP to verify whether the two proteins physically bind. Furthermore, EYS was 
shown to co-localise with RP1 in the monkey retina (unpublished data from our 
laboratory) and the same experimental approach could be used to test this 
interaction. Interestingly, mutations in RP1 have been shown to cause RP and the 
protein it encodes is specifically biosynthesised in the retina where it is a part of 
the ciliary axoneme (Liu et al., 2002; Pierce et al., 1999). It has also been shown 
that RP1 is a microtubule-associated protein that may be essential for the correct 
stacking of outer segment discs (Liu et al., 2003; Liu et al., 2004a). Co-localisation 
of EYS and RP1 could suggest that EYS, similarly to RP1, plays a role in structural 
organisation of the outer segment and proper stacking of membranous disks; Co-IP 
assays could be performed to verify whether the two proteins physically bind. This 
would enhance the hypothesis that EYS is a ciliary axoneme associated protein and 
it may have a structural function. 
One of the achievements of the project is the cloning and characterisation of 
EYS isoforms 2 and 3. They have been demonstrated to localise to the cytoplasm 
and, therefore, they could be used as baits in the GAL4 based Y2H system with 
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more success. Performing the Y2H screening using EYS isoforms 2 and 3 could be a 
major step in investigation of their role in the human retina and potentially other 
tissues such as testis. Looking into their interacting partners would provide 
insights into their potential function and the same interacting partners could be 
tested for EYS isoform 1 and 4. The technical issues encountered in this project 
could be avoided as EYS isoforms 2 and 3 constitute merely ~20 % of the longest 
isoform and their size should not affect the performance of Y2H. Furthermore, 
antibodies could be raised against EYS isoform 2 and 3 and they could be used for 
immunohistochemistry studies, which would provide information on their 
localisation in vivo. 
Moreover, the Y2H data obtained in this project have been validated using 
ICC and Co-IP. Further validation could be undertaken using ICH performed on 
human specimens. This would be the most illustrative model; however, the co-
localisation of EYS and AIPL1 could not be assessed unless new antibodies against 
any of the two proteins are available. It would also be interesting to examine 
whether any of the published disease causing mutations in either EYS or AIPL1 
impair the interaction between the two proteins.  
The subcellular localisation of EYS was investigated in the monkey retina 
and it appeared that EYS may be a ciliary axoneme associated protein. Further 
analysis would be necessary to validate whether this localisation is the same in the 
human retina, most preferably using electron microscopy.  
Studying EYS proteins is challenging mostly due to the size of EYS isoform 1. 
The second feature of EYS that adds difficulty is its absence in rodents, which 
excludes the most common animal models, i.e. mouse and rat, from the in vivo 
research of EYS. Instead, larger animals such as rabbits or dogs would have to be 
used to study EYS in vivo, which makes the research of EYS more challenging 
experimentally and ethically. Future perspectives for addressing these issues have 
arisen from the stem cell research, especially the development of the patient 
derived induced pluripotent stem cells (iPSC). Patient derived iPSC cells can be 
used for a variety of applications ranging from elucidating the mechanisms of 
disease causing mutations to drug screening and testing of gene therapy (reviewed 
in Jayakody et al., 2015; Yvon et al., 2015). Modelling of retinal degeneration has 
been successfully demonstrated using tissue material derived from RP patients 
with distinct mutations in RP1, RP9, PRPH2 and RHO genes. The obtained rod 
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photoreceptors were used for characterisation of the course of degeneration and 
for drug testing (Jin et al., 2011). A similar approach could be undertaken to study 
EYS and to begin with, its localisation could be looked into in wild type and 
mutated models. Stem cell based models are a promising tool for studying proteins 
like EYS and in that respect, the absence of EYS in mouse models of retinal diseases 
can be turned into an advantage. Rodent models of retinal degeneration could 
serve as null environment for stem cell based approaches, e.g. patient derived 
iPSCs could be differentiated into photoreceptors precursors and transplanted into 
mouse models; the comparison of photoreceptors derived from RP patients with 
the healthy controls would provide insights into the mechanisms underlying EYS 
specific arRP. Furthermore, the patient derived iPSCs could be subjected to 
CRISPR-based genome editing to correct the disease causing mutation and the 
obtained photoreceptor precursors could be transplanted into murine models to 
examine whether they can develop into properly functioning photoreceptors; such 
an approach could be turned into a therapeutic strategy for RP (reviewed in 
Tucker et al., 2014). Testing human derived stem cells in murine models has been 
successfully conducted, making the suggested approach feasible (Lamba et al., 
2009). 
More opportunities for further research come from the mutation screening 
performed in the project. This could be elaborated on further and the patients’ 
DNA samples should preferentially be submitted for the whole exome sequencing, 
enabling identification of the underlying cause of arRP. The effect of mutations on 
the homeostasis of the photoreceptor cells could subsequently be addressed 
experimentally. 
The research project presented herein aimed to elucidate the role of EYS in 
the human retina by identification and characterisation of its interacting partners. 
Indeed, it has brought us closer to understanding its function and determining why 
mutations in EYS cause arRP. Moreover, the results of the project have opened new 
avenues for long term and exciting future research opportunities. Since mutations 
in EYS are the major cause of arRP, it will be of paramount importance to 
undertake the challenge of researching EYS further in order for the individuals 
suffering from arRP and their families to receive benefit from the biomedical 
research. 
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Chapter 8: Appendices 
Appendix A. Mutations Identified in PROM1 to Date 
 Mutations in PROM1 have been shown to be causative of retinal 
degeneration. The causative variants reported to date are summarised in Table 8.1. 
 
 
Nucleotide 
change 
Amino acid change 
Inherit- 
ance 
Disease Reference 
1 c.1841delG p.G614Efs*13 R 
Retinal 
degeneration 
and 
polydactyly 
(Maw et al., 
2000) 
2 c.1726C>T p.Q576* R 
arRP 
accompanied 
by macular 
degeneration 
(Zhang et al., 
2007) 
3 c.1117C>T p.R373C D 
Autosomal 
dominant 
macular 
degeneration 
(Yang et al., 
2008) 
4 c.1349insT p.Y452fs*13 R 
Cone rod 
dystrophy 
(Pras et al., 
2009) 
5 c.869delG  p.S290Ifs*2 R arRP  
(Permanyer et 
al., 2010) 
6 c.1142–1G>A N/A R 
Cone rod 
dystrophy 
(Littink et al., 
2010) 
7 c.1557C>A pY519* R arRP 
(Song et al., 
2011) 
8 c.1532C>A p.T520K R arRP 
(Gonzalez-del 
Pozo et al., 
2011) 
9 c.442A>T p.K148* R arRP 
(Jinda et al., 
2014) 
10 
c.642T>A 
 c.1209_1229 
p.Y214* 
pQ403_S410delinsH 
R,  
comp. 
het  
arRP 
(Eisenberger et 
al., 2013) 
11 
c.2011A>T 
c.510-1G>A 
p.K671* 
p.? 
R,  
comp. 
het 
Simplex RP 
(Wang et al., 
2014) 
12 
c.730C>T 
c.1354_1355ins
T 
p.R244* 
p.Y452fs* 
R,  
comp. 
het 
Simplex RP 
(Wang et al., 
2014) 
13 
c.139delC 
c.1238T>A 
p.H47Ifs*12 
p.V413D 
R,  
comp. 
het 
arRP (Xu et al., 2014) 
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14 c.1157T>A p.L386* ? 
Cone rod 
dystrophy 
(Glöckle et al., 
2014) 
15 c.1530>CG p.Y510* R arRP 
(Abu-Safieh et 
al., 2013) 
16 c.1984-1G>T N/A R arRP 
(de Castro-Miró 
et al., 2014)  
17 c.2373+5G>T N/A R arRP 
(Chen et al., 
2013) 
18 
c.1355_1356ins
T 
c.622delA 
p.Y453Lfs 
p.T208Lfs 
R,  
comp. 
het) 
arRP 
(Zhao et al., 
2015) 
19 
c.1983+1G>T 
c.730c>7 
p.R228* 
R,  
comp. 
het) 
cone rod 
dystrophy 
(Zhang et al., 
2014) 
Table 8.1 Summary of mutations reported in PROM1 to date.  Variants were annotated in 
accordance with recommendations of Human Genome Variation Society (HGVS). R - 
recessive inheritance, D – dominant inheritance, R comp. het. – recessive inheritance, 
compound heterozygote, ? – inheritance unspecified.  
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Appendix B. Oligonucleotides for Sequencing EYS cDNA 
In this study, the cloning of genes of interest was performed on several 
different occasions and each time inserts were sequenced to check the integrity of 
the sequence and to verify the reading frame. Primers used for sequencing of EYS, 
PROM1 and AIPL1 are summarised in Table 8.2, Table 8.3 and Table 8.4 
respectively. 
 
Table 8.2 Summary of primers used for sequencing EYS cDNA. 
  
Primer Sequence (5' ->3')
Forward 1  ATGACTGACAAATCAATCGTCA
Reverse 1 CCCAAAAACCAGCAATCTCTG
Forward 2 GACAGTGAAACAGCAGTTCTG
Reverse 2 CACATTCACAAATGAAAC
Forward 3 GTGAGTTTTCATTAGTACCATGTCA
Forward 4 TTCTTTCTGGCTGCAAACTG
Forward 5  CAAGTGTGTCCCAGGATTTA
Reverse 5 CTTCCCAATCAGATAGGCAC
Forward 6 TATGTCTGTGCCCACCCCTT
Forward 7 TGTGAAATAAATCTAGATGA
Forward 7A GGATCTGTGTTGATGGGC
Reverse 7 GATATTCATTAATAAGTTCTGTGC
Forward 8 ATCACCATGTCTACATGGTG
Forward 8a  TTCTTTGTGGTGATGAAATA
Forward 9 CAGCAAAACACAGTCTTCTT
Forward 10 ATATCTAAACAGGTAACCAT 
Forward 11 CATTGTCCCTTCACAAACTA
Reverse 11 ATGCAACATTGGTGGTGAC
Forward 12 CTTCAGAATGGTCCAAATGG
Forward 12a CTTACTTTGTCTTCACTGGAA
Forward 13 CATGTACTCGGAAAACCCCT
Reverse 13 GTGGCATACATCCTGCTGGC
Forward 14 GGAACATAACAGAACTGTTA
Forward 15 GCCACGTCCCTTGGTGTGCT
Forward 16 AGGAGCGAGCCCCTCAATCT
Forward 16a CTGCATTTCATTACCTCATG
Forward 17 CTGCATTTCATTACCTCATG
Forward 18 CCATGGCAATAGAAAATGAA
Forward 19 GCTCAAAATGAAGAAAATGA
Forward 20 ACTATCATTCTAGAAACTCT
Forward 21 TTCTTACAGTTGCCTGTGTA
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Table 8.3 Primers used for sequencing PROM1 cDNA. 
 
 
 
Table 8.4 Primers used for sequencing AIPL1 cDNA. 
  
Primer Sequence (5'->3')
Forward 1 ATGGCCCTCGTACTCGGC
Reverse 1 GCAGGCAATTCATAATTCCAA
Reverse 2 CATAATCAATTTTGGATTCATAT
Forward 2 TGGAGAAATGCACCAGCGACAG
Forward 3 ATCAAATATATATTGGCCCAG
Forward 4 ATCCATCAAGTGAAACCTGC
Forward 5 CTTGAATTCCATTGGTTCAG
Forward 6 ATGCCACCCCGACCACCCG
Forward 7 GCATACTGGAAGCATAAG
Forward 8 ACAGGGAATGGATTGTTGGAG
Forward 9 CTGTGTAGCTACATTATCGAC
Primer Sequence (5' ->3')
Forward 1 ATGGATGCCGCTCTGCTCCTGAACG
Reverse 1 GGAGCTCGCCCGTGCCCCCGTGC
Forward 2 GAGTGGCACGTGCACACGTGC
Reverse 2 GTAATCACTCGGGGCATCAACCTGC
Forward 3 GCTGAAGAAGGAGGAGTACTATG
Forward 4 GCCACCCGCACAGTCATCCACAGAG
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Appendix C. Oligonucleotides for Gateway Cloning 
 For gateway cloning of proteins of interest, primers containing attB 
sequences had be designed.  The att flanked PCR products were cloned into 
pDONR/Zeo entry vectors then, into destination vectors of interest. The primer 
designed for cloning using Gateway system are summarised in Table 8.5, Table 8.6 
and Table 8.7. 
 
Primer Sequence (5' ->3') 
AIPL1-attB1-F - Forward 
GGGGACAAGTTTGTACAAAAAAGCAGGCTTC 
ATGGATGCCGCTCTGCTCCTGAACG 
AIPL1-attB2-R - Reverse, with stop codon 
GGGGACCACTTTGTACAAGAAAGCTGGGTG 
TCAGTGCTGCAGCGAGTGCCCTG 
AIPL1-attB2-R - Reverse, without stop codon 
GGGGACCACTTTGTACAAGAAAGCTGGGTG 
GTGCTGCAGCGAGTGCCCTG 
Table 8.5 Gateway compatible primers for cloning of AIPL1 into the pDONR/Zeo entry 
vector. Att sequences are highlighted in green and stop codon is in red. 
 
 
Primer Sequence (5'->3') 
PROM1-attb1-F - Forward 
GGGGACAAGTTTGTACAAAAAAGCAGGCTTC 
ATGGCCCTCGTACTCGGCTCCCTG 
PROM1-attb2-R - Reverse, with stop codon 
GGGGACCACTTTGTACAAGAAAGCTGGGTG 
TCAATGTTGTGATGGGCTTGTC 
PROM1-attb2-R - Reverse, without stop codon 
GGGGACCACTTTGTACAAGAAAGCTGGGTG 
ATGTTGTGATGGGCTTGTC 
Table 8.6 Gateway compatible primers for cloning of PROM1 into the pDONR/Zeo entry 
vector. Att sequences are highlighted in green and stop codon is in red. 
 
Primer Sequence (5' ->3') 
NUB1-attB1-F - Forward 
GGGGACAAGTTTGTACAAAAAAGCAGGCTTC 
ATGGCACAAAAGAAATATCTTCAAG 
NUB1-attB2-R - Reverse, with stop codon 
GGGGACCACTTTGTACAAGAAAGCTGGGTGTTA 
GTTTTTCTTTGTTGCTGACTTC 
NUB1-attB2-R - Reverse, without stop codon 
GGGGACCACTTTGTACAAGAAAGCTGGGTG 
GTTTTTCTTTGTTGCTGACTTC 
Table 8.7 Gateway compatible primers for cloning of NUB1 into the pDONR/Zeo entry 
vector. Att sequences are highlighted in green and stop codon is in red. 
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Appendix D. Oligonucleotides for Cloning EYS isoforms 2 and 3 
 In the study, GFP and 3XFLAG tagged EYS isoforms 2 and 3, and EYS 
N-terminal (1-1635 aa) fragment were used. Primers used for cloning each of the 
proteins into the pEGFP-C3 vector are summarised in Table 8.8 whereas Table 8.9 
shows primers used for cloning into the p3XFLAG-Myc-CMV vector.  
 
 
Table 8.8 Summary of primers used for cloning of EYS isoforms 2 and 3 and N-terminal 
(1-1635 aa) fragment into pEGFP-C3 vector. 
 
 
Table 8.9 Summary of primers used for cloning of EYS isoforms 2 and 3 and N-terminal 
(1-1635 aa) fragment into p3XFLAG-Myc-CMV vector. 
  
Primer
Restriction 
site
Sequence (5'->3')
EYS isoform 2 Forward XhoI CCCTCGAGATGACTGACAAATCAATCGTC
EYS isoform 2 Reverse KpnI GGGGTACCTATTCTTACGATAAATCCCACC
EYS isoform 3 Forward XhoI CCCTCGAGATGACTGACAAATCAATCGTC
EYS isoform 3 Reverse KpnI GGGGTACCAATGATACATAAATACCTGGG
EYS N-terminal (1-1635 aa) Forward XhoI CCCTCGAGATGACTGACAAATCAATCGTC
EYS N-terminal (1-1635 aa) Reverse KpnI GGGGTACCACTCTTTTTAGAAGGAAATAAAG
Primer
Restriction 
site
Sequence (5'->3')
EYS isoform 2 Forward EcoRI GGAATTCAATGACTGACAAATCAATCGTC
EYS isoform 2 Reverse KpnI GGGGTACCTATTCTTACGATAAATCCCACC
EYS isoform 3 Forward EcoRI GGAATTCAATGACTGACAAATCAATCGTC
EYS isoform 3 Reverse KpnI GGGGTACCAATGATACATAAATACCTGGG
EYS N-terminal (1-1635 aa) Forward BglIII CAGATCTGATGACTGACAAATCAATCGTC
EYS N-terminal (1-1635 aa) Reverse KpnI GGGGTACCACTCTTTTTAGAAGGAAATAAAG
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Appendix E. Oligonucleotides Used for RT-PCR Analysis 
 RT-PCR analysis was performed to examine the expression levels of EYS 
isoforms 2 and 3 in a panel of human tissue derived cDNA samples as well as cell 
lines. It was also used to check the expression of PROM1 gene in Y79 cells by 
amplification of its fragment. Expression of HPRT gene was used as a quality 
control of cDNA samples. The primer pairs are summaries in Table 8.10. 
 
Primer Sequence (5'->3') 
EYS isoform 2 Forward CCCGAAAATGACTGACAAATC 
EYS isoform 2 Reverse GCCACTAAATCAAACTTATATTC 
    
EYS isoform 3 Forward CCCGAAAATGACTGACAAATC 
EYS isoform 3 Reverse CTGCTCAAATGATACATAAATACC 
    
PROM1 Forward ACAGGGAATGGATTGTTGGAG 
PROM1 Reverse GTTCATTCTTAAAGCACTACCCAGA 
    
HPRT Froward GGGACATAAAAGTAATTGGTG 
HPRT Reverse GCGACCTTGACCATCTTTGG 
Table 8.10 Primer pairs used in the RT-PCR analysis throughout the study. 
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Appendix F. Oligonucleotides Specific for Vectors 
 Vector specific primers were used to verify the integrity of cloned inserts 
or, in case of pGADT7-Rec vector, to identify the insert Table 8.11. In case of 
pBD-GAL4-DEST vector, primers anchored in the insert were used to verify the 
frame and the integrity of cloned insert; hence they are not listed here.  
 
Vector Primer Sequence (5'->3') 
pDONR/Zeo 
M13 Forward GTAAACGACGGCCAG 
M13 Reverse CAGGAAACAGCTATGAC 
      
pGADT7-Rec   
MATCHMAKER 5' AD LD-Insert 
Screening Amplimer   
CTATTCGATGATGAAGATACCCCACCAAACCC 
MATCHMAKER 3' AD LD-Insert 
Screening Amplimer  
GTGAACTTGCGGGGTTTTTCAGTATCTACGATT 
 T7 Sequencing Primer            TAATACGACTCACTATAGGGC  
 3' AD Sequencing Primer   AGATGGTGCACGATGCACAG 
      
pAD-GAL4-
DEST 
pAD-GAL4-DEST Reverse AAACCACTGTCACCTGGTTGG 
pAD-GAL4-DEST Forward GTGCACGATGCACAGTTGAAGT 
Table 8.11 Summary of vector specific primers used in the study. 
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Appendix G. Sequences of Preys Identified in Y2H Screen 4 
 From all of the screens performed in the study, only Y2H screen 4 resulted 
in identification of preys carrying fragments of gene coding sequences. The outputs 
of sequencing are summarised in Table 8.12. 
 
Colony 
number 
Identified 
protein 
Sequence 
1 
Homo sapiens 
nuclear factor 
I/A (NFIA) 
CAMGAAAGGTWSWCTTCKATACAKACTSACTATCMSSGCRAGYK
CCRCCATGGAGTACCCATACGACGTACCAGATTACGCTCATATGG
CCATGGAGGCCAGTGAATTCCACCCAAGCAGTGGTATCAACGCAG
AGTGGCCATTATGGCCGGGGGGAGCAGCCAAGGCAAGGTGCAC
AACCCATTCCTTCCCACCCCAATGTTGCCACCGCCACCGCCACCAC
CGATGGCCAGGCCTGTGCCTCTGCCGGTGCCAGACACAAAGCCTC
CAACCACGTCAACAGAAGGAGGTGCAGCCTCCCCCACGTCACCAA
CCTACTCGACACCCAGCACCTCCCCCGCAAACCGATTCGTCAGTGT
TGGACCACGGGATCCAAGCTTTGTAAATATCCCTCAACAGACACA
GTCCTGGTACCTGGGATAAAAGTTGCAGCGTCCCACCATCCACCA
GACAAACCACCTGACCCCTTCTCAACTCTGTAACATGGACGCAACC
TCAACCCAGCGCAGTTACAACTTCACTATCAGCGGAAGGGGAGAA
AAACCGATTCAAATCAACTTGTACATGGAAACAGCAAGCATTATG
GTCAAACAGCAAGGCCATAACCTTTTGGGATTTTTTTTTTTTTAAA
AWAYTTTAGGRACKGTKGWAWTTTCTCAWAKGGKGCTGRAAAK
GGTTGGSCTTTGWAACATTTGAAGTGTTTCCAKGGWAGCGTGAG
MATWAGGTRACGTGGCTAGCGRAGRACWACCCTTGCTCACTGA
YTTCCTGTTGWAACACACTTTTCYTTACGRAGCCTGGCTGTTTCAM
AGTATTTTCATGAATTTTACCCACACAGGTGTGATCCTCCTTTGAG
CATTGAGGAGGCACATGCARAACTAAATCTTTTGTAGTAGCTGAR
ATCTGCAAWATATAACGGGACAGTCAAAGGCAATGTTTTTTCTGT
AAMAWATTGAAAAAAAAAAATGCAGTTAWATCCTTTTTTATTTG
TCATTAAGTTTGTTTTGGTCAGCAGTCAGCAGTTAAGTWATATAA
AMATGGACCCGCAAGAMAATGAAATCCACTCAMATGGCARAAC
CATTCGAAAATGCAAACTACTACTACTAACGCTCAGTCTTTAAAGT
TGAATGCTGCMACTTAAMATA 
2 
Homo sapiens 
small EDRK-rich 
factor 2 (SERF2) 
AAATAAAAGGAGWCTTTATACGACTCACTATAGGGCGAGCGCCG
CCATGGAGTACCCATACGACGTACCAGATTACGCTCATATGGCCA
TGGAGGCCAGTGAATTCCACCCAAGCAGTGGTATCAACGCAGAG
TGGCCATTATGGCCGGGGAAGGAGGAACCCAAGTGGCTTTGTGG
CTTCGTGTCCAACCCTCATGCCCTTCGCCTGTGTGCCTGGAGCCAG
TCCCACCACGCTCGCGTTTCCTCCTGTAGTGCTCACAGGTCCCAGC
ACCGATGGCATTCCCTTTGCCCTGAGTCTGCAGCGGGTCCCTTTTG
TGCTTCCTTCCCCTCAGGTAGCCTCTCTCCCCCTGGGCCACTCCCG
GGGGTGAGGGGGTTACCCCTTCCCAGTGTTTTTTATTCCTGTGGG
GCTCACCCCAAAGTATTAAAAGTAGCTTTGTAATACAAAAAAAAA
AAAAAAAAAAAAAAAAAAMMYYYYSSSCCCKCCCSSKCYYWWRR
GWGGGGGKWWYMWWWSSGRWWYWCWWMRKYYYMRRYYY
MMAAWWAAWYCMAAAWMMMRSAAAMMCCCCSYKTTYWM
MCA 
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4 
Homo sapiens 
eukaryotic 
translation 
initiation factor 
3, subunit L 
(EIF3L) 
AAAGSAAGGRGWCTTTAATACGACTCACTATAGGGCGAGCGCCR
CCATGGAGTACCCATACGACGTACCAGATTACGCTCATATGGCCA
TGGAGGCCAGTGAATTCCACCCAAGCAGTGGTATCAACGCAGAG
TGGCCATTATGGCCGGTGAGCAGATGCATGCGCTGCTGGCCATTG
CCCTCACGATGTACCCCATGCGTATCGATGAGAGCATTCACCTCCA
GCTGCGGGAGAAATATGGGGACAAGATGTTGCGCATGCAGAAAG
GTGACCCACAAGTCTATGAAGAACTTTTCAGTTACTCCTGCCCCAA
GTTCCTGTCGCCTGTAGTGCCCAACTATGATAATGTGCACCCCAAC
TACCACAAAGAGCCCTTCCTGCAGCAGCTGAAGGTGTTTTCTGAT
GAAGTACAGCAGCAGGCCCAGCTTTCAACCATCCGCAGCTTCCTG
AAGCTCTACACCACCATGCCTGTGGCCAAGCTGGCTGGCTTCCTG
GACCTCACAGAGCAGGAGTTCCGGATCCAGCTTCTTGTCTTCAAA
CACAAGATGAAGAACCTCGTGTGGACCAGCGGTATCTCAGCCCTG
GATGGTGAATTTCAGTCAGCCTCAGAGGTTGACTTCTACATTGAT
AAGGACATGATCCACATCGCGGACACCAAGGTCGCCAGGCGTTAT
GGGGATTTCTTCATCCGTCAGATCCACAAATTTGAGGAGCTTAATC
GAACCCTGAAGAAGATGGGACAGAGACCTTGATGATATTCACAC
ACATTCAGGAACCTGTTTTGATGTATTATAGGCAGGAAGTGTTTTT
GCTACCGTGAAACCTTTACCTAGATCAGCCATCAGCCTGTCAACTC
AGTTAACAAGTTAACGACCGAAGTGTTTCAAGTGGATCTCAGTAA
GGATCTTGGAGCCTACTMACAAACAAARAAAAGAGACYTGTKCG
GCGCTGGCTTTAAGGKGGCMTCGATCGGATCATCGAGYCARCTG
CTAATGATCGTAAATWCGAAACGTSAGTTCAC 
5 
Homo sapiens 
eukaryotic 
translation 
initiation factor 
3, subunit L 
(EIF3L) 
GSGTAAAAGAGWCTTTATACGACTCACTATAGGGCGAGCGCCRC
CATGGAGTACCCATACGACGTACCAGATTACGCTCATATGGCCAT
GGAGGCCAGTGAATTCCACCCAAGCAGTGGTATCAACGCAGAGT
GGCCATTATGGCCGGTGAGCAGATGCATGCGCTGCTGGCCATTGC
CCTCACGATGTACCCCATGCGTATCGATGAGAGCATTCACCTCCA
GCTGCGGGAGAAATATGGGGACAAGATGTTGCGCATGCAGAAAG
GTGACCCACAAGTCTATGAAGAACTTTTCAGTTACTCCTGCCCCAA
GTTCCTGTCGCCTGTAGTGCCCAACTATGATAATGTGCACCCCAAC
TACCACAAAGAGCCCTTCCTGCAGCAGCTGAAGGTGTTTTCTGAT
GAAGTACAGCAGCAGGCCCAGCTTTCAACCATCCGCAGCTTCCTG
AAGCTCTACACCACCATGCCTGTGGCCAAGCTGGCTGGCTTCCTG
GACCTCACAGAGCAGGAGTTCCGGATCCAGCTTCTTGTCTTCAAA
CACAAGATGAAGAACCTCGTGTGGACCAGCGGTATCTCAGCCCTG
GATGGTGAATTTCAGTCAGCCTCAGAGGTTGACTTCTACATTGAT
AAGGACATGATCCACATCGCGGACACCAAGGTCGCCAGGCGTTAT
GGGGATTTCTTCATCCGTCAGATCCACAAATTTGAGGAGCTTAATC
GAACCCTGAAGAAGATGGGACAGAGACCTTGATGATATTCACAC
ACATTCAGGAACCTGTTTTGATGTATTATAGGCAGGAAGTGTTTTT
GCTACCGTGAAACCTTTACCTAGATCAGCCATCAGCCTGTCAACTC
AGTTAACAAGTTAAGGACCGAAGTGTTTCAAGTGGATCTCAGTAA
AGGATCTTTGGAGCCTACAAACAAAAAGAAAAACYKKGKCGGSGC
TGGCTTWRAGRGGGKTGGCWYCGATWCGGGATYCCTCYCGRRYT
CRRAGYTGCAAAWGAATCSKAAAATCCGGAATCGCCCSCKTCTAT
TTTWTYYC 
Appendices 
276 
 
9 
Homo sapiens 
nuclear factor 
I/A (NFIA) 
AMAMAAGTWRWCTTCTGATACAKACTSACTATCMSSAGCRAGYK
CACGCCATGGAGTACCCATACGACGTACCAGATTACGCTCATATG
GCCATGGAGGCCAGTGAATTCCACCCAAGCAGTGGTATCAACGCA
RAGTGGCCATTATGGCCGGGGGGAGCAGCCAAGGCAAGGTGCA
CAACCCATTCCTTCCCACCCCAATGTTGCCACCGCCACCGCCACCA
CCGATGGCCAGGCCTGTGCCTCTGCCGGTGCCAGACACAAAGCCT
CCAACCACGTCAACAGAAGGAGGTGCAGCCTCCCCCACGTCACCA
ACCTACTCGACACCCAGCACCTCCCCCGCAAACCGATTCGTCAGTG
TTGGACCACGGGATCCAAGCTTTGTAAATATCCCTCAACAGACAC
AGTCCTGGTACCTGGGATAAAAGTTGCAGCGTCCCACCATCCACC
AGACAAACCACCTGACCCCTTCTCAACTCTGTAACATGGACGCAAC
CTCAACCCAGCGCAGTTACAACTTCACTATCAGCGGAAGGGGAGA
AAAACCGATTCAAATCAACTTGTACATGGAAACAGCAAGCATTAT
GGTCAAACAGCAAAGGCCATAACCTTTTGGGATTTTTTTTTTTTWA
AAATAYTTWAGGRACKGTKGWAWTTYCYCATAKGGKGCKGRAAA
KGGTKGGSCTTKGWAACATTTGAAGKGTTYCCAKGGTASCGKGAG
CATWAGGTRACGTGGCTAGCGRAGAACWACCCTKGCTCACKGAC
TYCYKGTTGTAACACACTTTCCTTACGGAGCCTGGCTGTTTCACAG
TATTTCATGAATTTACCCACACAGGTGTGATCCTCCTTGAGCATTG
AGGAGGCACATGAGAACTAAATCTTTTGTAGTAGCTGAGATCTGC
AATATAWAACGGGACAGTCAAAGGGCAATGTTTTTTTCTGTAAM
ATATTGAAAAARAAAAATGCAGTAWATCCTTTTTTATTGTTCCATT
AGTTTGTTGGTCAGCAGTCAGCAGTAGTAWAWAACATGGCCCCG
CAGACATGATCCACTCMATGCTGACATCGAAATGGCACTACTACT
MTACGTTCAGTTTCSCACAAGCCTTGGAAGTGCTGCACTTACAT 
11 
Homo sapiens 
aryl 
hydrocarbon 
receptor 
interacting 
protein-like 1 
(AIPL1) 
CCATAAAGGAGWCTTTATACGACTCACTATAGGGCGAGCGCCRC
CATGGAGTACCCATACGACGTACCAGATTACGCTCATATGGCCAT
GGAGGCCAGTGAATTCCACCCAAGCAGTGGTATCAACGCAGAGT
GGCCATTATGGCCGGGAGGCCAAGGCGGACCTCCAGAAAGTGCT
GGAGCTGGAGCCGTCCATGCAGAAGGCGGTGCGCAGGGAGCTG
AGGCTGCTGGAGAACCGCATGGCGGARAAGCAGGAGGAGGAGC
GGCTGCGCTGCCGGAACATGCTGAGCCAGGGTGCCACGCAGCCT
CCCGCAGAGCCACCCACAGAGCCACCCGCACAGTCATCCACAGAG
CCACCTGCAGAGCCACCCACAGCACCATCTGCAGAGCTGTCCGCA
GGGCCCCCTGCAGAGCCAGCCACAGAGCCACCCCCGTCCCCAGG
GCACTCGCTGCAGCACTGAGCCCCCTGAGGCCCACAGCCACCCAG
GCAGGGAGCAAGTGGCCTGGTCACTTCTGGTTCGATTGACCAGG
ATCGTGGTGTCACTTTTTAAAATTTAAAATTAATTTTTGAAATCAA
AGTCAGACACACCCATGGTAAAAAAAAAAAAAAAAAAAAAAAAA
AAMWSKKYYSSGSSSYYYSGSCYTYKRRRGGGTGGSWMYRRWYM
SGGRYYCCYYSRMSCYRGRYSKGMAAAWRAYYKWAAAWYKSGRA
AAACCAMMATTTTKTTMYMAAAAG 
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12 
Homo sapiens 
nuclear factor 
I/A (NFIA) 
TYSRKTRTWSTWCTYKATACAKACYSAMTATCMSSGCWAAGYKM
YRSCATGGAGTACCCATACGACGTACCAGATTACGCTCATATGGCC
MYGGAGGCCAGTGAATTCCACCCAAGCAGTGGTATCAACGCAGA
GTGGCCATTATGGCCGGGGGGAGCAGCCAAGGCAAGGTGCACA
ACCCATTCCTTCCCACCCCAATGTTGCCACCGCCACCGCCACCACC
GATGGCCAGGCCTGTGCCTCTGCCGGTGCCAGACACAAAGCCTCC
AACCACGTCAACAGAAGGAGGTGCARCCYCCCCCMMSKYMMCC
AACCTACTCGACACCCAGCACCTCCCCCGCAAACCGATTCGTCAGT
GTTGGACCACGGGATCCAAGCTTTGTAAATATCCCTCAACAGACA
CAGTCCTGGTACCTGGGAWAAAAGTTGCAGCGTCCCACCATCCA
CCAGACAAACCACCTGACCCCTTCTCAACTCTGTAACATGGACGCA
ACCTCAACCCAGCGCAGTTACAACTTCACTATCAGCGGAAGGGGA
RAAAAACCGATTCAAATCAACTTGTACATGGAAACAGCAAGCATT
ATGGTCAAACAGCAAGGGCCATAACCCTTTGGGATTTTTTTTTTTT
TTTTAAAAATACTTAGGGAMCKGKTTGTAAATTTTCTCATATGGTG
CTGGAAAATGGKTTGGGGCCTTTGTAMMATTTGGAAGTGTTTCC
ATGGTAGCGTGAGCATTAAGTGARCGTGCCTAGCGGGAGGACTA
CCCTTGCTCACTGACTTCCTGTTGTACACACTTTCTACGAGACCTG
GCTGTTCACAGTATTCATGATTTACCCMCAAGGKTGAATCCTCCTG
ACATTGAGAGCACATGGAAACTTAGTCTTTGATAGCTGGAATTCG
CATATASCGGACGTCAAGGCCAGTTTCGWACATGAG 
15 
Palmitoyl-
protein 
thioesterase 2 
(PPT2) 
TAAGAAAGAGWCTTTATACGACTCACTATAGGGCGAGCGCCGCC
ATGGAGTACCCATACGACGTACCAGATTACGCTCATATGGCCATG
GAGGCCAGTGAATTCCACCCAAGCAGTGGTATCAACGCAGAGTG
GCCATTATGGCCGGGCACAGGCACACCAAAGCCTGACATCTGCTT
TCCAAGGCCACCACTTGGTCTCTGGACCGAGGAGTTCCTGGGGAC
CCCTGAATATATCCTCAGGAGAGCCAAGGTTCAATGCAGGTCTCA
TAAAGGGTACGGTTGGAGTGCCAGGCTGTGTGGGARATACCGGC
CATTGGACACCTCACTATGACCCCCCGGGCCAATAGAGTCTTCAA
CCCAAAAGAATCCCGCAGATAAACCTTCAAGGTGGTCGAAGGGG
CGTGGAAGCATGGAAGAGAGACACAAGGAGAGACAAAGTGAGT
TACTGCTGGGATCCTGGACCTCCTCCCCACAGGGTGAACCCTTCA
GCTCAGGAGTCACAGAGAGGGCTCTGGAATAAGGTGGGACAGT
GGCTAGAAGGGGAAGTAATCCCAGGGGGCTCACCAGTTGCTCCT
CCATCTCCAGGAMGGTCTCATTTGCATCATAGAAACCAAAGAAGC
TACAAAGAGATTGGGGGGGARGTTATCAGAAGAGCTGGAGAAA
ATCTGGCCGGGCGCAGTGGCACACGCCTGTAATTGCAGCACTTTG
GGAGGCCAAGGAGGGCAAATCACCTGAGCCAGAGTTCAAGACCA
GCCTGACCAAAATGGTGAACCCCATCTCTACTAAAATACAAAATTA
GCTGGGCATGGTGGCAGATGCCTGCAGCCCAGCTACCCAGAGCT
GAAGCAGATATTACTTGACCAGAGGGKKGGAAGTTGCATTGAGT
CGAGATCGCACCACTGCACTCAGCTGGTGACGAGCGGACYCATCT
CAAAGAAGAAGGAKAGCAASAACAMATAAAAACCTGTSGCCSCT
CSCCTTTAARGGKGCATCGATCCGGATCMTCGAGCCTCGACTGCA
GAKATCTGCATCGAACGACGTYAATGTACGG 
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16 
Homo sapiens 
fibulin 1 (FBLN1) 
AATAYAGAGWCTTTATACGACTCACTATAGGGCGAGCGCCGCCA
TGGAGTACCCATACGACGTACCAGATTACGCTCATATGGCCATGG
AGGCCAGTGAATTCCACCCAAGCAGTGGTATCAACGCAGAGTGG
CCATTATGGCCGGGGGAAGGTGAGCCCCCACAGTGGGGTGGTGG
CCCTCACCAAGCCTGTCCCCGAGCCCAGGGACTTGCTCCTGACCG
TCAAGATGGATCTCTCTCGCCACGGCACCGTCAGCTCCTTTGTGGC
CAAGCTTTTCATCTTTGTGTCTGCAGAGCTCTGAGCACTCGCTTCG
CGTCGCGGGGTCTCCCTCCTGTTGCTTTCCTAACCCTGCCCTCCGG
GGCGTTAATAAAGTCTTAGCAAGCGTCCCACACAGCGAAAAAAAA
AAAAAAAAAAAAAAAAAAMYKKYSSSSCSSKYYSSSYYYYKRRRGG
GGGGSWWYMRWWSSGRRWWCYYYSRRKYYMRRYYKSMAAW
WRAWYSRAAAWWYSWRAAAAMCCSCSGGTSYMMMAAA 
19 
Homo sapiens 
small EDRK-rich 
factor 2 (SERF2) 
AAGAAAGAGWCTTTATACGACTCACTATAGGGCGAGCGCCGCCA
TGGAGTACCCATACGACGTACCAGATTACGCTCATATGGCCATGG
AGGCCAGTGAATTCCACCCAAGCAGTGGTATCAACGCAGAGTGG
CCATTATGGCCGGGGAAGGAGGAACCCAAGTGGCTTTGTGGCTT
CGTGTCCAACCCTCATGCCCTTCGCCTGTGTGCCTGGAGCCAGTCC
CACCACGCTCGCGTTTCCTCCTGTAGTGCTCACAGGTCCCAGCACC
GATGGCATTCCCTTTGCCCTGAGTCTGCAGCGGGTCCCTTTTGTGC
TTCCTTCCCCTCAGGTAGCCTCTCTCCCCCTGGGCCACTCCCGGGG
GTGAGGGGGTTACCCCTTCCCAGTGTTTTTTATTCCTGTGGGGCTC
ACCCCAAAGTATTAAAAGTAGCTTTGTAATACAAAAAAAAAAAAA
AAAAAAAAAAAAAAMYYKYYSSSSCCKCCYSSKYYYYWRRRWGGG
GGKWWMMWWYSSGRWWCCYYWMRKKYYRRMYYKMSAWWR
RAWYYWAAWMMSSWRAACAMCCCSSGGTTTTYMMCAAA 
22 
Homo sapiens 
eukaryotic 
translation 
initiation factor 
3 
TSARAAGAGWCTTTATACGACTSACTATAGGGCGAGCGCCRCCTG
GAGTACCCATACGACGTACCAGATTACGCTCATATGGCCATGGAG
GCCAGTGAATTCCACCCAAGCAGTGGTATCAACGCAGAGTGGCCA
TTATGGCCGGTGAGCAGATGCATGCGCTGCTGGCCATTGCCCTCA
CGATGTACCCCATGCGTATCGATGARAGCATTCACCTCCAGCTGC
GGGAGAAATATGGGGACAAGATGTTGCGCATGCAGAAAGGTGA
CCCACAAGTCTATGAAGAAMTTTTCAGTTACTCCTGCCCCAAGTTC
CTGTCGCCTGTAGTGCCCAACTATGATAATGTGCACCCCAACTACC
ACAAAGAGCCCTTCCTGCAGCAGCTGAAGGTGTTTTCTGATGAAG
TACAGCAGCAGGCCCAGCTTTCAACCATCCGCAGCTTCCTGAAGC
TCTACACCACCATGCCTGTGGCCAAGCTGGCTGGCTTCCTGGACCT
CACAGAGCAGGAGTTCCGGATCCAGCTTCTTGTCTTCAAACACAA
GATGAAGAACCTCGTGTGGACCAGCGGTATCTCAGCCCTGGATG
GKGAATTTCAGTCAGCCYCAGARGGTTGACTTCTACATTGATAAG
ACATGATCCACATCGCGGACACCAAGGTCGCCAGGCGTWTTKGG
GGRAWTTCTTCATCCGTCARATCCACAAATTTGGAGGGAGCTTAA
TCGAAACCCTGAAGAAGATGGACAGAGACCCTTGATGATATTCAC
ACACATTCAGAACTGGTTTTGATGTATATAGGCAGAAGKGKTTTTT
TGCYTACCGKGAACCTTACCTARATCAGCCATCAGCTGTCAACTCA
GTACAGTATGACCGAGTGTTCAGTGAATCTCAGTAAGGATCTTGA
GCCTAAAAAAAAAARAAAAAACTGCGCACTCGCYCTAAGGTGGG
CTGTACGAATCACTGGTCGACGYAGAKATCTGGATCAGACACGCT
ATATTAAWGGRAG 
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24 
Homo sapiens 
ubiquitin A-52 
residue 
ribosomal 
protein fusion 
product 1 
(UBA52) 
TCSGCAAGTGSWCTTTATACKACTCACTATAGGGCGAGCGCCRCC
ATGGAGTACCCATACGACGTACCAGATTACGCTCATATGGCCATG
GAGGCCAGTGAATTCCACCCAAGCAGTGGTATCAACGCARAGTG
GCCATTATGGCCGGGAGGTGGCATTATTGAGCCTTCTCTCCGCCA
GCTTGCCCARAAATACAACTGCGACAAGATGATCTGCCGCAAGTG
CTATGCTCGCCTTCACCCTCGTGCTGTCAACTGCCGCAAGAAGAA
GTGTGGTCACACCAACAACCTGCGTCCCAAGAAGAAGGTCAAATA
AGGTTGTTCTTTCCTTGAAGGGCAGCCTCCTGCCCAGGCCCCGTG
GCCCTGGAGCCTCAATAAAGTGTCCCTTTCATTGACTGGAAAAAA
AAAAAAAAAAAAAAAAAAAAAAYKKKSSSSSSSSKYYSSSYYYWWR
RRGGGGGGSWMWMMWWSSGRWMYCYMYSMKYYKMRSKYKS
MAWWKRAWYSWAAAWYKSWRAAAMCCSSSGGKKKTTTYMAA
AA 
26 
Homo sapiens 
cytochrome c 
oxidase subunit 
VIIc (COX7C), 
nuclear gene 
encoding 
mitochondrial 
protein 
TAAGAAGAGWCTTTATACGACTCACTATAGGGCGAGCGCCGCCA
TGGAGTACCCATACGACGTACCAGATTACGCTCATATGGCCATGG
AGGCCAGTGAATTCCACCCAAGCAGTGGTATCAACGCARAGTGG
CCATTATGGCCGGGGAAGGTCGTGAAAAAAAAGGTCTTGGTGAG
GTGCCGCCATTTCATCTGTCCTCATTCTCTGCGCCTTTCGCARAGCT
TCCAGCAGCGGTATGTTGGGCCAGAGCATCCGGAGGTTCACAAC
CTCTGTGGTCCGTAGGAGCCACTATGAGGAGGGCCCTGGGAAGA
ATTTACCATTTTCAGTGGAAAACAAGTGGTCGTTACTAGCTAAGAT
GTGTTTGTACTTTGGATCTGCATTTGCTACACCCTTCCTTGTAGTAA
GACACCAACTGCTTAAAACATAAGGATGTTTCAGTTCCTCCATTTA
ACAGATATGAAGAGCATTTTAAGAGGTGCAGCCTCTGGAAGTGG
ATCAAACTAGAACTCATATGCCATACTAGATATGTTCGTCAATAAA
CTTATGACGTGAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AARRRAAAAAAAAAAAAAAAAAAAAMYYYYTTYSSSSSSKKKKKKK
YYYWARRRWGGGGGYWMWWAWMSGGRWYCCCYYSRSYYSRR
YKYKRAAAAAAMYYMAAYAYWMSRAAAMCGGKTTTTTWWWYA
CAAA 
Table 8.12 Summary of coding sequences identified in Y2H screen 4. The sequencing 
outputs include the whole sequence identified using the pGADT7-Rec vector specific 
primers. 
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Appendix H. Summary of Preys Carrying Non-coding Sequences 
 The preys carrying non-coding sequences identified in Y2H screening are 
summarised in Table 8.13. 
 
Y2H screen 4, bait 3 
Colony 
number 
Prey identified 
3 Homo sapiens cDNA FLJ46255 fis, 
6 
Homo sapiens solute carrier organic anion transporter family, member 5A1 
(SLCO5A1) 
7 Homo sapiens ADP-ribosylation factor 1 (ARF1), transcript variant 2 
8 Homo sapiens ADP-ribosylation factor 1 (ARF1), transcript variant 2 
10 
Homo sapiens spleen focus forming virus (SFFV) proviral integration oncogene 
spi1 (SPI1), transcript variant 1 
13 unidentified sequence 
14 Homo sapiens carboxylesterase 2 (CES2), transcript variant 1 
17 Homo sapiens kinesin family member 1A (KIF1A), transcript variant 2 
18 unidentified sequence 
20 unidentified sequence - prey fragment smaller than 200 bp 
21 Homo sapiens ADP-ribosylation factor 1 
23 unidentified sequence - prey fragment smaller than 200 bp 
25 unidentified sequence 
27 unidentified sequence 
28 unidentified sequence 
Y2H screen 5, bait 6 
Colony 
number 
Prey identified 
1 Homo sapiens heterogeneous nuclear ribonucleoprotein A0 (HNRNPA0) 
2 
Homo sapiens mitofusin 2 (MFN2), nuclear gene encoding mitochondrial 
protein 
3 
Homo sapiens latent transforming growth factor beta binding protein 2 
(LTBP2) 
Y2H screen 6, bait 8 
Colony 
number 
Prey identified 
1 Homo sapiens MSTP112 (MST112) 
2 
Homo sapiens spleen focus forming virus (SFFV) proviral integration oncogene 
spi1 (SPI1) 
3 Homo sapiens solute carrier family 38, member 3 (SLC38A3) 
4 Homo sapiens chromosome 19 clone CTB-189B5, 
5 unidentified sequence 
6 Homo sapiens mRNA; cDNA DKFZp434J194 (from clone DKFZp434J194). 
7 Homo sapiens macrophage erythroblast attacher (MAEA), transcript variant 1 
8 Homo sapiens neurobeachin (NBEA), transcript variant 1 
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9 Homo sapiens kinesin family member 1A (KIF1A), transcript variant 2 
Y2H screen 7, bait 7 
Colony 
number 
Prey identified 
1 Homo sapiens MAU2 chromatid cohesion factor homolog (C. elegans) (MAU2) 
Table 8.13 Summary of preys carrying intronic sequences identified in Y2H. 
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Appendix I. Characterisation of Anti-EYS1 and Anti-EYS3 Antibodies 
 Anti-EYS1 rabbit antibody was a custom made antibody acquired by 
Bhattacharya laboratory. It was raised against an epitope that was common for all 
four EYS isoforms. As it was described in the chapter devoted to characterisation of 
EYS, the antibody is capable of detecting EYS isoforms 1 and 4 in the extracts from 
Y79 cells. To test if it as well able to detect EYS isoforms 2 and 3, immunoblotting 
was performed on protein extracts containing overexpressed 3XFLAG constructs. 
As a positive control, 3XFLAG-VAX2 was used whereas the negative control was 
extract from untransfected HeLa cells. As shown in Figure 8.1, anti-EYS1 antibody 
was unable to detect EYS isoforms 2 and 3. The bands detected by anti-EYS1 
antibody have the same pattern in all of the lanes and they were most likely non-
specifically detected by either primary or secondary antibodies.  
 
Figure 8.1 Immunoblotting testing whether anti-EYS1 antibody can detect EYS isoforms 2 
and 3. The blot on the left was probed with anti-FLAG mouse antibody whereas the blot on 
the right was probed with anti-EYS1 rabbit antibody. Secondary antibodies used were 
HRP conjugated anti-mouse and anti-rabbit antibodies. Precision Plus Protein standard 
was used to assess the band size. BCA assay was used to normalise loading. Expected 
protein sizes: 3xFLAG-EYS isoform 2 – ~72 kDa, 3xFLAG-EYS isoform 3 – ~69 kDa, 
3XFLAG-VAX2 - ~ 40 kDa. 
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 The same type of analysis was performed for anti-EYS3 polyclonal goat 
antibody which was purchased from SantaCruz, USA. The result is presented in 
Figure 8.2 and it can be concluded that this antibody is unable to detected EYS 
isoforms 2 and 3 either. 
 
 
 
Figure 8.2 Immunoblotting testing whether anti-EYS3 antibody can detect EYS isoforms 2 
and 3. The blot on the left was probed with anti-FLAG mouse antibody whereas the blot on 
the right was probed with anti-EYS3 goat antibody. Secondary antibodies used were HRP 
conjugated anti-mouse and anti-goat antibodies. Precision Plus Protein standard was used 
to assess the band size. BCA assay was used to normalise loading. Expected protein sizes: 
3xFLAG-EYS isoform 2 – ~72 kDa, 3xFLAG-EYS isoform 3. IB – immunoblotting. 
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